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Abstract
Introduction: Sleep disturbances and sleep quality have fluctuated over
time in the United States (US). Virtually every physiological process follows a
circadian pattern, and cellular processes (i.e., cell proliferation, DNA damage
response, and apoptosis) are often disrupted by sleep disturbances and other
factors, potentially giving rise to adverse health outcomes such as cancer.
Additionally, both genetic variation and epigenetic patterns within clock genes,
which may affect sleep quality, also may increase one’s risk for developing
cancer. The role of sleep disturbances in the formation of adenomas, precursor
lesions to colorectal cancer (CRC), has been explored previously; however, little
is known regarding the influences of genetic variation in the PERIOD3 (PER3)
variable number tandem repeat (VNTR) and epigenetic patterns of clock genes
on adenoma formation. Furthermore, few studies have attempted to fully
characterize sleep disorder trends in a national sample over time, as it has been
alleged that sleep quality has declined over time. Examination of sleep disorder
trends is of public health significance because individuals affected by sleep
disturbances may be at an increased risk for cancer development, particularly
CRC. Materials and Methods: In order to examine sleep disorder trends over
time and to determine the genetic and epigenetic influences of adenoma
formation, two studies were conducted. The first study utilizes data from a
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national sample of US Veterans across an eleven year span to carry out a serial
cross-sectional study to produce annual prevalences of sleep disorders, which
were further stratified by additional factors. Cases were defined as patients with
at least two outpatient sleep disorder diagnoses at least 30 days apart based on
ICD-9 codes and American Academy of Sleep Medicine (AASM) criteria.
Additional analyses were carried out to determine factors that were associated
with the development of new sleep disorders in the last year of the study using
multivariable unconditional logistic regression models to produce odds ratios
(OR) and 95% confidence intervals (95% CI).

The second study (Epigenetics and Diet in the Carcinogenesis Process,
EDCaP) provided information on epigenetic markers and PER3 VNTR variation.
The epigenetic marker study was carried out at local endoscopy center (South
Carolina Medical Endoscopy Center, Site 1 [n=107]). For the PER3 VNTR arm
of the study, data from Site 1 (n = 93) and an additional endoscopy center were
pooled (WJB Dorn Veterans Administration Medical Center [Site 2, n=53]). Cases
were defined as individuals with at least one histologically confirmed adenoma,
and controls were subjects with a normal colonoscopy, or a normal biopsy not
requiring heightened surveillance (e.g., hyperplastic polyp). To determine if
cases had differential promoter methylation in selected genes or an increased
odds of possessing at least 5-repeat allele in the PER3 VNTR compared to
controls, unconditional logistic regression analyses were used to calculate ORs
and 95% CIs, while adjusting for confounders. Results: In the study using a
national sample of US Veterans, apneas and insomnias were the first and
v

second most common sleep disorders diagnosed among Veteran patients,
respectively. Total sleep disorder prevalence rose six-fold across the study
period. Additional analyses indicated that several comorbid diseases may
influence the development of sleep disorders. In the methylation study,
compared to controls, cases were more likely to be hypomethylated in the
MINT1, PER1, and PER3 promoters. In the PER3 VNTR study, cases were more
likely to possess the 5-repeat PER3 genotype relative to controls. Discussion:
Given the evidence that diagnosed sleep disorder prevalence has risen over time
in the national sample study, a subset of individuals may be increasing their risk
for cancer, potentially through genetic or epigenetic mechanisms. Epigenetic
and genetic variations in clock genes appear to influence the development of
adenomas, which presents an opportunity to develop novel biomarkers in
accessible tissues (e.g., blood). It also is important to note that these genetic
and epigenetic markers may influence sleep disturbances, which have been
linked to cancer formation in previous studies.
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Chapter 1
Introduction and Specific Aims
1.1 Introduction
According to the most recent estimates by the American Cancer Society,
there will have been over 93,000 incident colorectal cancers (CRC) patients and
more than 39,000 deaths in the United States (US) in 2015, thus making it the
third most common cancer in both men and women.1 While these statistics are
alarming, CRC is one of the most preventable cancers. Colorectal adenomatous
polyps are considered precursor lesions for CRC.2 Certain characteristics of
adenomas such as size, number, and histology, confer a greater risk within an
individual.3-6 A deeper understanding of the factors related to the formation of
these adenomatous polyps and their progression to cancer is needed, but it
provides an extremely important opportunity for public health interventions. By
intervening in this pathway from adenoma to carcinoma formation, health
professionals will have the ability to reduce the number of new CRC cases by as
much as 90%.5,7

Colorectal adenomas have been estimated to have developed prior to 7090% of all CRCs.8 Despite screening programs, the incidence of CRC and deaths
due to CRC remains high.9 Current efforts are directed toward detection and
removal of asymptomatic adenomas. However, even after removal, the
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recurrence rate for adenomas, an effective surrogate endpoint for CRC, is
approximately 40-50%.10-12 Thus, continued surveillance via follow-up
colonoscopies is extremely important in avoiding cancer progression in the colon;
however, CRC surveillance compliance is still low (49 – 61% of CRC
survivors).13-17 It also illustrates the importance of finding alternative means of
CRC screening.

Because a series of genetic and epigenetic changes occur along the
pathway from normal tissue within the gastrointestinal (GI) tract to
carcinogenesis, it is important to understand the mechanism behind these
changes to help prevent formation of CRC or to better treat current cases of
CRC. Also, it has become important to discover novel biomarkers that predict
CRC risk, as some heavily-studied genetic markers cannot fully explain CRC
formation within certain individuals and populations as a whole especially in
readily-accessible tissues derived from the body (e.g., blood). Additionally,
several other genes have been implicated in the carcinogenesis process in the
GI system;18 hence, further investigation into other gene families such as the
Period family (PER1, PER2, and PER3) is warranted.19
The Period (Per) gene family plays a role in immunomodulation20-25 and
tumor suppression.26, 27 Thus, structural variation,19, 28, 29 deregulated expression
within tumor tissues,30-32 and epigenetic variation 33 within the Per genes have
shown some promise as novel biomarkers of cancer. For example, Chen et al
found dysregulated expression of PER1, PER2, and PER3 in breast tumor
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tissues compared to matched normal tissues within subjects.30 Within this same
gene family, Zhu et al have found that structural variation in one of these genes
in the form of a variable number tandem repeat (PER3 VNTR), which has been
previously been linked to various sleep phenotypes,34-40 also has been
associated with premenopausal breast cancer.19 Furthermore, this gene family
also has been known to influence sleep quality within people, suggesting a
mechanistic role in these genes in the pathway of sleep disruption, altered gene
variation and function within this family, and cancer formation and mortality in
both animals and humans.41-46 Variation within the PER3 gene also may explain
cancer susceptibility in certain subgroups of people that are more likely to
experience sleep disruption.19, 47 Additionally, little is known on the trends of
sleep disorders over time in a national sample. Because prior literature has
noted an association between sleep disruption and cancer, it is necessary to
characterize an at-risk population. .

1.2 Specific Aims
The specific aims of this proposal are as follows:

Aim 1a: To characterize sleep disorder prevalence among US Veterans over time
and determine what factors that may be driving an increased prevalence of sleep
disorders in Fiscal Years (FYs) 2000-2010, or new sleep disorder diagnoses in
FY2010

Research Question 1.1: Are sleep disorder diagnoses increasing
nationally among U.S. veterans or within specific subgroups?
3

Research Question 1.2: Are comorbidities such as obesity, diabetes,
cardiovascular disease, and post-traumatic stress disorder (PTSD)
influencing the increase of sleep disorders in US Veterans?

Research Question 1.3: What factors are increasing one’s risk for the
development of a new sleep disorder diagnosis?

Aim 2: To determine the association between Period (PER) gene methylation
patterns and other gene methylation markers from a panel of 20 candidate
markers and adenoma formation through the use of logistic regression

Research Question 2.1: Do methylation patterns in peripheral blood
leukocytes (PBLs) within the PER1, PER2, and PER3 genes differ for
those with adenomas compared to those without adenomas, after
adjustment for confounding factors?

Research Question 2.2: Is there a significant amount of concordance
between methylation patterns of the PER1, PER2, and PER3 genes in
PBLs, normal tissue, and polyp tissue?

Research Question 2.3: Do methylation levels of PER1, PER2, and PER3
genes in the PBLs, normal tissue, and polyp tissue predict mRNA levels of
the PER1, PER2, and PER3 genes in PBLs and tissue, respectively?

Research Question 2.4: Do mRNA levels of PER1, PER2, and PER3 in
PBLs predict adenoma risk, after adjustment for confounding factors?
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Research Question 2.5: Do mRNA levels of PER1, PER2, and PER3 in
PBLs agree with mRNA levels of PER1, PER2, and PER3 found in normal
and/or polyp tissue?

Aim 3: To evaluate the influence of the variable tandem repeat (VNTR) in the
PER3 gene on colorectal adenoma risk

Research Question 3.1: Are individuals with the PER3 4/5 and 5/5
genotype at an increased risk for adenoma formation compared to
individuals with the PER3 4/4 genotype?

Research Question 3.2: Does methylation or mRNA expression of the
PER1, PER2, or PER3 genes differ among those with different PER3
VNTR genotypes?

Research Question 3.3: Does methylation modify the relationship
between genetic variation in the PER3 VNTR gene and adenoma
formation?

5

Chapter 2
Background
National Sample of US Veterans
2.1 Adverse health outcomes associated with sleep disorders
Previous studies have found that more than 80% of people with clinically
significant sleep-disordered breathing are undiagnosed;48 and prior research has
shown that sleep duration and sleep disorders have been associated with
adverse health outcomes, which include but are not limited to: earlier mortality
(total and cause-specific),44, 49-51 cardiovascular disease (CVD),52, 53 type 2
diabetes, 53, 54 obesity, 53, 54 and psychiatric disorders.55-58 Furthermore, sleep
duration or sleep disorders have also been linked with cancer. In a study
examining cancer incidence in a large multicenter Spanish cohort, individuals
with severe apnea, with the Apnea-hypopnea index (AHI) of 43 or higher as a
proxy, had an increased cancer incidence density ratio compared to those with
the lowest AHI category; however, this association was only observed in
individuals aged 65 or younger. More recently, two meta-analyses revealed
inconsistent effects between short sleep duration and other circadian
disturbances such as shiftwork and exposure to light at night and breast
cancer.59, 60 Although both meta-analyses did not observe an association in
studies that examined short sleep duration, a positive association between
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shiftwork and breast cancer risk was detected in the study by He et al.59 This
subgroup tends to have shorter sleep duration compared to permanent day
workers.61 With the co-occurrence of sleep disorders and another chronic
disease, quality of life is severely impacted as well.62, 63 Little research has been
conducted on the etiology of sleep disorders in a national sample, and
identification of risk factors could improve detection and treatment of sleep
disorders.

2. 2 Sleep disorders in the United States
A 2010 study characterized the prevalence of sleep disorders and sleep
habits in the United States using the NHANES 2005-2006 sample.64 Among all
physician-diagnosed sleep disorders, sleep apnea was the most prevalent sleep
disorder in the civilian, non-institutionalized population (4.2%). In addition to
physician-diagnosed sleep disorders, 7% of the sample reported having trouble
falling asleep and a similar amount (6.9%) reported waking up in the night and
difficulty going back to sleep. Office visits for sleep disorders have significantly
increased across a decade,65 which potentially indicates either a true increase in
prevalence, increased awareness, or both. However, common sleep disorders
such as sleep apnea and insomnia remain underdiagnosed and therefore go
untreated.

Ram et al found several differences in sleep-related metrics and/or
symptoms have been observed when stratified by demographic characteristics.64
Middle-aged adults were more likely to report worse sleep characteristics
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compared to younger and older adults. In regard to gender, women were more
likely to report worse sleep habits such as trouble falling asleep, feeling unrested
during the day, not getting enough sleep and taking sleeping pills. Sleep-related
difficulties such as difficulty concentration and remembering were reported at
higher rates among women. In regard to race/ethnicity, while EAs had higher
rates of sleeping pill use and excessive daytime sleepiness, AAs reported higher
rates of sleep-related difficulties, shorter sleep durations, and longer sleep
latencies (minutes needed to fall asleep). 65 Despite this study’s strengths,
several limitations must be noted. First, it relied on data that was self-reported
that was not validated through physical examinations or medical chart reviews;
second, self-report of these sleep symptoms are subject to recall bias, where
subjects with a physician-diagnosed sleep disorder may recall symptoms
differently from individuals who do not have a physician-diagnosed sleep
disorder; and third, as a result of NHANES being a cross-sectional study design,
it is difficult to determine the temporal relationship between sleep
disorders/habits and daily activities and trends in sleep habits across time.

Previous studies have also supported some of the findings found in the
national sleep disorder prevalence data, particularly in terms of differences by
race and ethnicity.66, 67 Other studies have found that black participants had a
doubling of risk for obstructive sleep apnea, reduced sleep satisfaction, and more
frequent napping compared to white participants.66, 68 However, Ram et al’s
findings could not be replicated in a more recent study examining office visits for
sleep disturbances over time.65 For example, Ford et al reported that men higher
8

rates of office visits for medical care for sleep difficulties compared to women.
Moreover, no racial differences could be detected for any sleep disorder or
insomnia, and EAs had higher office visits related to sleep apnea compared to
AAs. Lack of consistency may be due to failure to control for factors that may
impact prevalence rates, such as physical and mental comorbidities and
socioeconomic status;69, 70 additionally, previous studies have not been
adequately powered to examine differences in prevalence rates by various
factors. Regardless, increased burden of sleep disorders and disturbances in
certain subgroups could partially explain disparities that have been observed in
other diseases. Given that sleep disorders in general are undiagnosed, the
characterization of sleep disorders and factors contributing to the development of
sleep disorders deserve further investigation.

As a result of the drawbacks in the recent prevalence studies and previous
studies, it is of high importance to examine populations where data does not rely
on self-report of sleep disorder diagnoses across time. One potential source of
looking at objective measures of sleep disorder diagnoses is in the Veterans’
Health Administration’s (VHA) electronic medical record system. Furthermore,
this group presents a unique opportunity to see the effects of various
comorbidities on sleep disorders. Because this group is particularly susceptible
to post-traumatic stress disorder (PTSD), a condition that has been linked to both
sleep disorders 71 and early mortality,72, 73 veterans are at a much higher than
usual risk for adverse outcomes. Preliminary de-identified data extracted from
Veterans’ Integrated Services Network 7 (VISN-7) between 2000 and 2008
9

suggests that sleep disorder diagnoses may have increased over time among
veterans, despite no differences in first time sleep disorder diagnoses and total
first time diagnoses from VISN-7 medical centers, community-based outpatient
clinics, and primary care clinics. If a relationship between sleep disorders and
certain adverse health outcomes (e.g., mortality) exists, this group bears a
heavier burden of disease and mortality compared to civilians.

Sleep disruption has increased and sleep quality has decreased in the
United States for a variety of reasons and certain subgroups, such as veterans,
may be at an increased risk for unfavorable health outcomes. It is critical to
assess factors that may be driving the increase in sleep disorder prevalence.
Because veterans are a vulnerable population, better behavioral therapies to
achieve improved sleep quality could effectively reduce costs associated with
subsequent adverse effects of sleep disruption. The public health implications of
increased sleep disorder prevalence among veterans are not fully understood.
Sleep disorders are associated with increased mortality and cancer, likely
through pathways involving immunomodulation and tumor suppression, it stands
to reason that sleep disorders may increase cancer risk. In support of this, sleep
apnea was associated with increased cancer incidence.51 A descriptive
characterization of the sleep disorder epidemiology is vital for beginning to
understand the impact on long term comorbid disease and mortality risks.
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2. 3 Colorectal cancer (CRC) in the United States
While the number of incident cases and deaths due to CRC is alarming,
these numbers have decreased in the last two decades in the United States due
to removal of precancerous lesions during screening, 74, 75 which has increased
three to eight-fold during this same time period.76 Another factor contributing to
the decline is the improvement in treatment of CRC, allowing for the survival of
over 1 million cases of CRC. Despite the decrease in incident cases of CRC and
deaths due to CRC, the lifetime risk for being diagnosed with CRC is 5% for men
and women, with men being at a higher risk compared to women (57.2 per
100,000 vs 42.5 per 100,000, respectively). Men are also at a higher risk for
death due to CRC compared to women (21.2 per 100,000 vs 14.9 per 100,000,
respectively).77 Differences in rates by gender can be attributed to hormones
and exposure to other risk factors that are related to gender.78-80 In addition to
gender differences, burdens in CRC incidence and mortality by race/ethnicity are
evident. EAs have a lower incidence rate compared to AAs (44.7 per 100,000 vs
53.1 per 100,000, respectively).77 Also, AA men are more likely to die from CRC
compared to EA men (30.5 per 100,000 vs. 20.9 per 100,000, respectively).
Similarly, AA women are more likely to die from CRC compared to EA women.77
These statistics are reflected at a state level such as in South Carolina.81 In
addition to gender and racial/ethnic differences, there is geographic variation in
CRC incidence and mortality that is likely driven by access to screening and
treatment centers.9 Because of this combination of factors, only 62% of eligible
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adults, defined as adults 50 to 75 years of age, have been screened for CRC. As
a result, there has been an increase in research effort in finding markers of
increased risk within readily accessible samples such as blood to improve CRC
screening compliance.

2. 4 Risk factors for CRC
Previous studies have indicated several factors that do or may increase
the risk for CRC. Lifestyle and environmental factors such as diets high in total
fat and red meat, sedentary lifestyle, cigarette smoking, low doses of vitamin D
and/or calcium, alcohol consumption, tobacco use, and obesity.82 Previous
studies have also found that personal history of colorectal adenomas increase
the risk of developing CRC. Research has shown that patients with adenomas
had a 25% increased risk of CRC at that particular site.83 Removal of adenomas
has also been shown to decrease the risk of incident CRC.

Another factor playing a role in the carcinogenesis process is chronic
inflammation, where several factors may interfere with the balance between antitumor immunity and tumor-promoting inflammation. According to prior studies,
up to 20% of cancers are linked to chronic infections,84 30% are due to inhalation
of pollutants (e.g., tobacco smoke),85 and 35% to dietary factors.86 Inflammation
also appears to play a role at several stages during the carcinogenesis process.
In terms of tumor initiation, a pro-inflammatory environment may increase the
likelihood of mutations, genomic instability, and epigenetic modifications, thus
extending survival of premalignant cells. These pro-inflammatory conditions
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allow premalignant cells to accumulate further mutations and form early tumor
nodules. Early tumor nodules continue to thrive in the presence of inflammation,
facilitating their growth into advanced tumors, and subsequently, spread of these
mutated cells (metastasis).

In addition to these risk factors, several genes have been found to play a
significant role in CRC risk, where molecular events involving these genes result
in chromosomal instability, gene hypermethylation of cytosine-phosphateguanine (CpG) islands, and microsatellite instability. In 1990, Fearon and
Vogelstein proposed a mechanism explaining how multiple genes play a role in
colorectal carcinogenesis.87 For example, loss of the Adenomatous Polyposis
Coli (APC) gene, which is responsible for tumor suppression, is one of the
earliest events in the chromosomal instability colorectal tumor pathway and
germline mutations have been shown to be associated with conditions that
predispose individuals to colorectal tumors, such as familial adenomatous
polyposis (FAP).87 However, germline mutations that lead to FAP are a minority
(5-6%) of CRC cases. A large number of CRC cases (approximately 75%) are
sporadic, meaning that there is no apparent family history of CRC and may be
due to a common exposure, a genetic background (i.e., sporadic mutation) that
would put an individual at a high risk for developing CRC, or a combination of
both.88 More recently, a study looking at 13000 genes found that tumors have an
average of 90 mutant genes. Among these genes, 69 genes were relevant to the
pathogenesis of CRC, and individual CRCs had an average of nine mutant genes
per tumor, revealing a multigenic process in the carcinogenesis in the colon.18
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Also, this study revealed that there may be alternative explanations as to why
certain populations are more susceptible to cancer than others, such as shift
workers, who have been found to have gene dysregulation, particularly in the
Period (PER) gene family. Details on molecular changes in the carcinogenesis
process are described further in section 2.5 below.

2. 5 Clock genes, circadian disruption, sleep disruption, and cancer
While several genes have been identified as being linked to CRC
formation, some genes, known as clock genes, which are involved in circadian
rhythm regulation, have not been studied as frequently. In prokaryotic and
eukaryotic organisms, most physiological and behavioral (such as sleep and
wakefulness, body temperature, blood pressure, immune responses) functions
are expressed rhythmically according to light-dark cycles to allow for adaptation
to changes in the environment and ensure survival. There are three components
in this circadian rhythm: input pathway, central pacemaker, and output pathway.
The central pacemaker, which is located in the suprachiasmatic nucleus (SCN) of
the anterior hypothalamus, is of particular interest due to its role in
synchronization of the rhythm with the environment. At least nine core clock
genes have been found to play a role in circadian oscillation: PER1, PER2,
PER3, CRY1, CRY2, CLOCK, BMAL1, TIM, and CK1ε ,33 which are responsible
for ~2-10% of the diurnal expression of most tissues in the mammalian
genome.89 Because of the central role that circadian rhythm plays in both
homeostatic and non-homeostatic functions,26, 90 it is essential for the body to
maintain this rhythm. However, a variety of environmental (e.g., shiftwork) 91-93 or
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genetic factors (genetic polymorphisms or epigenetic modifications) 30, 94 can
confuse the master clock, thus disrupting the phase or amplitude of circadian
rhythms and the physiological processes they help regulate, such as cell
proliferation and apoptosis.95 Disruption of these processes has been suspected
of increasing the risk of cancer in certain populations (e.g., shiftworkers).96
Effects found in epidemiological studies have been confirmed in studies using
mouse model systems. For example, ablation of the SCN in mice resulted in an
accelerated tumor growth rate compared to mice with an intact SCN.97
Differential methylation of clock genes can lead to differential epigenetic
regulation of gene expression, and thus alter individual susceptibility to certain
cancers.30 While consistent evidence between circadian rhythm disruption and
cancers of the breast and prostate exists,42, 98-102 very few studies have examined
the role of circadian rhythm disruption due to genetic and/or environmental
factors and CRC in human populations; however, these few studies suggest a
relationship.103-105 For example, Schernhammer et al found a 35% increase in
risk for CRC for nurses who engaged in long-term rotating shift work three nights
per month compared to those who never worked rotating night shifts.106
As a consequence of circadian rhythm disruption, disordered sleep may
arise. Certain groups such as shiftworkers are more likely to suffer from
disordered sleep than those who work day shifts. For example, nurses who work
night shifts have shorter sleep duration compared to their sleep duration after a
day shift.107 It is believed that the pathway between this factor and outcome may
be mediated by the immune system dysregulation following sleep loss.
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Experimental sleep deprivation and epidemiological studies looking at fatigue
have found increased circulating levels of inflammatory markers such as
interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), with
significant elevations,20-25 even after one night of sleep loss.23 Because previous
studies have shown that sleep deprivation affects the inflammatory process and
that sleep quality has decreased across time, it may be important to elucidate the
relationship between sleep disruption and cancer.
Several mechanisms have been proposed that link sleep disruption to
cancer formation. The first may be due to reduced melatonin release as a result
of sleep disruption, thus leading to a reduction in natural killer (NK) cells and
cytokines responsible for cancer inhibition (IL-2, IL-12, and TNF-α) and
development of cancer cells; however, evidence supporting this mechanism is
limited. Another mechanism suggests that the carcinogenesis process arises
due to issues with melatonin acting upon cells locally by halting the cell
proliferation process in cancer cells.41
Not only have sleep disorders been implicated in the carcinogenesis
process, but factors related to sleep disorders (such as sleep disordered
breathing) also played a role on cancer-related mortality,44 possibly through
reduced oxygen delivery to tumor tissues, a factor that predicts cancer
progression and poor prognosis.108, 109 In summary, genes related to circadian
rhythm regulation have a role in sleep disruption and inflammatory processes
related to tumor suppression/cancer inhibition either through genetic variation or
alterations in function due to epigenetic changes. Also, there is reason to believe
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that these genes could serve as a marker for both cancer risk and survival due to
the physiological role that sleep has on carcinogenesis and cancer-related
mortality. While previous studies have made strides in closing the gap, these
gaps in research warrant further study.
2. 6 Biological markers for CRC
The adenoma-carcinoma sequence within the colon has been widely
studied due to the ability to observe genetic alterations at several stages. Not
only do gene variants existing in the form of single nucleotide polymorphisms
(SNPs) play a role in conferring risk, but gene expression and the epigenetic
modifications that influence gene expression (via methylation, histone
modification, phosphorylation) are believed to influence the carcinogenesis
process in the GI tract. Epigenetic modifications often involve methylation at the
CpG islands within the promoter regions of the genes and methylation of these
areas lead to gene silencing (reduced gene expression in the form of lower
mRNA levels). Therefore, methylation of genes responsible for tumor
suppression, DNA repair, and other physiological processes that control cell
division and growth could lead to dysregulation of metabolic processes, thus
leading to cancer formation. Epigenetic events are often due to simply inheriting
epigenetic markers from parents or from external sources from the environment,
such as diet. Because of the reversibility of epigenetic modifications and their
influence on the carcinogenesis process, this area is being actively studied as a
potential therapeutic modality.
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2.6.a Genetic markers in CRC
Genetic markers have been explored to predict risk for cancer. Unique
genetic markers are particularly favorable because certain cancers cannot be
fully explained by heavily studied genes (BRCA1, BRCA2, APC), especially
among younger individuals with cancer.110, 111 For example, in 2005, Zhu et al
found that women who had at least one 5-repeat allele (~50% are heterozygous
for the 5-repeat allele and 10% are homozygous for the 5-repeat allele) in the
PER3 variable number tandem repeat (VNTR) had an increased risk for
premenopausal breast cancer.19 This gene, where individuals may possess a
4/4, 4/5, or 5/5 genotype, may be responsible for variations in circadian rhythm
(diurnal preference, delayed sleep phase syndrome, sleep-wake patterns).34-40
This may be due to the fact that certain individuals with the 4/5 or 5/5 genotype
may have a different pattern of secretion of hormones related to sleep-wake
cycles (i.e., melatonin). Other studies have revealed apparent tumor suppressor
properties of the Period genes (PER1, PER2, and PER3), particularly in cancers
of the breast, endometrial lining, and prostate.19, 27, 30, 112-116 Among these genes,
PER3 has been studied extensively and it has been associated with various
phenotypes potentially including adverse health outcomes (bipolar disorder,
heroin dependence, poorer cognitive performance after sleep deprivation) and
recently has been considered a candidate genetic marker of cancer risk.19, 29
Other genes that play a role in circadian timing, such as CLOCK, BMAL1, and
NPAS, have also presented associations with cancer risk, providing evidence of
the link between clock gene variation and cancer. The pathophysiological
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processes that drive many of these associations remain to be determined. With
regard to PER3, it is believed that variation in the VNTR affects patterns of
cortisol secretion,117 and disturbances in cortisol secretion have been linked to
hyperactivity of pro-inflammatory processes118 and increases in pro-inflammatory
cytokines, such as IL-6,24 which create an ideal microenvironment for the
carcinogenesis process to take place

2.6.b Gene expression in CRC
Due to the series of molecular alterations that lead to CRC, gene
expression has also been examined as a way to broaden knowledge on which
genes act as either oncogenes or tumor suppressors. Inter-individual variation of
gene expression levels has been found by tissue type. For many genes involved
or suspected to be involved in CRC formation, tumor tissues in the colon
compared to normal, adjacent tissue exhibited differential expression.30, 119, 120
However, some tumor tissues are difficult to obtain in order to examine gene
expression; therefore, it is important to develop other alternative, less invasive
methods to detect predictive biomarkers, particularly in blood. Because disease
status is believed to cause biochemical changes in blood, it is believed that these
changes caused by disease state will alter gene expression levels of certain
genes in blood cells.121, 122
To complement gene expression levels found in blood, some studies have
looked at relationships between gene expression levels in blood, normal tissue,
and tumor tissue. For example, in a study by Schena et al, investigators set out
to compare expression levels of several genes known to be a part of the
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nucleotide excision repair pathway (ERCC1, ERCC2, ERCC4, XPA, XPC,
XRCC1, XRCC3, APEX, OGG1, and MGMT) in normal and tumor tissues from
non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer
(HNSCC) patients with blood expression levels within the same person. First, it
was found that expression of these genes were generally higher in these target
tissues compared to blood. Second, moderately high (Pearson’s correlations
coefficient (r) of 0.5 to 0.7) positive correlations were found between gene
expression levels in blood and tumor tissue, tumor and normal tissue, and blood
and normal tissues. This finding highlights the potential usefulness of gene
expression levels detected in peripheral blood as a proxy for those levels in
tumor tissue. However, there are some drawbacks to using gene expression
levels in blood. For example, certain genes that are highly expressed in target
tissues may not necessarily be expressed in blood. Also, as gene expression is
dependent on cDNA concentration and quality, cDNA quality is dependent on
mRNA quality. Because mRNA degrades readily under suboptimal conditions,
gene expression levels may not be accurate, thus producing a spurious
relationship between gene expression levels and the outcome of interest (e.g.,
tumor formation). Relationships between gene expression levels in PBLs,
normal tissue, and adenoma polyp tissue has yet to be fully characterized for the
Period gene family.
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2.6.c Epigenetic markers in CRC
A 2012 report by the Centers for Disease Control and Prevention showed
that both eligible men and women (people over the age of 50 years) still fell short
of the Healthy People 2020 target CRC screening rate of 70.5%. 123 Because of
various factors that limit the ability of individuals to be screened for CRC, 124-128
several studies have undertaken the task of identifying epigenetic markers in
blood to assess risk of CRC. This method of assessing risk is particularly
favorable due to the fact that patient compliance is likely to increase due to the
ease of obtaining samples, thereby increasing the chance of detection of disease
in earlier stages and improving survival of CRC, especially among groups who
have low screening rates (e.g., racial/ethnic minorities, those without health
insurance).123 For example, in a 2007 pilot study by Cui, loss of imprinting (LOI),
an epigenetic event in the IGF2 gene, had a significant relationship with both
family history and personal history of CRC, suggesting that LOI of IGF2 could
serve as a predictor of CRC risk.129 Although LOI in this same gene could not be
evaluated in PBLs, another study by Woodson et al confirmed findings by Cui et
al by discovering that LOI in IGF2 was associated with a fivefold increased risk of
adenoma formation in women.130 More recently, a study by Tänzer et al
examined the epigenetic markers in SEPT9 in plasma and its association with
colorectal lesions (hyperplastic and adenomatous polyps). Researchers found
that prevalences in methylation differed by case status: 9% in controls; 29% of
subjects with precancerous lesions presented; and 73% of CRC patients.131
Additionally, as a result of common differential methylation patterns being found
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in tumor tissues (MLH1, p16, and methylated in tumors [MINT1, MINT2, and
MINT31]), a subtype of CRC has been identified: CpG Island Methylation
Phenotype (CIMP).132 This phenotype has been observed in a feature present in
variable amounts among adenomas (0-44%),133, 134 colon cancers (30-40%), and
distal and rectal cancers (3-12%).135-138 Discovery of this particular molecular
marker in CRC led to further understanding of alternative carcinogenesis
pathways, especially in terms of epigenetics. In regards to the epigenetic profiles
of PER1, PER2, and PER3, and their association with cancer risk, Chen et al
found deregulated expression of PER1, PER2, and PER3 in breast tumor tissues
compared to normal tissues. Furthermore, it was found that promoter
methylation influenced expression of these genes.30 No published studies have
looked at epigenetic markers of these genes in circulating blood cells and their
association with cancer risk in human populations.
2. 7 Summary and public health significance
Sleep disorders and variation of clock genes have demonstrated
associations with various health outcomes that can have a significant impact on
disease morbidity and mortality. Thus far, no study has assessed trends in sleep
disorders among veterans at a national level (Specific Aim 1), evaluated the
performance of PBL methylation levels in PER1, PER2, and PER3 on predicting
colorectal adenoma formation (Specific Aim 2), or has investigated the impact of
PER3 variation on adenoma risk (Specific Aim 3). Results derived from this
project not only would have the ability to identify vulnerable sub-populations
among Veterans who are at risk for the development of sleep disorders but also
22

will add to the scientific body of knowledge on adenoma formation and could
provide information on alternative strategies to identify colorectal adenoma cases
more effectively. Furthermore, disparities in CRC incidence and mortality
observed along racial/ethnic, gender, and geographic lines could partially be
explained by sleep disorders and/or differential methylation of certain clock
genes.
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Chapter 3
The National Veteran Sleep Disorder Study I: Descriptive Epidemiology and
Secular Trends, 2000-2010 1

Alexander M,1 Ray MA, Hébert JR, Youngstedt SD, Zhang H, Steck SE, Bogan
RK, Burch JB. Accepted to Sleep. Reprinted here with permission of publisher
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3.1 Abstract
Introduction: Sleep disturbances are alleged to be on the rise in the
United States (US), and veterans are particularly vulnerable to factors that elicit
or exacerbate sleep disorders. A large proportion of individuals affected by sleep
disorders are untreated and susceptible to accidents, injuries, long-term
sequelae (e.g., risk of cardiovascular disease, cancer, psychiatric disorders), and
earlier mortality. Few studies have examined the scope and magnitude of sleep
disorder diagnoses in the US. This serial cross-sectional study characterized
secular trends in diagnosed sleep disorders among veterans seeking care in the
US over an eleven-year span (Fiscal Years [FY] 2000-2010, N=9,798,034).
Materials and Methods: Data from the Veterans Administration Informatics and
Computing Infrastructure (VINCI) electronic medical record were accessed.
Cases were defined as patients with at least two outpatient sleep disorder
diagnoses at least 30 days apart using American Academy of Sleep Medicinespecified diagnostic codes. Age-adjusted annual prevalence was summarized by
sex, race, combat exposure, body mass index (kg/m2) and comorbid diagnoses
(cardiovascular disease, cancer, mental disorders). Results: Sleep apnea (47%)
and insomnia (26%) were the most common diagnoses among patients with
sleep disorders. There was a six-fold relative increase in total sleep disorder
prevalence over the study period. Post-traumatic stress disorder (PTSD) tripled
over the same time period, and veterans with PTSD had the highest prevalence
of sleep disorders (16%) among the comorbid conditions evaluated.
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Discussion: The results indicate a growing need for integration of sleep disorder
management in patient care and health care planning among veterans.

3.2 Introduction

Sleep is considered a physiological necessity, and inadequate sleep has
been associated with a wide range of adverse physical, mental and behavioral
outcomes.139 Previous studies have linked abnormal sleep duration or a sleep
disorder diagnosis with an increased incidence of: obesity, hypertension or
metabolic syndrome,53, 54, 140, 141 type 2 diabetes,53, 54, 142 cardiovascular
disease,52, 143, 144 stroke,145, 146 and cancer59, 60, 147-150 (although results for cancer
have been less consistent). Other studies have linked inadequate sleep with an
increased risk of psychiatric disorders (e.g., depression, post-traumatic stress
disorder [PTSD]), suicides, accidents, injuries, reduced quality of life, and
increased mortality.65, 139, 144, 151-158 The impacts of sleep disruption may be
mediated by several pathophysiological processes. These include sympathetic
nervous system hyperarousal, the disruption of circadian rhythms,
neuroendocrine or immune system dysregulation, inflammation, or metabolic
dysfunction.159-162

Military personnel are particularly vulnerable to sleep disturbances due to
the irregularity of their sleep/wake schedules, austere living conditions (e.g.,
extremes in temperature, noise, physical exertion), the stress of combat,
elevated rates of physical and psychological injury, and issues associated with
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post-deployment psychosocial reintegration.155, 163 Some of these conditions can
have residual effects well after the period of service is over. Therefore, veterans
can be plagued with multiple comorbidities that adversely influence sleep. Some
of these are over-represented in this population (e.g., musculoskeletal pain,
traumatic brain injury [TBI], smoking, substance abuse, hypertension,
depression, PTSD), while others mirror trends in the general US population (e.g.,
obesity, aging-related chronic disease).155, 156, 163-166 Consequently, sleep
disruption tends to be more common among veterans than in the general
population.155, 167-170 However, the national scope and characteristics of this
problem have not been described previously.

Despite evidence indicating that a lack of recognition or poor management
of sleep disorders can have myriad detrimental health consequences, many
patients can remain undiagnosed or untreated. Sleep disorders also may be
overlooked by physicians;171, 172 it was estimated that 80-90% of people with
clinically significant sleep-disordered breathing may remain undiagnosed.48 In a
representative sample of United States (US) adults, 26% of survey respondents
met criteria for high-risk obstructive sleep apnea173 in contrast to an estimated
prevalence of ~4-10%.64, 174, 175 An increasing trend in office visits for sleep
disorders was reported from 1999 to 2010, although it is unclear whether this
was due to a true increase in sleep disorder prevalence, increasing awareness
among physicians or their patients, or a combination of both.65 Differences in
sleep disorder case definitions, diagnostic criteria, population demographics, or
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the presence of co-morbid disease also can contribute to inconsistencies among
population-based sleep disorder estimates.

The co-occurrence of a sleep disorder with another co-morbid chronic
disease can predict poor quality of life62, 63 and earlier mortality relative to those
without a sleep disorder.144, 158, 176 This suggests that appropriate sleep disorder
management may improve quality of life and longevity. In some studies,
psychiatric disorders were predictive of sleep problems,55, 57 but in other cases
sleep disorders predicted increased risks for psychiatric disorders.177-179 This
apparent bi-directionality can complicate etiologic studies, but it also provides an
opportunity to implement more effective disease prevention and control
strategies through delivery of care that integrates appropriate sleep
management.

The information described above suggests that sleep disorder surveillance
can play an important role in patient care and long-term health care planning.
The characterization of trends in sleep disorder diagnoses among population
subgroups may allow clinicians to identify and target high-risk patients who would
benefit from management of sleep disorders and their sequelae. Most
epidemiologic studies examining sleep disorders have been limited to: highly
specific study populations (e.g., sleep clinics), relatively small population sizes, or
to a single type of sleep disorder or risk factor of interest. This study evaluated
all diagnosed sleep disorders in a national sample of US veterans who utilized
health services through the Veterans Health Administration (VHA) between
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Fiscal Years (FY) 2000 and 2010. The VHA is the largest integrated health care
system utilizing electronic medical records (EMRs) in the US.180 The approach
facilitated the examination of comorbid diseases that appear at higher rates
among veterans relative to the general population (e.g., PTSD and other mental
health disorders), as well as other individual or clinical factors that may influence
the onset or severity of sleep disorders.

3.3 Materials and Methods

Study Population

The study population consisted of all US veterans seeking care in the VHA
system between FY2000 and FY2010. Following regulatory approvals, outpatient
electronic medical records were accessed from MedSAS Dataset and VA
Corporate Data Warehouse files in the VINCI system. Requested data elements
from different VA system files were linked via social security number by a system
data manager, and then scrambled and replaced with a unique patient ID
number. Unique identifiers were inaccessible to the study investigators. Patients
excluded were: <18 years old on January 1 of each year, veterans who died in a
given fiscal year, spouses of veterans receiving care, and non-veterans.

Case Ascertainment

De-identified outpatient sleep disorder diagnoses were grouped according
to American Academy of Sleep Medicine (AASM) International Classification of
Sleep Disorder181 categories based on the following ICD-9 codes: apneas
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(organic sleep apnea [327.20-29], unspecified sleep apnea [780.57]); insomnias
(organic insomnias [327.00-09], insomnias, unspecified [780.51-780.52],
nonorganic insomnias [307.41-307.42]); other sleep disorders (other organic
sleep disorder [327.80], specific disorders of sleep of nonorganic origin [307.40307.49], other sleep disturbances, unspecified [780.50, 780.56, 780.59], other
sleep disorders [291.82, 292.85]); hypersomnias (organic hypersomnias [327.1019], nonorganic hypersomnias [307.43-.44], hypersomnias, unspecified [780.53780.54], other hypersomnias [347.00-347.01, 347.10-347.11]); parasomnias
(organic parasomnias [327.40-327.49], nonorganic parasomnias [307.46307.47]); sleep disruption movement disorders (organic sleep related movement
disorders [327.51-327.59], sleep related movement disorder, unspecified
[780.58], Restless Legs Syndrome [333.94]); and circadian rhythm disorders
(organic circadian rhythm sleep disorders [327.30-39], circadian rhythm sleep
disorder of nonorganic origin [307.45], disruption of 24 hour sleep-wake cycle,
unspecified [780.55]). Veterans were assigned a specific sleep disorder
diagnosis if their ICD-9 code occurred at least two times within a given fiscal
year, and the codes occurred thirty or more days apart.182 This method was used
to reduce the chance of misclassification due to “rule out” diagnoses, which are
ICD-9 codes that are entered by providers as the reason for ordering a diagnostic
test).
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Covariates

Data on covariates (age, race/ethnicity, sex, smoking status, body mass
index [BMI], income, comorbid diagnoses, sleep-related medical procedures,
service period [World War II, Korean War, Vietnam War, Persian Gulf War,
Operation Enduring Freedom/Operation Iraqi Freedom, and other], and combat
deployment) were retrieved from the VHA’s Vital Status and MedSAS databases.
Income was divided into three categories: less than $20,000 a year, $20,000 or
more, or unknown.58 Race and ethnicity were categorized as: Non-Hispanic
White, Non-Hispanic Black, Hispanic or Mexican, or “Other” (includes American
Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, or more
than one race). Missing race may be associated with lower rates of utilization and
fewer comorbid diseases,183 and thus was included as a separate category. Age,
in years, was calculated by subtracting the year of birth from the fiscal year of
contact with the VHA system and grouped into the following categories: 18-29
years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80
years or older. The twenty-one Veterans Integrated Service Networks (VISNs)
were collapsed into US census regions (VISNs 1-5: Northeast; 10-15 and 23,
Midwest; 6-9, 16, 17, South; 18-22, West). Those with missing or infrequent
VISN assignment were coded as unknown. BMI was calculated using height and
weight after excluding biologically implausible values; height was restricted to 4884 inches (122-213 cm), and weight was restricted to 75-500 pounds (34-227
kg).184 If a value for height was missing for a given record, any appearance of
height across the study period was used. Multiple entries for biologically
31

plausible values of weight were averaged within the fiscal year. BMI was
categorized into the following groups: underweight (<18.5 kg/m2), normal (18.5 to
<25 kg/m2), overweight (≥ 25 and < 30 kg/m2), and obese (≥30 kg/m2). The
underweight BMI category (<1% of study population) was combined with the
normal BMI group. Smoking status was assessed as described previously;185
data extracted from EMRs were compared to self-reported smoking data found in
the Veterans Aging Cohort Study (VACS-8) and VACS Virtual Cohort (VACS-VC)
study, which yielded kappa (κ) statistics of 0.66 and 0.61, respectively.
ICD-9 codes for comorbid disease were grouped into the following
categories: asthma (493), cancer (150-151, 153-155, 157, 162, 172, 174, 183,
185, 188-189, 191, 200, 202, 204-208.9), chronic obstructive pulmonary disease
(COPD) (496.0), cardiovascular disease (CVD) (390-459), diabetes (249-250),
fibromyalgia (729.1), gastrointestinal (GI) disease (520-579), human
immunodeficiency virus (HIV) (042-044), any mental disorder (290-319), renal
disease (508-589), and stroke (434.91) using the same criteria as described for
sleep disorders. Diagnoses of any mental disorder/mental disability were broken
down into the following subgroups for further analyses: depression [296.3], posttraumatic stress disorder [PTSD] [309.81], other mental health disorders with the
exception of PTSD and depression [e.g., psychosis [290-299], neurotic disorders,
personality disorders, and other nonpsychotic mental disorders [300–316],
mental disability [317–319]).
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Sleep-related medical procedures were ascertained using the following
current procedural technology (CPT) codes: 0203T (sleep study, unattended,
simultaneous recording of: heart rate, oxygen saturation, respiratory analysis and
sleep type; type II device), 0204T (sleep study, unattended, simultaneous
recording of: heart rate, oxygen saturation, respiratory analysis and sleep type;
type IV device), 95805 (multiple sleep latency or maintenance of wakefulness
testing, recording analysis and interpretation of physiological measurements of
sleep during multiple trials to assess sleepiness), 95806 (sleep study,
unattended, simultaneous recording of heart rate, oxygen saturation, respiratory
airflow and respiratory effort [EEG, thoracoabdominal movement] with Type III
device), 95807 (sleep study, simultaneous recording of ventilation, respiratory
effort, ECG or heart rate, and oxygen saturation, attended by a technologist),
99508 (home visit for polysomnography and sleep studies), G0398 (home sleep
study test [HST] with Type II portable monitor, unattended; minimum of 7
channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and
oxygen saturation), G0399 (HST with Type III portable monitor, unattended;
minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate, and 1
oxygen saturation), and G0400 (HST with Type IV portable monitor, unattended;
minimum of 3 channels).

Statistical Analysis

Annual sleep disorder prevalence was calculated as the proportion of total
sleep disorder diagnoses among eligible patients seeking care in the VHA
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system each fiscal year of the study. The numerator was defined as the total
number of primary sleep disorder diagnoses (or specific sleep disorder subtype)
that occurred during each fiscal year, and the denominator was the total number
of Veterans seeking care through the VHA during in the same fiscal year. Annual
prevalence was adjusted for possible changes in the age distribution over time
via direct age standardization using the 2000 US standard population and the
following age groups: 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80 years or
older.186 Absolute change in prevalence across the study period was defined as
the age-adjusted prevalence estimate for FY2000 subtracted from the ageadjusted prevalence for a given fiscal year. Two-sample proportion tests were
used to compare proportions of select factors in FY2000 and FY2010. Relative
changes were described as well. Prevalence and absolute change in prevalence
of sleep disorders were stratified by comorbid CVD and cancer diagnoses, as
they represent the top causes of mortality in the US, PTSD (a common diagnosis
among US Veterans), and other selected factors (sex, race, BMI, combat
exposure).

3.4 Results

Data for 9,786,778 veteran patients were included in the analysis (Table
3.1). Changes in the population from FY2000 to FY2010 are found in Table 3.2.
The following groups seeking care in the VHA system had the greatest absolute
increases over time: white veterans, those aged 60-69 years of age and over 80
years of age, unmarried veterans, those living in the southern region of the US,
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those who served in the Persian Gulf, obese veterans, current smokers, and
those with at least one mental health disorder. Figure 3.1 summarizes inclusions
and exclusions among patients who sought care through the VHA during the
study period. The study population was comprised primarily of men (93%) who
were married (54%). Among veteran patients diagnosed with at least one sleep
disorder (n of unique individuals: 751,502; n of diagnoses: 953,575), apneas
made up the majority of the diagnoses (47%, Figure 3.2); followed by insomnias
(26%), other sleep disorders (11%), hypersomnias (10%), movement disorders
(4%), parasomnias (3%), and circadian rhythm sleep disorders (0.1%). A majority
of those diagnosed with a sleep disorder were prescribed at least one sleep
medication (91%, data not shown), and the proportion of veterans with any sleep
disorder who were prescribed a sleep medication for the entire time they sought
VHA care within the study period ranged from 24% to 64% based on the number
of years of follow-up (data not shown).
Total sleep disorder diagnoses increased nearly six-fold over the elevenyear study period (Figure 3.3). Sleep apnea and insomnia prevalence exhibited
more than a seven-fold relative increase; age-adjusted sleep apnea prevalence
increased from 0.4% in FY2000 to 3.0% in FY2010 (a relative increase of 650%);
and age-adjusted insomnia prevalence increased from 0.2% in FY2000 to 1.5%
in FY2010 (a 650% relative increase). The prevalence of other sleep disorders
rose from 0.4% in FY2000 to 0.6% in FY2010 (a relative increase of 50%). Less
prevalent sleep disorder subtypes also increased over time (relative increases
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were: movement disorders: 1,048%; hypersomnias: 50%; parasomnias: 750%;
circadian rhythm disorders: 900%).
When the pattern of CPT codes for sleep procedures was inspected over
time, there was nearly a three-fold increase in the proportion of veteran patients
receiving a sleep-related procedure during the study period (0.2% in FY2000,
0.15% in FY2010). These proportions were considerably lower than diagnosed
sleep disorders; 1/6th to 1/13th of the observed prevalence of sleep disorder
diagnoses (Figure 3.4). CPT code 95807 (sleep study, simultaneous recording of
ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended
by a technologist for obstructive sleep apnea) was the most common code in
FY2000 (0.09%) and exhibited a small increase in prevalence by the end of the
study period (0.11%). CPT code 95806 (sleep study, unattended, simultaneous
recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory
effort) was the second most common procedure for sleep in FY2000 (0.05%), but
became the most common sleep procedure by FY2010 (0.30%), which
corresponds to a five-fold relative increase during the study period.
Veterans diagnosed with CVD had a larger absolute increase in sleep
apnea prevalence over time compared to veterans without CVD (5.8% and 1.6%,
respectively, Figure 3.5). Veterans with a CVD diagnosis also experienced an
absolute increase of insomnia prevalence (2.6%) more than double the absolute
increase among veterans without CVD (1.1%). Less common sleep disorder
subtypes also exhibited greater increases in sleep disorder prevalence among
those with CVD compared to those without CVD.
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Figure 3.6 presents changes in sleep disorder prevalence stratified by
cancer diagnosis. From FY2000 to FY2010, absolute increases sleep apnea and
insomnia prevalence were 3.7% and 2.0%, respectively, among veterans with
cancer. These absolute rate increases were greater than those recorded among
veterans who were not diagnosed with cancer (2.5% and 1.3%, respectively).
The remaining sleep disorders, with the exception of other sleep disorders,
exhibited larger increases in prevalence among those diagnosed with cancer
compared to those who were not.

Absolute changes in sleep apnea and insomnia over the study period
were the largest among veterans with PTSD (5.7% and 4.3%, respectively,
Figure 3.7). Smaller absolute increases in prevalence were observed for the
other sleep disorder subtypes, ranging from 0.02% (circadian rhythm disorders)
to 1.4% (other sleep disorders). Increases in sleep disorder subtypes over time
also were observed when the data were stratified by any mental health disorder
diagnosis (Figure 3.8), any depression diagnosis (Figure 3.9), or by mental
health disorders other than PTSD or depression (Figure 3.10), the largest
absolute increases were observed among those with sleep apnea.

Since combat can be related to development of PTSD and mental health
disorders, sleep disorder types were stratified by combat exposure as well
(Figure 3.11). In FY2010, the prevalence of sleep apnea and insomnia was 7.6
times and 6.3 times greater among combat veterans than noncombat veterans,
respectively. A similar pattern was observed for other sleep disorders; by 2010,
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there was a greater than seven-fold relative difference in total sleep disorder
prevalence among veterans or without combat experience.

Sleep disorder prevalence also was examined across BMI categories
(Figures 3.12a-3.12g). As expected, obese veterans (BMI ≥30 kg/m2)
experienced the largest increase (5.6%) in sleep apnea prevalence over time
(1.4% in FY2000, 7.0% in FY2010, Figure 3.12a). For insomnia, veterans who
were underweight or had normal BMI were the fastest growing group, with a
1.8% absolute increase in insomnia prevalence over time (0.3% in FY2000, 2.1%
in FY2010, Figure 3.12b).
Figure 3.13 presents sleep disorder prevalence stratified by gender. Male
veterans consistently had a higher prevalence of sleep apnea across the study
period. Female veterans either had the same or higher insomnia prevalence until
FY2008; thereafter, their rates were exceeded by those of male veterans.
Figures 3.14a-3.14g present trends in sleep disorder prevalence by race and
ethnicity. The prevalence of sleep apnea increased by 3.1% among Hispanic or
Mexican-American veterans over the study period (0.5% in FY2000 to 3.6% in
FY2010, Figure 3.14a), the largest increase among all race/ethnicity groups that
were evaluated. This group also had the highest prevalence of sleep apnea
among those studied. Veterans of unknown race/ethnicity had the largest
absolute increase (1.5%) in insomnia prevalence over time (0.3% in FY2000 to
1.8 % in FY2010, Figure 3.14b). The northeast and southern US regions
dominated increases observed in sleep disorder prevalence (Figures 3.15a3.15g). Specifically, the northeast region experienced the greatest absolute
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increases in sleep apnea, circadian rhythm disorders, parasomnias, and other
sleep disorders; whereas the southern region experienced increases in
insomnias, hypersomnias, and movement disorders.
3.5 Discussion
Results from this study indicate a notable rise in sleep disorder diagnoses,
especially for sleep apnea and insomnia, among US veterans who sought care
through the VHA from FY2000 through FY2010. The largest increases were
noted among veterans grouped according to certain demographic or clinical
characteristics, particularly those with PTSD, other mental health disorders, or
combat experience. The increasing trends observed in this study are consistent
with recent results from the National Ambulatory Medical Care Survey,65 where a
442% relative increase in office visits for sleep apnea was reported within a
similar time period (1999-2010).65 Those investigators acknowledged uncertainty
as to whether this represented a true increase in prevalence or if it was due to
heightened awareness, or a combination of factors. In 2004, veterans requiring
the use of breathing assistance equipment, such as continuous positive airway
pressure (CPAP) devices, were granted a service-connected disability benefit for
sleep apnea,187 which likely led to more veterans discussing sleep complaints
with their provider. However, increases in sleep disorders in the present study
were still observed prior to 2004; for example, apnea prevalence nearly doubled
between FY2000 and FY2003. Thus, the changes in sleep disorder prevalence
may not have been attributable solely to this administrative change. In addition,
rates for other sleep disorders not covered by the new disability rating also
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increased during the same period. Potential administrative bias was evaluated in
this study by examining trends in the utilization of clinical procedures (CPT
codes) for a sleep disorder diagnosis. The increases in prevalence observed for
sleep apnea or other sleep disorders did not match the magnitude or frequency
of diagnostic procedures for sleep that were recorded during the same period
(Figure 3.4). Some veterans may have sought medical care outside of the VHA
system.188 A previous investigation found that ~28% of veterans reported dualuse primary care (VA and non-VA).189 It is unknown whether such patients may
have preferentially sought care for sleep disorders at non-VHA facilities, but the
possibility cannot be excluded.
Other study uncertainties included a lack of information on the relative
proportions or influx of certified sleep physicians entering the VHA system during
the study period, or the extent to which updates in diagnostic criteria may have
influenced national trends in sleep disorder diagnoses among VHA providers.
The Accreditation Council on Graduate Medical Education (ACGME) initiated a
national sleep medicine training and certification program in 2004-2005,190 which
coincides with an increase in movement disorder diagnoses that were virtually
absent within the VHA medical record in prior years. This suggests that providers
may not have been trained to recognize these sleep disorders, and that veterans
may have been under-diagnosed for these conditions prior to the initiation of this
program. The trajectory of sleep disorder diagnoses over the study period
suggests that upward trends may continue beyond FY2010.
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Only a few studies have examined the prevalence of diagnosed sleep
disorders in a national sample, and several of those studies focused on
veterans.58, 183, 191 Prior investigations examined prevalence over a shorter time
frame (i.e., across one or two fiscal years) and/or evaluated a single type of sleep
disorder.58, 183, 191 In the current study, sleep apnea prevalence ranged from
0.4% to 3.0%, and insomnia prevalence ranged from 0.4% to 1.5%. A large
cohort study examining the relationship between sleep apnea and psychiatric
comorbidities reported a sleep apnea prevalence of 2.9% in a two-year period
(FY1998-FY2001),191 which exceeds the current study’s prevalence of 0.4% in
FY2001. Another investigation of sleep apnea among veterans ≥65 years old
utilized criteria similar to the present study (apnea cases were defined as
individuals with two outpatient diagnoses at least seven days apart, or one
inpatient diagnosis) and reported a sleep apnea prevalence of 4.4%.183
In the current study, age-adjusted sleep disorder prevalence did not differ
notably from crude rates (data not shown). When the current study population
was restricted to veterans ≥65 years old in FY2005, a sleep apnea prevalence of
3.6% was obtained, which is reasonably consistent with the previous studies.183,
191

A recent study of insomnia prevalence reported that 3.4% of veterans in

FY2010 had insomnia,58 which is more than double the prevalence found in the
current study in the same year (1.5%), but is consistent with the prevalence of
self-reported, physician-diagnosed insomnia that was recently described in a
nationally representative sample of the non-institutionalized US population
(1.2%).64 Inconsistencies in sleep disorder prevalence reported among different
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studies may be due to differences in case definitions (e.g., some studies used a
single occurrence of sleep disorder, which could overestimate case frequencies),
or a tendency for physicians to consider sleep impairment as a comorbid
symptom rather than a diagnosable disorder. Differences in population
demographics, comorbidities, or the time period studied also may contribute to
differences among published studies.
An increase in the prevalence of comorbid diseases may have contributed
to the increasing trend of sleep disorder diagnoses in the current study. Veterans
with cardiovascular disease, cancer, or mental health disorders (particularly
PTSD) experienced higher rates of sleep disorder diagnoses, a phenomenon that
has been observed in other populations.192-194 Veterans tend to have more
mental disorders compared to the general population,49, 144, 158, 176, 195-197 and the
co-occurrence of sleep disorders among those with PTSD or other psychiatric
disorders has been described previously.55, 57, 177-179, 198 The current study used
two occurrences of a PTSD diagnosis to identify veterans with PTSD, which has
a positive predictive value (PPV) of 82%, whereas a single diagnosis only had a
PPV of 75%.199 A 12-month prevalence study of DSM-IV disorders indicated that
3.5% of Americans had PTSD,200 which is similar to what was observed in the
present study during the same time period (FY2001-2003, 3.3-3.5%). PTSD
prevalence in this study also was consistent with the previously reported range
among veterans (2-17%).201 PTSD rates among veterans increased three-fold
over the eleven-year period, an absolute increase of almost 7%. It was the
greatest change among the mental health disorders evaluated, resulting in a
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PTSD prevalence of 10% by FY2010. The US’ multiple-front war effort that
occurred during this period likely contributed to this striking trend.202
Sleep disturbances are a significant component of PTSD; some studies
report that sleep disturbances can predict the development of PTSD or
depression.156 However, there is no clear consensus on the cause-effect
relationship between sleep disorders and psychiatric outcomes, and these
relationships may be bi-directional. For example, one study found that insomnia
preceded a current anxiety disorder in less than 20% of cases, that anxiety
appeared prior to insomnia in 44% of cases, and that these disorders cooccurred in approximately 40% of the cases.179 In a community-based sample of
adolescents with comorbid disorders, nearly 75% of subjects had anxiety prior to
their insomnia diagnosis, but prior insomnia was not associated with onset of
anxiety disorders in that study. Another investigation found that generalized
anxiety disorder and/or depression predicted increases in sleep problems over
time.177 This suggests that mental health disorders including PTSD may drive
increases in sleep disorder prevalence among veterans over time, although the
cross-sectional nature of the current study precludes an ability to infer causality.
Some studies indicate that sleep problems can persist even after amelioration of
PTSD or TBI symptoms, and that sleep improvement can facilitate better
responses to PTSD therapy.156 Others reported that successful treatment of
sleep apnea led to clinically meaningful improvements in PTSD symptoms.203
This highlights the importance of integrated strategies to ameliorate the long-term
combined impacts of mental and sleep-related disorders among VHA patients.
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An aging population has been frequently cited as a factor that could be
driving an increase in sleep disorder prevalence, particularly sleep apnea. The
use of age-standardization in the present study eliminated potential biases that
may have been introduced due to a shift in the age distribution among veteran
patients during the study period. Additionally, examination of changes within
specific age groups over time did not provide strong evidence for aging to explain
the observed trends. One unexpected finding was that sleep apnea prevalence
did not display a monotonic increase with age (data not shown), which has been
previously cited as a strong predictor of this disorder.204 Instead, the prevalence
of sleep apnea was highest among veterans 40-69 years old (data not shown).
Also, veterans in both the 40-49 and 50-59 age groups decreased by almost 7%,
while those aged 60-69 years increased by 6%. A previous study using either
clinical or laboratory-based criteria found that sleep apnea prevalence peaked
among middle-aged men.205 Discrepancies with other reports may be due to
differences in the criteria used to diagnose sleep apnea, the types of sleep apnea
included in the analyses (i.e., obstructive, central, and mixed), not accounting for
apnea therapy or other comorbid conditions, or a combination of these factors.
Other reasons to explain this finding also have been offered.58 First, older
veterans may be less likely to seek medical care for sleep disruption symptoms.
Moreover, as older veterans are more likely to be retired and the consequences
of sleep disruption may be less likely to interfere with daily activities. Although
veteran patients ≥80 years old exhibited the largest increase among age groups
over time (Table 3.2), they consistently had among the lowest rates of sleep
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disorder diagnoses in this population. Another explanation may be related to
provider practices.58 As more veterans return from recent conflicts, more PTSD
or other comorbid diagnoses arise, which may make it more likely that providers
diagnose these veterans with sleep disorders relative to older veterans.58
The obesity epidemic has been cited as another factor driving elevated
sleep disorder prevalence, and veterans have experienced increases in obesity
over time similar to the general population.165, 184 The increased prevalence of
obesity could account, in part, for increases in sleep apnea prevalence observed
in this study over time. Previous investigations have reported an increased
incidence of insomnia among obese individuals.206 However, the prevalence of
insomnia, the second-most common sleep disorder, rose fastest among veteran
patients in the normal BMI category, which suggests that other factors, such as
comorbid disease, may have had a predominant role in the trends observed in
the present study. Obesity and overweight are risk factors for many major chronic
diseases including CVD and cancer.
The strengths of this study included its large sample size, use of validated
methods for characterizing sleep outcomes and important covariates, and a
medical care system that ensured equal access to care. Furthermore, prevalence
estimates were age-adjusted to account for changes in age distribution, and CPT
codes for sleep procedures were examined to evaluate potential reporting bias
over time. This study consisted of serial cross-sectional data, and was therefore
subject to limitations typically associated with this type of study design, including
a lack of appropriate temporality between sleep disorder diagnoses and their
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predictors or modifiers. Furthermore, this investigation used only data from
veterans who sought care through the VHA system, resulting in an overrepresentation of older men with multiple comorbidities; thus potentially limiting
the generalizability of the results to other populations or to veterans who did not
utilize VHA services.207 Sleep disorder prevalence may have been overestimated
due to the distribution of age or comorbid disease in this population. However,
prevalence values were age-adjusted and stricter criteria for case definitions (two
diagnostic codes thirty or more days apart) were used to reduce potential
misclassification. This likely resulted in more conservative estimates of sleep
disorder prevalence relative to some other studies.
In summary, results from this study suggest that prevalence of sleep
disorder diagnoses increased among US veterans between FY2000 and
FY2010, which may have important implications for the health and longevity of
this population. Sleep disturbances are linked with increased mortality; for
example recent meta-analyses reported 10-12% increases in mortality risk
among those with short sleep duration.152, 153 Also, clinically significant, untreated
sleep apnea has been associated with increases in cardiovascular disease and
all-cause mortality.208 Since many sleep disorders are undiagnosed and therefore
untreated, clinicians should take special care to recognize high-risk patients.
Early identification and adequate treatment of individuals in the expanding
population of sleep disorder patients may lead to lower health care utilization and
improved quality of life. The cross-sectional nature of the current study design
precludes resolution of the complex interrelationships between obesity, comorbid
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disease, and sleep disorder diagnoses. Thus, further examination of these
issues using other study designs is warranted.
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Table 3.1. Characteristics of veterans who sought care through the Veterans
Health Administration (VHA) system: FY2000 to FY2010)
Total population
(N =9,786,778)1
Characteristic
Categories
N (%)
Female
664,880 (6.8)
Sex
Male
9,121,898 (93.2)
White
2,730,235 (27.9)
Black or African American
575,770 (5.9)
Hispanic
241,914 (2.5)
Race
Other
162,966 (1.7)
Unknown
6,075,893 (62.1)
Married
5,272,298 (53.9)
Not Married
3,755,025 (38.4)
Marital Status
Unknown
759,455 (7.8)
263,306 (2.7)
Asthma
Cancer
768,351 (7.9)
CVD
5,088,157 (52.0)
COPD
875,006 (8.9)
Diabetes
1,873,235 (19.1)
Fibromyalgia
114,406 (1.2)
GI Disease
3,077,094 (31.4)
2
HIV
33,755 (0.3)
Comorbid diseases
Hypertension
4,258,724 (43.5)
Mental disorder
3,469,637 (35.5)
Depression
420,284 (4.3)
PTSD
757,673 (7.7)
Other mental disorder
3,224,565 (33.0)
Renal Disease
430,010 (4.4)
Stroke
11,324 (0.1)
Abbreviations: COPD, Chronic Pulmonary Obstructive Disease; CVD,
Cardiovascular Disease; HIV, Human Immunodeficiency Virus; PTSD, PostTraumatic Stress Disorder. 1Number of veterans entering the system with age
and gender information; 2Disease categories are not mutually exclusive.

48

Table 3.2. Distribution and absolute percent change in population characteristics in veterans seeking care through the
Veterans Health Administration, FY2000 - FY2010

Characteristic

Sex

Race/Ethnicity
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Age Category
(years)*

Marital Status

Annual Income

Categories
Female
Male
White
Black/African American
Hispanic
Other
Unknown
18-29
30-39
40-49
50-59
60-69
70-79
80 years or older
Married
Not Married
Unknown
Less than 20K
More than 20K
Unknown

FY2000
(n=3,467,444)
(%, SE)

FY2010
(n=5,634,519)
(%, SE)

12.10 (0.02)
87.90 (0.02)
20.60 (0.02)
7.82 (0.01)
2.43 (0.01)
1.57 (0.01)
67.58 (0.03)
2.97 (0.01)
6.71 (0.01)
15.65 (0.02)
23.17 (0.02)
23.38 (0.02)
23.56 (0.02)
4.56 (0.01)
48.59 (0.03)
41.58 (0.03)
9.52 (0.03)
67.90 (0.03)
25.82 (0.02)
6.29 (0.01)

13.84 (0.01)
86.16 (0.01)
33.22 (0.02)
9.88 (0.01)
4.60 (0.01)
2.75 (0.01)
49.55 (0.02)
4.82 (0.01)
5.69 (0.01)
9.11 (0.01)
16.28 (0.02)
29.76 (0.02)
17.68 (0.02)
16.66 (0.02)
47.67 (0.02)
45.19 (0.02)
6.72 (0.02)
59.58 (0.02)
32.98 (0.02)
7.44 (0.01)

Percentage point
change from FY2000 to
FY2010
% (95% CI)
1.74 (-1.77, 5.25)
-1.74 (-5.25, 1.77)
12.62 (8.63, 16.62)
2.06 (-1.16, 5.28)
2.17 (-0.39, 4.73)
1.18 (-1.10, 3.46)
-18.03 (-22.25, -13.82)
1.85 (-0.79, 4.48)
-1.02 (-4.00, 1.97)
-6.54 (-10.02, -3.05)
-6.89 (-10.72, -3.06)
6.38 (2.37, 10.40)
-5.89 (-9.75, -2.02)
12.10 (8.88, 15.31)
-0.92 (-0.99, -0.85)
3.64 (3.57, 3.71)
-2.72 (-2.72, -2.72)
-8.31 (-12.51, -4.12)
7.16 (3.08, 11.24)
1.15 (-1.89, 4.20)
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Northeast
South
Midwest
VA Region
West
Unknown
World War II
Korean War
Vietnam War
Service Period
Persian Gulf War
OEF/OIF
Other
No
Combat Exposure
Yes
Normal
Overweight
BMI (kg/m2)
Obese
Unknown
Never
Former
Smoker Status
Current
Unknown
Asthma
Cancer
CVD
Comorbid
diseases
COPD
Diabetes
Fibromyalgia

6.77 (0.01)
19.31 (0.02)
7.83 (0.01)
9.93 (0.02)
56.16 (0.03)
11.26 (0.02)
6.55 (0.01)
26.76 (0.02)
28.88 (0.02)
0.23 (0.00)
26.32 (0.02)
83.72 (0.02)
16.28 (0.02)
14.76 (0.02)
20.81 (0.02)
18.24 (0.02)
46.19 (0.03)
2.36 (0.01)
8.07 (0.01)
2.09 (0.01)
87.49 (0.02)
1.25 (0.01)
1.81 (0.01)
22.07 (0.02)
2.56 (0.01)
7.90 (0.01)
0.38 (0.00)

7.18 (0.01)
23.87 (0.02)
9.06 (0.01)
11.56 (0.01)
48.33 (0.02)
3.00 (0.01)
4.48 (0.01)
18.42 (0.02)
50.83 (0.02)
1.83 (0.01)
21.44 (0.02)
83.75 (0.02)
16.25 (0.02)
15.73 (0.02)
27.43 (0.02)
30.80 (0.02)
26.04 (0.02)
17.45 (0.02)
17.73 (0.02)
20.48 (0.02)
44.35 (0.02)
1.66 (0.01)
1.83 (0.01)
23.47 (0.02)
2.15 (0.01)
9.66 (0.01)
0.74 (0.00)

0.41 (-2.65, 3.47)
4.56 (0.68, 8.44)
1.22 (-1.97, 4.42)
1.63 (-1.73, 5.00)
-7.83 (-12.11, -3.55)
-8.26 (-11.30, -5.21)
-2.07 (-4.98, 0.83)
-8.34 (-12.27, -4.42)
21.95 (17.77, 26.13)
1.60 (-0.17, 3.37)
-4.88 (-8.84, -0.91)
0.03 (-3.66, 3.72)
-0.03 (-3.72, 3.66)
0.97 (-2.67, 4.60)
6.63 (2.68, 10.58)
12.56 (8.63, 16.49)
-20.15 (-24.32, -15.98)
15.09 (12.05, 18.14)
9.66 (6.22, 13.09)
18.39 (15.31, 21.47)
-43.14 (-47.00, -39.28)
0.41 (-1.68, 2.50)
0.02 (-2.20, 2.24)
1.40 (1.34, 1.46)
-0.41 (-2.78, 1.96)
1.76 (-1.46, 4.98)
0.36 (-1.27, 1.99)

GI Disease
12.69 (0.02)
14.57 (0.01)
1.88 (-1.67, 5.43)
HIV
0.58 (0.00)
0.45 (0.00)
-0.13 (-1.76, 1.50)
Hypertension
16.02 (0.02)
19.48 (0.02)
3.46 (-0.28, 7.20)
Mental disorder
19.81 (0.02)
30.67 (0.02)
10.86 (6.90, 14.82)
Depression
2.16 (0.01)
3.41 (0.01)
1.25 (-1.19, 3.69)
PTSD
3.43 (0.01)
10.07 (0.01)
6.64 (3.70, 9.58)
Other
17.81 (0.02)
23.04 (0.02)
5.23 (1.39, 9.07)
Renal Disease
0.61 (0.004)
1.33 (0.005)
0.72 (0.71, 0.73)
Stroke
0.02 (0.00)
0.01 (0.00)
-0.01 (-0.68, 0.66)
*Not age-standardized. Abbreviations: FY, Fiscal Year; SE, Standard Error; CI, Confidence Interval; OEF/OIF,
Operation Enduring Freedom/Operation Iraqi Freedom; BMI, Body Mass Index; CVD, Cardiovascular Disease, COPD,
Chronic Obstructive Pulmonary Disease; GI, Gastrointestinal; HIV, Human Immunodeficiency Virus; PTSD, PostTraumatic Stress Disorder
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Figure 3.1. Flowchart of veterans who entered the Veterans Health Administration (VHA) system from FY2000 to FY2010

53

Figure 3.2. Proportions of sleep disorder subtypes diagnoses among all sleep disorder diagnoses (n of unique
individuals=751,502; n of diagnoses = 953,575), FY2000 – FY2010
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Figure 3.3. Age-adjusted prevalence of sleep disorders among United States Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.4. Age-adjusted prevalence of CURRENT PROCEDURAL TERMINOLOGY (CPT) CODES for sleep procedures
among all Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.5. Age-adjusted prevalence of sleep disorders by CARDIOVASCULAR DISEASE status among all Veterans
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.6. Age-adjusted prevalence rate of sleep disorders by CANCER status among all Veterans seeking care through
the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.7. Age-adjusted prevalence of sleep disorders by POST-TRAUMATIC STRESS DISORDER (PTSD) status
among all Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.8. Age-adjusted prevalence of sleep disorders by MENTAL DISORDER status among all Veterans seeking care
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.9. Age-adjusted prevalence of sleep disorders by DEPRESSION status among all Veterans seeking care
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.10. Age-adjusted prevalence of sleep disorders by OTHER MENTAL HEALTH DISORDER status among all
Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.11. Age-adjusted prevalence of sleep disorders by COMBAT EXPOSURE among all Veterans seeking care
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.12a. Age-adjusted prevalence of APNEAS by BODY MASS INDEX (BMI) groups among all Veterans seeking
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)

64

Figure 3.12b. Age-adjusted prevalence of INSOMNIAS by BODY MASS INDEX (BMI) groups among all Veterans
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)

65

Figure 3.12c. Age-adjusted prevalence of OTHER SLEEP DISORDERS by Body Mass Index (BMI) groups among all
Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.12d. Age-adjusted prevalence of HYPERSOMNIAS by Body Mass Index (BMI) groups among all Veterans
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.12e. Age-adjusted prevalence of MOVEMENT DISORDERS by Body Mass Index (BMI) groups among all
Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.12f. Age-adjusted prevalence of PARASOMNIAS by Body Mass Index (BMI) groups among all Veterans seeking
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.12g. Age-adjusted prevalence of CIRCADIAN RHYTHM DISORDERS by Body Mass Index (BMI) groups among
all Veterans seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.13. Age-adjusted prevalence of sleep disorders by gender among all Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010
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Figure 3.14a. Age-adjusted prevalence of APNEAS by race/ethnicity among all Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.14b. Age-adjusted prevalence of INSOMNIAS by race/ethnicity among all Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.14c. Age-adjusted prevalence of OTHER SLEEP DISORDERS by race/ethnicity among all Veterans seeking
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.14d. Age-adjusted prevalence of HYPERSOMNIAS by race/ethnicity among all Veterans seeking care through
the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.14e. Age-adjusted prevalence of MOVEMENT DISORDERS by race/ethnicity among all Veterans seeking care
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.14f. Age-adjusted prevalence of PARASOMNIAS by race/ethnicity among all Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.14g. Age-adjusted prevalence of CIRCADIAN RHYTHM DISORDERS by race/ethnicity among all Veterans
seeking care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15a. Age-adjusted prevalence of APNEAS by region among all Veterans seeking care through the Veterans
Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15b. Age-adjusted prevalence of INSOMNIAS by region among all Veterans seeking care through the Veterans
Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15c. Age-adjusted prevalence of OTHER SLEEP DISORDERS by region among all Veterans seeking care
through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15d. Age-adjusted prevalence of HYPERSOMNIAS by region among all Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15e. Age-adjusted prevalence of MOVEMENT DISORDERS by region among all Veterans seeking care through
the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15f. Age-adjusted prevalence of PARASOMNIAS by region among all Veterans seeking care through the
Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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Figure 3.15g. Age-adjusted prevalence of CIRCADIAN RHYTHM DISORDERS by region among all Veterans seeking
care through the Veterans Health Administration (VHA), FY2000 – 2010 (N= 9,786,778)
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The National Veteran Sleep Disorder Study II: Determinants of New Sleep
Disorders among United States Veterans 2
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4.1 Abstract

Introduction: Individuals with untreated or poorly managed sleep
disorders are vulnerable to an increased risk of chronic disease, a poor quality of
life, and earlier mortality. Sleep disturbances are common among veterans but
few studies have examined factors influencing sleep disorder diagnoses in this
population. This study identified risk factors for sleep disorder diagnoses among
United States veterans seeking care in FY2010 through the Veterans
Administration (VA) (N=5,492,156). Materials and Methods: De-identified
electronic medical record data were accessed, and incident sleep disorder
diagnoses were defined using American Academy of Sleep Medicine specified
ICD-9 codes. Unconditional multiple logistic regression was used to calculate
odds ratios (ORs) and 95% confidence intervals (CIs) that identified demographic
characteristics or pre-existing clinical conditions associated with a new sleep
disorder diagnosis, after adjustment for potential confounding. Results: There
were 128,679 new sleep disorder diagnoses in the study population (2.3% of all
patients). Conditions that resulted in the greatest adjusted odds of sleep disorder
onset included a pre-existing history of post-traumatic stress disorder (OR: 2.56
95% CI: 2.51-2.62), and obesity (OR: 2.41, 95% CI: 2.35-2.47). Patients with a
sleep disorder diagnosis also were more likely to have a pre-existing diagnosis
of: asthma, cancer, cardiovascular disease, chronic obstructive pulmonary
disease, diabetes, fibromyalgia, gastrointestinal illness, renal disease, or a
mental disorder compared to those without sleep disorders. Discussion: Results
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from this study can assist health care providers in identifying high risk patients
and in developing effective prevention and control strategies for sleep disorders.

4.2 Introduction

Sleep disorders arise due to complex circumstances that can include
genetic, environmental, behavioral, or psychosocial risk factors. They often cooccur with chronic diseases,179 but due to the interplay between sleep disorders
and other comorbidities, the directionality of the relationship is often unclear. For
example, sleep disorders can act as independent predictors of psychiatric
disorders,55, 57 but it also has been reported that psychiatric disorders are
predictive of sleep disturbances.177-179 The number of outpatient visits that occur
due to sleep complaints has been increasing over time.65 However, few studies
have examined the role of pre-existing diseases on sleep disorder development
while accounting for other known risk factors. Also, the use of hypnotics to treat
sleep disorders is a common practice, although this practice may have
deleterious health or safety consequences.209 Thus, alternative strategies for
sleep disorder prevention or treatment that target modifiable risk factors may be
prudent for health care providers to consider. The identification of predictive
factors also may allow clinicians to target high-risk groups that could benefit from
timely diagnosis and treatment.

Despite the presence of symptoms, a large proportion of those afflicted
with a sleep disorder can remain undiagnosed or untreated. For example, more
than 80% of individuals with clinically significant sleep apnea may remain
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undiagnosed.48 Under-diagnosis or poor sleep disorder management can have
adverse health consequences. Previous studies have linked sleep disorders with
higher health care utilization183 and increased risks for: obesity,53, 54 type 2
diabetes,53, 54 cardiovascular disease,52 cancer,59, 60, 147-150 or psychiatric
disorders.55-58 Alterations in circadian rhythms, neuroendocrine function, the
immune system and inflammation, or energy utilization and metabolism have
been suggested as biological processes altered by sleep disruption that can
influence chronic disease risks.159-162 The co-occurrence of a sleep disorder with
another comorbid chronic disease can predict a poor quality of life62, 63 and earlier
mortality relative to those with the comorbid disease but without a sleep
disorder.49, 144, 158, 176, 195, 196 These findings underscore the importance of
identifying independent sleep disorder risk factors, particularly in vulnerable
populations.

Sleep disruption is common among veterans and they tend to be
susceptible to the onset of sleep disorders.155, 156, 163, 165, 167, 168 However,
etiological models for new sleep disorder diagnoses have not been previously
described in a national sample of veterans or others in the United States (US).
To address this issue, this study identified independent risk factors for new sleep
disorder diagnoses, including an assessment of pre-existing chronic diseases or
disorders, by studying US veterans who utilized health services in FY2010
through the Veterans Health Administration (VHA), which is the largest integrated
health care system utilizing electronic medical records (EMRs) in the US.180 The
approach allowed for an examination of objectively determined pre-existing
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diseases that occur at higher rates among veterans relative to the general
population (e.g., PTSD, other mental health disorders), as well as demographic
characteristics that may influence sleep disorder onset.

4.3 Materials and Methods

Study Population

The study population consisted of all US veterans seeking care through
VHA system in FY2010, along with data extracted from EMRs since FY2000.
Following regulatory approvals, veteran’s outpatient records were accessed from
the MedSAS Dataset files and the VHA Corporate Data Warehouse (CDW) in the
Veterans Administration Informatics and Computing Infrastructure (VINCI)
system. Requested data elements from different VHA system files were linked by
social security number, and each patient’s social security number was then
scrambled and replaced with a unique subject identifying number. Thus, personal
identifying information was inaccessible to the study investigators;65, 179, 209 only
the VINCI data manager was able to access or link social security numbers with
unique subject identifiers. Patients <18 years old on January 1 as of FY2010,
spouses of veterans receiving care, non-veterans, or veterans who died in
FY2010 were excluded.

Case Ascertainment

De-identified outpatient sleep disorder diagnoses were grouped according
to the American Academy of Sleep Medicine’s International Classification of
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Sleep Disorders (see Table 4.1 for ICD-9 codes defining: sleep apnea, insomnia,
hypersomnia, circadian rhythm disorder, parasomnia, sleep disruption movement
disorder, and other sleep disorders).181 Veterans were assigned a specific sleep
disorder diagnosis if the diagnostic ICD-9 code appeared two or more times in
their medical record, and at least two codes in the record occurred thirty or more
days apart.182 The first occurrence of the diagnostic code was used to define the
date of the primary diagnosis. No previous sleep disorder diagnoses were
associated with these veterans dating back to October 1, 1999. Sleep disorders
that were neither sleep apnea nor insomnia were collapsed into one category
(other sleep disorders). The comparison group was comprised of all other eligible
veteran patients seeking care in FY2010 without a sleep disorder diagnosis.

Covariates

Covariate data (age, sex, smoking status, body mass index [BMI], income,
pre-existing diagnoses) were retrieved from VHA databases (Vital Status File and
MedSAS, Table 1). Annual income was grouped into three categories (less than
$20,000, $20,000 or more, or unknown) because a large proportion of veterans
had an annual income less than $20,000. Age in years was calculated by
subtracting the year of birth from 2010.

BMI was calculated by dividing weight in pounds (lbs) by height in inches
(in) squared and multiplying by a conversion factor of 703 to obtain BMI in
kilograms/meter2. Biologically implausible heights and weights were excluded
(height was restricted to 48-84 inches [122-213 cm], and weight was restricted to
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75-500 pounds [34-227 kg].184 If height was missing, any appearance of height
across FY2010 was used. Multiple entries for biologically plausible values of
weight were averaged. Those in the underweight BMI category (<1% of study
population) were merged into the normal BMI category, and the following
categories were used in the analysis: low-to-normal: <25 kg/m2, overweight: ≥25
to <30 kg/m2, and obese: ≥30 kg/m2.
The following ICD-9 codes dating back as far as October 1, 1999 were
used to categorize pre-existing disease: cancer (150-151, 153-155, 157, 162,
172, 174, 183, 185, 188-189, 191, 200, 202, 204-208.9), diabetes (249-250),
mental disorder or mental retardation (290-319, except for 309.81),
cardiovascular disease (CVD) (390-459), post-traumatic stress disorder (PTSD,
309.81), chronic obstructive pulmonary disease (COPD, 496.0), asthma (493),
fibromyalgia (729.1), gastrointestinal (GI) disease (520-579), human
immunodeficiency virus (HIV) infection (042-044), and renal disorder (580-589)
using the same criteria as described for sleep disorders. Smoking status (current,
former, never) was assessed as described previously.185 To validate smoking
status, data extracted from the EMRs was compared to self-reported smoking
data found in the Veterans Aging Cohort Study (VACS-8) and VACS Virtual
Cohort (VACS-VC) studies, which yielded kappa (κ) statistics of 0.66 and 0.61,
respectively.
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Statistical Analysis

All analyses were conducted using SAS 9.3 statistical software (Cary,
NC). Patients with a pre-existing sleep disorder diagnosis or without at least one
visit prior to FY2010 were excluded from the analysis. Veterans with a new sleep
disorder diagnosis concurrent with a first-time diagnosis of a chronic disease or
disorder of interest also were excluded; thus only pre-existing diseases and
disorders were evaluated.

Unconditional multivariable logistic regression was used to determine
whether pre-existing diseases or other personal or lifestyle factors were
associated with a first time sleep disorder diagnosis in 2010, after adjusting for
other covariates. Odds ratios (ORs) with corresponding 95% confidence intervals
(CIs) were used to assess the relationship between each variable of interest and
any sleep disorder diagnosis, or a specific sleep disorder subtype (sleep apnea,
insomnia, all other sleep disorders).

Initially, covariates listed in Table 4.2 were evaluated separately in relation
to each sleep disorder type, and those associated with a new diagnosis (p-value
≤0.20) were further evaluated in multivariable models. Models were further
reduced via manual backward selection, and all variables with a p-value ≤0.05
were retained in the final adjusted model.

Due to the high rate of missing race/ethnicity data (>50%), sensitivity
analyses were conducted to determine if estimates for the various risk factors
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differed among the following models: a.) race/ethnicity excluded entirely from the
model, b.) race/ethnicity included except those with missing race/ethnicity data,
and c.) including all those with race/ethnicity data; those with missing
race/ethnicity data were coded was as a separate category. Estimates in the
model did not appreciably change for each of these scenarios; therefore,
race/ethnicity was left out of the final models and not reported.

Because 8.4% of individuals with a new sleep disorder diagnosis had
multiple new sleep disorder subtypes, sensitivity analyses also were carried out
to examine any changes in estimates for models that included or excluded these
individuals. Among those with sleep apneas, 9% had some other sleep disorder
diagnosis, 3% had an insomnia diagnosis, and <0.1% had both insomnia and
some other sleep disorder diagnosis. Among those with insomnia, 5% had a
sleep apnea diagnosis, 6% had some other sleep disorder diagnosis, and
approximately 2% had sleep apnea and some other sleep disorder diagnosis.
Among those with ‘other’ primary sleep disorder diagnoses (hypersomnia,
circadian rhythm disorder, parasomnia, sleep disruption movement disorder,
other), 19% also had comorbid sleep apnea, 7% had comorbid insomnia, and 2%
had comorbid sleep apnea and insomnia. When sensitivity analyses were
performed among those with more than one sleep disorder either included or
excluded from the analysis, no major differences in the effect estimates (>10%)
were observed. Results presented below were based on data from individuals
with more than one sleep disorder.
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4.4 Results

In FY2010, 5,484,890 veterans were eligible for evaluation. The majority
of this analytical sample was male (93%) and married (55%) (Table 4.2), and had
an average age (± standard deviation) of 63±16 years. A total of 128,679 incident
sleep disorder cases were identified (2.3% of the study population).

Those with a new sleep disorder diagnosis were more likely to be male,
married, have a higher income, and a higher BMI compared to those without
sleep disorders (Table 4.2). Veterans with a new sleep disorder diagnosis were
six years younger than those without sleep disorders, on average (57±15 years
vs. 63±16 years, respectively). Additionally, those with a new sleep disorder had
a higher proportion of the following pre-existing diseases compared to those
without a sleep disorder: asthma, cancer, CVD, COPD, diabetes, fibromyalgia,
GI, or renal disease, or a mental health disorder. Similar differences were found
when comparing only veterans with sleep apnea, insomnia, or other sleep
disorders relative to those without a sleep disorder, except for patients with HIV
(see Tables 4.3, 4.4, and 4.5, respectively).

Table 4.6 presents crude and adjusted ORs for associations between
variables of interest and new sleep disorder diagnoses. Veterans with a new
sleep disorder diagnosis were more likely to be overweight or obese (OR: 1.36,
95% CI: 1.32, 1.39; OR: 2.41 95% CI: 2.35, 2.47, respectively) relative to those
without a sleep disorder. Veterans who developed a new sleep disorder also
were more likely to have a pre-existing diagnosis of PTSD or another type of
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mental health disorder compared to those without a sleep disorder (PTSD OR:
2.56, 95% CI: 2.51, 2.62; other mental health disorder OR: 2.16, 95% CI: 2.12,
2.20, Table 4.6). The next largest risk estimates for sleep disorders among those
with pre-existing diseases were: CVD (OR: 1.71, 95% CI: 1.68, 1.74),
fibromyalgia (OR: 1.69, 95% CI: 1.56, 1.83), COPD (OR: 1.67, 95% CI: 1.62,
1.72), asthma, (OR: 1.66, 95% CI: 1.59, 1.74), GI disorder (OR: 1.46, 95% CI:
1.44, 1.49), renal disorder (OR: 1.24, 95% CI: 1.19, 1.30), diabetes (OR: 1.06,
95% CI: 1.04, 1.08), and cancer (OR: 1.06, 95% CI: 1.02, 1.10) (Table 4.6). After
adjustment, male veterans and those who were married also had increased odds
of a new sleep disorder diagnosis (Table 4.6).

Veterans who developed sleep apnea had a two- or greater than six-fold
odds of being overweight or obese, respectively (Table 4.7), relative to veterans
without a sleep disorder. The following pre-existing diseases were each
associated with increased odds of a new sleep apnea diagnosis, in order of
decreasing magnitude of the effect estimates: PTSD (OR: 2.00, 95% CI: 1.94,
2.05), COPD (OR: 1.95, 95% CI: 1.88, 2.03), CVD (OR: 1.86, 95% CI: 1.82,
1.90), asthma (OR: 1.76, 95% CI: 1.66, 1.86), other mental health disorders (OR:
1.67, 95% CI: 1.63, 1.71), fibromyalgia (OR: 1.58, 95% CI: 1.41, 1.78), GI
disease (OR: 1.42, 95% CI: 1.38, 1.45), renal disorder (OR: 1.30, 95% CI: 1.23,
1.37), and diabetes (OR: 1.14, 95% CI: 1.12, 1.17) (Table 4.7). Veterans
diagnosed with sleep apnea were almost one-third less likely to have an HIV
infection (OR: 0.70, 95% CI: 0.58, 0.86) (Table 4.7).
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The odds of pre-existing PTSD or another mental health disorder were
four times or three times greater among those with new onset of insomnia,
respectively, relative to those without insomnia (Table 4.8). The next largest
association between a pre-existing disease and an insomnia diagnosis was
fibromyalgia (OR: 1.63, 95% CI: 1.42, 1.87), followed by: GI disease (OR: 1.50,
95% CI: 1.45, 1.55), CVD (OR: 1.46, 95% CI: 1.41, 1.51), asthma (OR: 1.27,
95% CI: 1.15, 1.40), COPD (OR: 1.24, 95% CI: 1.17, 1.31), renal disorder (OR:
1.23, 95% CI: 1.13, 1.34), and cancer (OR: 1.16, 95% CI: 1.09, 1.25) (Table
4.8). Unlike the association between diabetes and any new sleep disorder, those
with diabetes were less likely to be diagnosed with insomnia (OR: 0.84, 95% CI:
0.81, 0.88, Table 8).

Finally, veterans with other sleep disorders were nearly two times more
likely to be overweight or obese (Table 4.9). Similar to insomnia, pre-existing
PTSD had the largest association with other sleep disorder diagnoses (OR: 3.16,
95% CI: 3.04, 3.29), followed by: other mental health disorders (OR: 2.44, 95%
CI: 2.36, 2.53), fibromyalgia (OR: 1.89, 95% CI: 1.65, 2.17), asthma (OR: 1.66,
95% CI: 1.53, 1.81), CVD (OR: 1.65, 95% CI: 1.60, 1.71), COPD (OR: 1.61, 95%
CI: 1.52, 1.71), GI diseases (OR: 1.54, 95% CI: 1.49, 1.60), and renal disorder
(OR: 1.19, 95% CI: 1.09, 1.29) (Table 4.9).

4.5 Discussion
This study identified several determinants of new sleep disorder
diagnoses in a national sample of veterans. Non-disease determinants of a new
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sleep disorder diagnosis included: male sex, being married, and being
overweight or obese. Pre-existing diseases that were associated with a new
sleep disorder diagnosis included: asthma, cancer, CVD, COPD, diabetes,
fibromyalgia, GI disease, renal disorder, and mental health disorders, especially
PTSD. Several disease risk factors identified in this study were consistent with
findings from prior investigations among veterans,179, 210, 211 namely the link
between PTSD and sleep disorders.170, 191, 212 Knowledge of risk factors for new
sleep disorder diagnoses, particularly pre-existing diseases, provides an
opportunity to improve the quality of life among veterans who may be at a higher
risk for developing long-term sequelae of sleep disorders. This may include
several types of chronic disease or psychiatric disorder,52-58 and early mortality49,
59, 144, 158, 176, 195, 196

relative to those without sleep disorders.

There were some unexpected findings in this study. First, the
development of a new sleep disorder was less likely with increasing age, which is
contrary to some reports,213 although there have been inconsistencies. For
example, older age was a risk factor for sleep apnea in one previous study,204
whereas results from another study indicated that sleep apnea prevalence
peaked among middle-aged rather than older men.205 Another study among
veterans over 65 years of age found that increasing age was protective of new
sleep apnea diagnoses.183 Results from the present study were consistent with a
previous study that examined correlates of prevalent insomnia among veterans in
FY2010 after adjusting for several confounders. A lower prevalence of insomnia
among older veterans was observed, and multivariable analyses did not identify
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an association between age and insomnia.58 Because those with prevalent sleep
disorders were excluded from the present study, it is possible that older veterans
who were retained in the analysis tended to be healthier and less likely to be
diagnosed with a sleep disorder relative to younger veterans. An alternative
explanation for this observation may be a tendency for medical providers to
overlook sleep problems as symptoms of another comorbid disease rather than a
separate disorder requiring diagnosis, or because older veterans are less likely to
discuss sleep complaints with their physician. Although the relatively small
reduction in odds with increasing age was statistically significant, the clinical
significance of this observation is uncertain. Finally, middle age veterans may
have other attributes that differ from older veterans, such as a greater likelihood
of participation in the recent Middle East war effort.
Another unexpected finding was the inverse association of tobacco
consumption with sleep disorder diagnosis. Nicotine acts as a stimulant and it
interferes with the release of neurotransmitters that play a key role in regulation
of the sleep-wake cycle, and thus may be involved in the onset of sleep
disturbances.214, 215 Because smoking status was assessed within the same time
period as the sleep disorder diagnosis, these associations could be attributed to
reverse causation. That is, individuals who were diagnosed with a new sleep
disorder may have avoided smoking in an effort to improve their sleep and
health.
An unexpected protective association between HIV infection and sleep
apnea also was observed. In an era where HIV patients with antiretroviral
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therapy are living longer, this subpopulation may be experiencing increased
morbidity from conditions unrelated to HIV infection. Few large-scale studies
have examined this issue. A positive association between HIV infection and
sleep apnea was recently observed in a large cohort study.216 However, a prior
study among veterans observed a three-fold lower prevalence of sleep apnea
among those with HIV compared to those without HIV.217 The investigators
reported that veterans with HIV had fewer sleep apnea risk factors, but noted that
sleep apnea also may be underdiagnosed in this population.
Veterans have elevated rates of mental health disorders compared to the
general population. The prevalence of pre-existing PTSD in the current study
population (5.7%) falls within the range of previously reported rates among
veterans (2-17%).201 Results from the current study suggest that pre-existing
PTSD or other mental health disorders may have a considerable role in the
development of a new sleep disorder, more so than other pre-existing medical
conditions. Those with a new diagnosis of any sleep disorder, sleep apnea,
insomnia, or other sleep disorders were two to four times more likely to have preexisting PTSD; one of the strongest associations observed. These observations
are consistent with results reported in a prospective study of incident chronic
insomnia, which was defined as not having insomnia at baseline and
subsequently developing insomnia that lasted at least one year.218 Associations
between psychiatric disturbances, especially anxiety disorders (e.g., PTSD), and
sleep disorders have been described previously,55, 57, 58, 177-179, 191, 212 although
the inter-related nature of these conditions may have produced inconsistencies in
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terms of cause and effect.219 Relationships between sleep and psychiatric
disturbances may be bi-directional, and also may be subject to misclassification
bias if symptomatic patients remain undiagnosed. Through careful selection of
veterans with and without pre-existing diseases, the design of this study allowed
for sleep disorder risk factors to be assessed while preserving the temporality of
the relationship. Previous investigators have observed that anxiety disorders
tended to precede an insomnia diagnosis rather than co-occur or occur as a
consequence of insomnia.177-179 For example, anxiety appeared prior to insomnia
in 44% of people diagnosed with insomnia, which is higher than the proportion of
those who developed an anxiety disorder after insomnia diagnosis (20%), or
those who had co-occurring diagnoses (40%).179 Also, sleep disturbances have
persisted despite successful treatment of PTSD,220 suggesting that although
disturbed sleep is a core PTSD symptom, it also may be a pre-disposing factor,
or may develop as a separate disorder during the course of PTSD.
While there is a growing literature on the role of anxiety disorders in the
development of insomnia, little is known about their role in the development of
sleep apnea. A recent study found an association between higher PTSD
symptom severity and risk for obstructive sleep apnea (OSA) among Iraq and
Afghanistan veterans presenting at a VHA outpatient PTSD clinic.221 In the
current study, veterans with a new sleep apnea diagnosis were nearly twice as
likely to have pre-existing PTSD after controlling for several other known
predictors including BMI. The underlying mechanism has yet to be fully
elucidated, but it has been suggested that those afflicted with PTSD may lack the
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ability to suppress anxiety while dreaming, resulting in an increase in the
frequency of sleep disordered breathing events.222 This may have clinical
implications since PTSD reduces adherence to continuous positive airway
pressure (CPAP) therapy,223 and untreated sleep apnea has been associated
with numerous adverse sequelae including all-cause mortality and cardiovascular
disease.208 Longitudinal studies are needed to confirm this association while
accounting for sleep apnea treatments.
While it is possible for underlying disease processes to influence
subsequent sleep disorder development, there are other explanations for the
observed relationships. First, veterans with a chronic disease or mental health
disorder are more likely to use VHA care, thus increasing their likelihood of being
diagnosed with a sleep disorder. A study of utilization of VHA non-mental health
services indicated that veterans with PTSD or mental disorders other than PTSD
had 91% and 55% higher utilization, respectively, than those without a mental
disorder. The increased utilization may be related to combat exposure, which has
been associated with both mental and physical ailments, and the combination of
these conditions increases the likelihood of a veteran seeking services in a
primary care setting.224 It also is possible that VHA clinicians in primary care
settings are more likely to look for sleep issues when evaluating veterans with
mental health disorders. In 2005, the VHA expanded its capacity for mental
health services, which included the integration of mental health providers into
primary care settings.225 However, one study found that mental health status and
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primary care visits had only a modest effect on utilization of non-mental health
services.224
Veterans are experiencing an obesity epidemic similar to the general
population,165, 184 and results from the present study suggest that weight
management may provide an opportunity to prevent sleep disorders associated
with this condition. Obese veterans in the present study were about twice as
likely to receive a diagnosis of any sleep disorder, sleep apnea, or other sleep
disorders relative to non-obese individuals. However, the ORs for insomnia
marginally decreased as BMI increased, which is inconsistent with previous
reports.206, 218 This suggests that current BMI may not predict insomnia or that
other factors, such as unstudied comorbid conditions, or their treatment, could
influence the relationship between BMI and insomnia. For example, psychiatric
disorders increase the risk of obesity,226-228 and both factors increase the
likelihood of sleep disturbances. Explaining the nature of these complex
relationships requires further examination using either prospective or
experimental study designs.
Strengths of this study included a large sample size, the use of validated
measures for outcomes and important variables of interest, and a medical care
system that ensured equal access to care. The robust sample size provided
ample statistical power and tended to reduce standard errors of the effect
estimates (inflated standard errors can arise due to multicollinearity when
multiple risk factors with overlapping effects are evaluated). Since the objective
was to examine multiple sleep disorder risk factors, steps were taken to reduce
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the likelihood of multicollinearity, including careful a priori consideration of
variables to be included in the analyses. For example, combat exposure is
associated with the onset of mental health disorders; therefore, combat and
mental health disorders were not simultaneously included in the analyses.
Similarly, analyses of hypertension, metabolic syndrome, and stroke were
avoided since they have risk factors that overlap with CVD.
Some limitations are also noteworthy. Information on medication use or
substance abuse was not included in the analysis, which may have impacted the
strength or direction of the reported associations. Data on treatment efficacy or
management of specific pre-existing diseases also was not available, which may
have impacted sleep disorder onset. Caution is advised when interpreting small,
unanticipated effects since residual confounding may have been present, and
since statistical significance does not always correspond to clinical significance.
Finally, this investigation was limited to veterans seeking care through the VHA
system, who tend to be older males with multiple comorbidities.207 This limits the
potential for generalizability to all veterans, or to the general US population. It is
also possible that multiple synchronous sleep disorder diagnoses could have
influenced the results (~8% of new sleep disorder diagnoses in FY2010).
However, no appreciable change in the risk estimates was observed after
removal of individuals with multiple sleep disorder diagnoses from the analysis.
In summary, sleep disorders are reportedly on the rise and these
conditions can have long-term deleterious health consequences.65 In this study, a
predictive analysis of factors influencing sleep disorder onset was performed
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among US veterans seeking care in the VHA system in FY2010. The findings
suggest that early identification and targeting of high-risk groups, such as
veterans with PTSD or elevated BMI, may lead to more focused sleep disorder
prevention or management strategies that may convey lower health care
utilization, improved quality of life, and reduced mortality risk to those individuals.
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Table 4.1. International Classification of Sleep Disorders181
Sleep Disorder

ICD-9 codes

Sleep Apnea

Organic Sleep Apnea (327.20-29)
Unspecified Sleep Apnea (780.57)

Insomnia

Hypersomnia

Circadian Rhythm Disorder

Parasomnia

Sleep Disruption Movement
Disorders

Other Sleep Disorders

Organic Insomnias (327.00-09)
Insomnias, unspecified (780.51-780.52)
Non Organic Insomnias (307.41307.42)
Organic Hypersomnias (327.10-19)
Non Organic Hypersomnias (307.43.44)
Hypersomnias, unspecified (780.53780.54)
Other Hypersomnias (347.00-347.01,
347.10-347.11)
Organic Circadian Rhythm Sleep
Disorders (327.30-39)
Circadian Rhythm Sleep disorder of
Non Organic (307.45)
Disruption of 24 hour sleep wake cycle,
unspecified (780.55)
Organic Parasomnias (327.40-327.49)
Non Organic Parasomnias (307.46307.47)
Organic sleep related movement
disorders (327.51-327.59)
Sleep Related Movement Disorder,
unspecified (780.58)
Restless Legs Syndrome (333.94)
Other Organic Sleep Disorder (327.80)
Specific disorders of sleep of Non
Organic origin (307.40-307.49)
Other Sleep disturbances, unspecified
(780.50, 780.56, 780.59)
Other Sleep Disorders (291.82, 292.85)
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Table 4.2. Characteristics of United States veterans with and without a primary sleep disorder diagnosis who sought
care in the Veterans Health Administration (VHA) in FY2010
Characteristic

Classification

Age (years)

Mean (SD)

Sex

Male
Female
Not Married
Married
Unknown
<$20,000
≥$20,000
Unknown
Normal
Overweight
Obese
Unknown
Never
Former
Current
Unknown
No
Yes
No
Yes
No

Marital Status

Annual Income
106

BMI (kg/m2)

Tobacco Use

Asthma
Cancer
CVD

Total Population
(N = 5,484,890)1
63 (16)
N (%)
5,119,403 (93)
365,487 (7)
2,205,522 (40)
3,014,017 (55)
265,351 (5)
3,012,254 (55)
2,144,375 (39)
328,261 (6)
964,244 (18)
1,712,320 (31)
1,705,000 (31)
1,103,326 (20)
920,168 (17)
1,249,110 (23)
956,402 (17)
2,359,210 (43)
5,409,347 (99)
54,461 (1)
5,260,565 (96)
163,904 (3)
3,371,891 (61)

Sleep Disorder
(N = 128,679)1
57 (15)
N (%)
120,560 (94)
8,119 (6)
50,710 (39)
73,601 (57)
4,368 (3)
71,837 (56)
56,711 (44)
131 (0.1)
15,087 (12)
36,999 (29)
74,119 (58)
2,474 (2)
30,458 (24)
37,395 (29)
30,192 (23)
30,634 (23)
123,611 (96)
2,961 (2)
122,332 (95)
4,100 (3)
52,173 (41)

No Sleep Disorder
(N = 5,356,211)1
63 (16)
N (%)
4,998,843 (93)
357,368 (7)
2,154,812 (40)
2,940,416 (55)
260,983 (5)
2,940,417 (55)
2,087,664 (39)
328,130 (6)
949,157 (18)
1,675,321 (31)
1,630,881 (30)
1,100,852 (21)
889,710 (17)
1,211,715 (23)
926,210 (17)
2,328,576 (43)
5,285,736 (99)
51,500 (1)
5,138,233 (96)
159,804 (3)
3,319,718 (62)

p-value2
<0.01
<0.01
<0.01

<0.01

<0.01

<0.01

<0.01
<0.01

Table 4.2. Characteristics of United States veterans with and without a primary sleep disorder diagnosis who sought
care in the Veterans Health Administration (VHA) in FY2010
Total Population
Sleep Disorder
No Sleep Disorder
p-value2
(N = 5,484,890)1
(N = 128,679)1
(N = 5,356,211)1
Yes
1,820,644 (33)
58,582 (46)
1,762,062 (33)
No
5,246,370 (96)
116,863 (91)
5,129,507 (96)
<0.01
COPD
Yes
177,253 (3)
7,160 (6)
170,093 (3)
No
4,547,121 (83)
95,089 (74)
4,452,032 (83)
<0.01
Diabetes
Yes
813,430 (15)
26,189 (20)
787,241 (15)
No
5,458,590 (99)
126,501 (98)
5,332,089 (99)
<0.01
Fibromyalgia
Yes
13,243 (0.2)
924 (0.7)
12,319 (0.2)
No
4,606,681 (84)
86,897 (68)
4,519,784 (84)
<0.01
GI disease
Yes
653,361 (12)
26,831 (21)
626,530 (12)
No
5,465,179 (99)
63,016 (49)
5,336,966 (99)
0.28
HIV Infection
Yes
17,921 (0.3)
49,688 (39)
17,518 (0.3)
None
4,083,480 (75)
55,400 (43)
4,028,080 (75)
<0.01
3
PTSD
Mental disorder
310,470 (6)
16,723 (13)
293,747 (5)
Other4
748,787 (14)
29,587 (23)
719,200 (13)
No
5,338,066 (97)
123,048 (96)
5,215,018 (97)
<0.01
Renal disorder
Yes
95,334 (2)
3,107 (2)
92,227 (2)
Note: All numbers are presented as counts and percentages unless otherwise indicated. 1Cells may not add up to total
for column due to missing values; 2Chi-square test for differences in proportions for categorical variables or Student’s ttest for differences in means for continuous variables; 3Any diagnosis of PTSD, does not exclude other pre-existing
mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety disorders, emotional and
behavioral disorders, and mood disorders). Abbreviations: BMI: body mass index; CVD, cardiovascular disease;
COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human immunodeficiency virus; PTSD, posttraumatic stress disorder
Characteristic

Classification
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Table 4.3. Characteristics of United States veterans with and without a primary SLEEP APNEA diagnosis who sought
care in the Veterans Health Administration (VHA) in FY2010
Characteristic

Classification

Age (years)

Mean (SD)

Sex

Male
Female
Not Married
Married
Unknown
<$20,000
≥$20,000
Unknown
Normal
Overweight
Obese
Unknown
Never
Former
Current
Unknown
No
Yes
No
Yes
No

Marital Status

Annual Income
108

BMI (kg/m2)

Tobacco Use

Asthma
Cancer
CVD

Total Population
(N = 5,426,333)1
63 (16)
N (%)
5,065,833 (94)
360,500 (7)
2,178,818 (40)
2,984,256 (55)
263,259 (5)
2,977,794 (55)
2,120,340 (39)
328,199 (6)
952,469 (18)
1,690,661 (31)
1,681,033 (31)
1,102,170 (20)
906,634 (17)
1,232,979 (23)
939,838 (17)
2,346,882 (43)
5,352,660 (99)
53,316 (1)
5,205,036 (96)
161,911 (3)
3,344,548 (62)

Apneas
(N = 70,122)1
58 (13)
N (%)
66,990 (96)
3,132 (4)
24,006 (34)
43,840 (63)
2,276 (3)
37,377 (53)
32,676 (47)
69 (0.1)
3,312 (5)
15,340 (22)
50,152 (72)
1,318 (2)
16,924 (24)
21,264 (30)
13,628 (19)
18,306 (26)
66,924 (95)
1,816 (3)
66,803 (95)
2,107 (3)
24,830 (35)

No Apneas
(N = 5,356,211)1
63 (16)
N (%)
4,998,843 (93)
357,368 (7)
2,154,812 (40)
2,940,416 (55)
260,983 (5)
2,940,417 (55)
2,087,664 (39)
328,130 (6)
949,157 (18)
1,675,321 (31)
1,630,881 (30)
1,100,852 (21)
889,710 (17)
1,211,715 (23)
926,210 (17)
2,328,576 (43)
5,285,736 (99)
51,500 (1)
5,138,233 (96)
159,804 (3)
3,319,718 (62)

p-value2
<0.01
<0.01
<0.01

<0.01

<0.01

<0.01

<0.01
0.41
<0.01

Table 4.3. Characteristics of United States veterans with and without a primary SLEEP APNEA diagnosis who sought
care in the Veterans Health Administration (VHA) in FY2010
Total Population
Apneas
No Apneas
p-value2
(N = 5,426,333)1
(N = 70,122)1
(N = 5,356,211)1
Yes
1,796,450 (33)
34,388 (49)
1,762,062 (33)
No
<0.01
5,192,395 (96)
62,888 (90)
5,129,507 (96)
COPD
Yes
174,210 (3)
4,117 (6)
170,093 (3)
No
<0.01
4,500,153 (83)
48,121 (69)
4,452,032 (83)
Diabetes
Yes
804,090 (15)
16,849 (24)
787,241 (15)
No
<0.01
5,401,182 (99)
69,093 (99)
5,332,089 (99)
Fibromyalgia
Yes
12,754 (0.2)
435 (0.6)
12,319 (0.2)
No
<0.01
4,567,647 (84)
47,863 (68)
4,519,784 (84)
GI disease
Yes
640,749 (12)
14,219 (20)
626,530 (12)
No
<0.01
5,406,918 (99)
69,952 (99)
5,336,966 (99)
HIV Infection
Yes
17,659 (0.3)
141 (0.2)
17,518 (0.3)
None
<0.01
4,063,737 (75)
35,657 (51)
4,028,080 (75)
3
PTSD
Mental disorder
302,482 (6)
8,735 (12)
293,747 (5)
Other4
733,366 (14)
14,166 (20)
719,200 (13)
No
<0.01
5,281,718 (97)
66,700 (95)
5,215,018 (97)
Renal disorder
Yes
94,106 (2)
1,879 (3)
92,227 (2)
Note: All numbers are presented as counts and percentages unless otherwise indicated
1Cells may not add up to total for column due to missing values; 2Chi-square test for differences in proportions for
categorical variables or Student’s t-test for differences in means for continuous variables; 3Any diagnosis of PTSD, does
not exclude other pre-existing mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety
disorders, emotional and behavioral disorders, and mood disorders). Abbreviations: BMI: body mass index; CVD,
cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human
immunodeficiency virus; PTSD, post-traumatic stress disorder
Characteristic

Classification
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Table 4.4. Characteristics of United States veterans with and without a primary INSOMNIA diagnosis who sought care
in the Veterans Health Administration (VHA) in FY2010
Characteristic

Classification

Age (years)

Mean (SD)

Sex

Male
Female
Not Married
Married
Unknown
<$20,000
≥$20,000
Unknown
Normal
Overweight
Obese
Unknown
Never
Former
Current
Unknown
No
Yes
No
Yes
No

Marital Status

Annual Income
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BMI (kg/m2)

Tobacco Use

Asthma
Cancer
CVD

Total Population
(N = 5,394,500)1
63 (16)
N (%)
5,033,736 (93)
360,764 (7)
2,173,430 (40)
2,958,722 (55)
262,348 (5)
2,963,517 (55)
2,102,812 (39)
328,171 (6)
957,541 (18)
1,690,139 (31)
1,645,260 (31)
1,101,560 (20)
898,691 (17)
1,222,063 (23)
937,535 (17)
2,336,211 (43)
5,322,840 (99)
52,166 (1)
5,174,528 (96)
161,055 (3)
3,338,285 (62)

Insomnia
(N = 38,289)1
55 (17)
N (%)
34,893 (91)
3,396 (9)
18,618 (49)
18,306 (48)
1,365 (4)
23,100 (60)
15,148 (40)
41 (0.1)
8,384 (22)
14,818 (39)
14,379 (38)
708 (2)
8,981 (23)
10,348 (27)
11,325 (30)
7,635 (20)
37,104 (97)
666 (2)
36,295 (95)
1,251 (3)
18,567 (48)

No Insomnia
(N = 5,356,211)1
63 (16)
N (%)
4,998,843 (93)
357,368 (7)
2,154,812 (40)
2,940,416 (55)
260,983 (5)
2,940,417 (55)
2,087,664 (39)
328,130 (6)
949,157 (18)
1,675,321 (31)
1,630,881 (30)
1,100,852 (21)
889,710 (17)
1,211,715 (23)
926,210 (17)
2,328,576 (43)
5,285,736 (99)
51,500 (1)
5,138,233 (96)
159,804 (3)
3,319,718 (62)

p-value2
<0.01
<0.01
<0.01

<0.01

<0.01

<0.01

<0.01
<0.01
<0.01
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Yes
1,776,727 (33)
14,665 (38)
1,762,062 (33)
No
<0.01
5,165,002 (96)
35,495 (93)
5,129,507 (96)
COPD
Yes
171,897 (3)
1,804 (5)
170,093 (3)
No
<0.01
4,483,727 (83)
31,695 (83)
4,452,032 (83)
Diabetes
Yes
792,417 (15)
5,176 (14)
787,241 (15)
No
<0.01
5,369,607 (99)
37,518 (98)
5,332,089 (99)
Fibromyalgia
Yes
12,622 (0.2)
303 (0.8)
12,319 (0.2)
No
<0.01
4,545,038 (84)
25,254 (66)
4,519,784 (84)
GI disease
Yes
634,473 (12)
7,943 (21)
626,530 (12)
No
<0.01
5,375,047 (99)
38,081 (99)
5,336,966 (99)
HIV Infection
Yes
17,696 (0.3)
178 (0.5)
17,518 (0.3)
None
<0.01
4,039,287 (75)
11,207 (29)
4,028,080 (75)
2
PTSD
298,893 (6)
5,146 (13)
293,747 (5)
Mental disorder
3
Other
729,498 (14)
10,298 (27)
719,200 (13)
No
5,251,903 (97)
36,885 (96)
5,215,018 (97)
<0.01
Renal disorder
Yes
92,990 (2)
763 (2)
92,227 (2)
Note: All numbers are presented as counts and percentages unless otherwise indicated
1Cells may not add up to total for column due to missing values; 2Chi-square test for differences in proportions for
categorical variables or Student’s t-test for differences in means for continuous variables; 3Any diagnosis of PTSD, does
not exclude other pre-existing mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety
disorders, emotional and behavioral disorders, and mood disorders). Abbreviations: BMI: body mass index; CVD,
cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human
immunodeficiency virus; PTSD, post-traumatic stress disorder

Table 4.5. Characteristics of United States veterans with and without a primary OTHER SLEEP DISORDER diagnosis
who sought care in the Veterans Health Administration (VHA) in FY2010
Characteristic

Classification

Age (years)

Mean (SD)

Sex

Male
Female
Not Married
Married
Unknown
<$20,000
≥$20,000
Unknown
Normal
Overweight
Obese
Unknown
Never
Former
Current
Unknown
No
Yes
No

Marital Status
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Annual Income

BMI (kg/m2)

Tobacco Use

Asthma
Cancer

Total Population
(N = 5,387,8851
63 (16)
N (%)
5,028,180 (93)
359,705 (7)
2,167,417 (40)
2,958,404 (55)
262,064 (5)
2,958,211 (5)
2,101,511 (39)
328,163 (6)
953,480 (18)
1,685,317 (31)
1,647,666 (31)
1,101,422 (20)
897,234 (17)
1,220,969 (23)
934,175 (17)
2,335,507 (43)
5,316,166 (99)
52,269 (1)
5,168,338 (96)

Other Sleep
Disorders
(N = 31,674)1
57 (15)
N (%)
29,337 (93)
2,337 (7)
12,605 (40)
17,988 (57)
1,081 (3)
17,794 (56)
13,847 (44)
33 (0.1)
4,323 (14)
9,996 (32)
16,785 (53)
570 (2)
7,524 (23)
9,254 (29)
7,965 (25)
6,931 (21)
30,430 (96)
769 (2)
30,105 (95)

No Other Sleep
Disorders
(N = 5,356,211)1
63 (16)
N (%)
4,998,843 (93)
357,368 (7)
2,154,812 (40)
2,940,416 (55)
260,983 (5)
2,940,417 (55)
2,087,664 (39)
328,130 (6)
949,157 (18)
1,675,321 (31)
1,630,881 (30)
1,100,852 (21)
889,710 (17)
1,211,715 (23)
926,210 (17)
2,328,576 (43)
5,285,736 (99)
51,500 (1)
5,138,233 (96)

p-value2
<0.01
<0.01
<0.01

<0.01

<0.01

<0.01

<0.01
<0.01
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Yes
160,896 (3)
1,092 (3)
159,804 (3)
No
<0.01
3,333,044 (62)
13,326 (42)
3,319,718 (62)
CVD
Yes
1,776,691 (33)
14,629 (46)
1,762,062 (33)
No
<0.01
5,158,291 (96)
28,784 (91)
5,129,507 (96)
COPD
Yes
171,953 (3)
1,860 (6)
170,093 (3)
No
<0.01
4,475,845 (83)
23,813 (75)
4,452,032 (83)
Diabetes
Yes
793,626 (15)
6,385 (20)
787,241 (15)
No
<0.01
5,363,084 (99)
30,995 (98)
5,332,089 (99)
Fibromyalgia
Yes
12,619 (0.2)
300 (1)
12,319 (0.2)
No
<0.01
4,540,794 (84)
21,010 (66)
4,519,784 (84)
GI disease
Yes
633,798 (12)
7,268 (23)
626,530 (12)
No
0.10
5,368,505 (99)
31,539 (99)
5,336,966 (99)
HIV Infection
Yes
17,643 (0.3)
125 (0.4)
17,518 (0.3)
None
<0.01
4,040,261 (75)
12,181 (38)
4,028,080 (75)
2
PTSD
Mental disorder
298,571 (6)
4,824 (15)
293,747 (5)
Other3
727,050 (13)
7,850 (25)
719,200 (13)
No
<0.01
5,245,383 (97)
30,365 (96)
5,215,018 (97)
Renal disorder
Yes
92,978 (2)
751 (2)
92,227 (2)
Note: All numbers are presented as counts and percentages unless otherwise indicated
1Cells may not add up to total for column due to missing values; 2Chi-square test for differences in proportions for
categorical variables or Student’s t-test for differences in means for continuous variables; 3Any diagnosis of PTSD, does
not exclude other pre-existing mental health diagnoses; 4Any mental health diagnosis other than PTSD (e.g., anxiety
disorders, emotional and behavioral disorders, and mood disorders). Abbreviations: BMI: body mass index; CVD,
cardiovascular disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV, human
immunodeficiency virus; PTSD, post-traumatic stress disorder

Table 4.6. Crude and adjusted odds ratios for a sleep disorder diagnosis in
FY2010 among United States veterans who sought care in the Veterans Health
Administration (VHA).
Characteristic
Age
Sex
Marital Status
Annual Income
BMI (kg/m2)

Tobacco Use
Asthma
Cancer
CVD
COPD
Diabetes
Fibromyalgia
GI disease

Mental disorder
Renal disorder

Classification
Continuous years
Female
Male
Not Married
Married
<$20,000
≥$20,000
Normal
Overweight
Obese
Never
Former
Current
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
None
PTSD2
Other3
No
Yes
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Crude

Adjusted1

OR (95% CI)
0.98 (0.98, 0.98)
ref
1.06 (1.04, 1.09)
ref
1.06 (1.05, 1.08)
ref
1.11 (1.10, 1.12)
ref
1.39 (1.36, 1.42)
2.86 (2.81, 2.91)
ref
0.90 (0.89, 0.92)
0.95 (0.94, 0.97)
ref
2.46 (2.39, 2.55)
ref
1.08 (1.04, 1.09)
ref
2.12 (2.09, 2.14)
ref
1.85 (1.80, 1.89)
ref
1.56 (1.54, 1.58)
ref
3.16 (2.96, 3.38)
ref
2.23 (2.20, 2.26)
ref
4.14 (4.07, 4.21)
2.99 (2.95, 3.03)
ref
1.43 (1.38, 1.48)

OR (95% CI)
0.97 (0.97, 0.97)
ref
1.29 (1.25, 1.33)
ref
1.26 (1.24, 1.28)
ref
0.95 (0.94, 0.97)
ref
1.36 (1.32, 1.39)
2.41 (2.35, 2.47)
ref
0.91 (0.89, 0.93)
0.74 (0.73, 0.76)
ref
1.66 (1.59, 1.74)
ref
1.06 (1.02, 1.10)
ref
1.71 (1.68, 1.74)
ref
1.67 (1.62, 1.72)
ref
1.06 (1.04, 1.08)
ref
1.69 (1.56, 1.83)
ref
1.46 (1.44, 1.49)
ref
2.56 (2.51, 2.62)
2.16 (2.12, 2.20)
ref
1.24 (1.19, 1.30)

1 Each

Odds ratio is adjusted for all other variables; 2Any diagnosis of PTSD,
but may have other mental health disorders; 3Any mental health diagnosis
other than PTSD (e.g., anxiety disorders, emotional and behavioral disorders,
mood disorders); ORs for unknown categories were not reported for marital
status (n = 265,619), income (n = 328,267), BMI (n = 1,103,374), or tobacco
use (n = 2,361,066). Abbreviations: BMI: body mass index; OR, odds ratio; CI,
confidence interval; CVD, cardiovascular disease; COPD, chronic obstructive
pulmonary disease; GI, gastrointestinal; PTSD, post-traumatic stress disorder
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Table 4.7. Crude and adjusted predictors of primary SLEEP APNEA (Cases)
relative to subjects without sleep apnea, United States Veterans Health
Administration (VHA) patients, FY2010
Characteristic

Crude

Adjusted1

OR (95% CI)
0.98 (0.98, 0.98)
ref
1.53 (1.48, 1.59)
ref
1.34 (1.32, 1.36)
ref
1.23 (1.21, 1.25)
ref
2.62 (2.53, 2.73)
8.81 (8.51, 9.13)
ref
0.92 (0.90, 0.94)
0.77 (0.76, 0.79)
ref
2.79 (2.66, 2.92)
ref
2.61 (2.57, 2.65)
ref
1.98 (1.91, 2.04)
ref
1.98 (1.95, 2.02)
ref
2.73 (2.48, 3.00)
ref
2.14 (2.10, 2.19)
ref
0.62 (0.52, 0.73)
ref

OR (95% CI)
0.97 (0.97, 0.97)
ref
1.69 (1.62, 1.77)
ref
1.43 (1.40, 1.46)
ref
0.99 (0.97, 1.01)
ref
2.28 (2.17, 2.39)
6.13 (5.86, 6.41)
ref
0.93 (0.90, 0.95)
0.69 (0.67, 0.71)
ref
1.76 (1.66, 1.86)
ref
1.86 (1.82, 1.90)
ref
1.95 (1.88, 2.03)
ref
1.14 (1.12, 1.17)
ref
1.58 (1.41, 1.78)
ref
1.42 (1.38, 1.45)
ref
0.70 (0.58, 0.86)
ref

Classification

Continuous years
Female
Sex
Male
Not Married
Marital Status
Married
<$20,000
Annual
Income
≥$20,000
Normal
2
Overweight
BMI (kg/m )
Obese
Never
Former
Tobacco Use
Current
No
Asthma
Yes
No
CVD
Yes
No
COPD
Yes
No
Diabetes
Yes
No
Fibromyalgia
Yes
No
GI disease
Yes
No
HIV Infection
Yes
None
Mental
PTSD2
3.35 (3.28, 3.44)
2.00 (1.94, 2.05)
disorder
Other3
2.23 (2.19, 2.27)
1.67 (1.63, 1.71)
No
ref
ref
Renal disorder
Yes
1.59 (1.52, 1.67)
1.30 (1.23, 1.37)
1 Estimates are mutually adjusted for all other variables; 2Any diagnosis of
PTSD, but may have other mental health disorders; 3Any mental health
diagnosis other than PTSD (e.g., anxiety disorders, emotional and behavioral
Age
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disorders, and mood disorders); ORs for unknown categories were not
reported for marital status (n = 265,619), income (n = 328,267), BMI (n =
1,103,374), and tobacco use (n = 2,361,066). Abbreviations: BMI: body mass
index; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease;
COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HIV,
human immunodeficiency virus; PTSD, post-traumatic stress disorder
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Table 4.8. Crude and adjusted predictors of new INSOMNIA (Cases) relative to
subjects without insomnia, United States Veterans Health Administration (VHA)
patients, FY2010
Characteri
stic

Crude

Classification

Adjusted1

OR (95% CI)
OR (95% CI)
Continuous years
Age
0.98 (0.98, 0.98)
0.98 (0.98, 0.98)
<$20,000
ref
ref
Annual
Income
≥$20,000
0.92 (0.91, 0.94)
0.87 (0.84, 0.89)
Normal
ref
ref
BMI
Overweight
1.00
(0.98,
1.03)
1.03
(0.99,
1.07)
(kg/m2)
Obese
0.99 (0.97, 1.02)
0.90 (0.87, 0.94)
Never
ref
ref
Tobacco
Former
0.85 (0.82, 0.87)
0.87 (0.84, 0.90)
Use
Current
1.21 (1.17, 1.25)
0.77 (0.74, 0.80)
No
ref
ref
Asthma
Yes
1.84 (1.71, 1.99)
1.27 (1.15, 1.40)
No
ref
ref
Cancer
Yes
1.11 (1.05, 1.17)
1.16 (1.09, 1.25)
No
ref
ref
CVD
Yes
1.49 (1.46, 1.52)
1.46 (1.41, 1.51)
No
ref
ref
COPD
Yes
1.53 (1.46, 1.61)
1.24 (1.17, 1.31)
No
ref
ref
Diabetes
Yes
0.92 (0.90, 0.95)
0.84 (0.81, 0.88)
ref
ref
Fibromyal No
gia
Yes
3.50 (3.12, 3.92)
1.63 (1.42, 1.87)
No
ref
ref
GI
Yes
disease
2.27 (2.21, 2.33)
1.50 (1.45, 1.55)
None
ref
ref
Mental
2
PTSD
6.30 (6.09, 6.51)
4.20 (4.03, 4.37)
disorder
3
Other
5.15 (5.01, 5.29)
3.52 (3.40, 3.64)
No
Ref
ref
Renal
disorder
Yes
1.17 (1.09, 1.28)
1.23 (1.13, 1.34)
1 Estimates are mutually adjusted for all other variables; 2Any diagnosis of
PTSD, but may have other mental health disorders; 3Any mental health
diagnosis other than PTSD (e.g., anxiety disorders, emotional and behavioral
disorders, and mood disorders); ORs for unknown categories were not
reported for marital status (n = 265,619), income (n = 328,267), BMI (n =
1,103,374), and tobacco use (n = 2,361,066). Abbreviations: BMI: body mass
index; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease;
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COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; PTSD,
post-traumatic stress disorder
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Table 4.9. Crude and adjusted predictors of new OTHER SLEEP DISORDER
(Cases) relative to subjects without other sleep disorders, United States
Veterans Health Administration (VHA) patients, FY2010
Characteristic

Classification

Crude

Adjusted1

OR (95% CI)
OR (95% CI)
Continuous years
0.98 (0.98, 0.98) 0.98 (0.98, 0.98)
Age
Not Married
ref
ref
Marital Status
Married
1.05 (1.02, 1.07) 1.27 (1.23, 1.31)
<$20,000
ref
ref
Annual Income
≥$20,000
1.10 (1.07, 1.12) 0.94 (0.91, 0.97)
Normal
ref
ref
2
Overweight
1.31 (1.26, 1.36) 1.31 (1.25, 1.38)
BMI (kg/m )
Obese
2.26 (2.19, 2.34) 1.95 (1.86, 2.04)
Never
ref
ref
Former
0.90 (0.88, 0.93) 0.92 (0.88, 0.95)
Tobacco Use
Current
1.02 (0.99, 1.05) 0.76 (0.73, 0.80)
No
ref
ref
Asthma
Yes
2.59 (2.41, 2.79) 1.66 (1.53, 1.81)
No
ref
ref
Cancer
Yes
1.17 (1.10, 1.24) 1.11 (1.03, 1.19)
No
ref
ref
CVD
Yes
2.07 (2.02, 2.12) 1.65 (1.60, 1.71)
No
ref
ref
COPD
Yes
1.95 (1.86, 2.04) 1.61 (1.52, 1.71)
No
ref
ref
Diabetes
Yes
1.52 (1.48, 1.56) 1.05 (1.01, 1.09)
No
ref
ref
Fibromyalgia
Yes
4.19 (3.74, 4.70) 1.89 (1.65, 2.17)
No
ref
ref
GI disease
Yes
2.50 (2.43, 2.56) 1.54 (1.49, 1.60)
None
ref
ref
2
PTSD
5.43 (5.25, 5.62) 3.16 (3.04, 3.29)
Mental disorder
3
Other
3.61 (3.51, 3.71) 2.44 (2.36, 2.53)
No
ref
ref
Renal disorder
Yes
1.40 (1.30, 1.50) 1.19 (1.09, 1.29)
1 Estimates are mutually adjusted for all other variables; 2Any diagnosis of
PTSD, but may have other mental health disorders; 3Any mental health
diagnosis other than PTSD (e.g., anxiety disorders, emotional and behavioral
disorders, and mood disorders); ORs for unknown categories were not
reported for marital status (n = 265,619), income (n = 328,267), BMI (n =
1,103,374), and tobacco use (n = 2,361,066). Abbreviations: BMI: body mass
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index; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease;
COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; PTSD,
post-traumatic stress disorder
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Polyp Formation 3

Alexander M, Burch JB, Steck SE, Chen C-F, Hurley TG, Cavicchia P, Shivappa
N, Guess J, Zhang H, Youngstedt SD, Creek KE, Lloyd S, Jones K, Hébert JR.
Submitted to International Journal of Colorectal Diseases.
3

122

5.1 Abstract

Introduction: Colorectal cancer (CRC) is one of the most common and
preventable forms of cancer, yet it remains the second leading cause of cancerrelated death. Colorectal adenomatous polyps (adenomas) are precursor lesions
that develop in 70-90% of all CRC cases. Identification of peripheral biomarkers
for adenomas would help to enhance efficiency of screening efforts. This
exploratory study examined the methylation status of 20 candidate markers in
peripheral blood leukocytes to determine whether epigenetic modification of
these genes was associated with adenoma case status. Materials and
Methods: Patients recruited from a local endoscopy clinic provided informed
consent, and completed an interview to ascertain demographic, lifestyle, and
adenoma risk factors. Cases were defined as individuals with a
histopathologically confirmed adenoma, and controls included patients with a
normal colonoscopy, or those with histopathological findings not requiring
heightened surveillance (normal biopsy, hyperplastic polyp). Methylation-specific
polymerase chain reaction was used to characterize candidate gene promoter
methylation. Odds ratios and 95% confidence intervals (OR, 95% CI) were
calculated using unconditional multivariable logistic regression to test the
hypothesis that candidate gene methylation differed between cases and controls,
after adjustment for potential confounding factors. Results: Complete data were
available for 107 participants; 36% had adenomas (men: 40%, women: 31%).
Hypomethylation of the MINT1 locus (OR: 5.3, 95% CI: 1.0-28.2), and the PER1
(OR: 2.9, 95% CI: 1.1-7.7) and PER3 (OR: 11.6, 95% CI: 1.6-78.5) clock gene
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promoters was more common among adenoma cases. While specificity was
moderate to high for the three markers (71-97%), sensitivity was relatively low
(18-45%). Discussion: Follow-up of these epigenetic markers is suggested to
further evaluate their utility for adenoma screening or surveillance.

5.2 Introduction

Despite recent decreases in colorectal cancer (CRC) incidence and
associated mortality, CRC remains one of the most common and deadly forms
of cancer in the United States, with a lifetime risk for diagnosis of 5%.1
Colonoscopies not only present an opportunity screen for CRC, but to also
remove colorectal adenomas (precursor lesion for CRC), thus facilitating primary
CRC prevention. However, in 2012, the Centers for Disease Control and
Prevention reported that CRC screening rates among eligible men and women
fell far short of the Healthy People 2020 target of 70.5%.123 Only ~25-60% of
eligible adults undergo CRC screening due to socioeconomic, racial, geographic,
or other barriers that contribute to a lack of compliance,229-232 highlighting a need
for accessible screening methods.

Stool-based tests (fecal occult blood test [FOBT] or the fecal
immunochemical test [FIT]) have been developed as a less invasive alternative
to colonoscopies. Despite high sensitivity for CRC, this screening modality has
reduced adenoma detection sensitivity (FOBT: 7-23%; FIT: 13-26%) compared to
a colonoscopy, which has the ability to detect 73-94% of adenomas.233-236 A
recent meta-analysis of stool-based DNA, another alternative CRC screening
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strategy, found that these tests may provide a diagnostic benefit for CRC or
advanced adenoma detection in high-risk, but not average-risk, populations,237
and is a cost-prohibitive screening tool.238 Interestingly, methylation markers
provided better diagnostic performance for adenoma detection than did
mutations (67% sensitivity vs. 10% sensitivity, respectively),237 FOBT, or FIT
(≤26%).235, 236 Because blood-based measures can increase compliance with
CRC screening and surveillance, genetic and epigenetic biomarkers in circulation
are under active investigation.239, 240
The polyp→carcinoma sequence within the colon has been widely
studied, and both genetic87 and epigenetic241 alterations have been observed at
different stages of CRC development. An extensive literature describes the
genetic lesions involved in this process, and an estimated 30% of CRC cases
can be attributed to heritable factors.242 However, highly penetrant genetic
markers account for only ~5% of CRC cases.242 Epigenetic modification
represents an important and early event in the adenoma→CRC sequence.
Methylation within gene promoter regions can lead to gene silencing and reduced
gene expression.241, 243 Promoter methylation of genes responsible for tumor
suppression, DNA repair, or other critical pathways involved in the
carcinogenesis process may reduce their expression and thereby promote tumor
development. Aberrant methylation of several CRC-related loci (e.g., MLH1,
CDKN2A [p16], MINT1, MINT2, MINT31) corresponds to a specific CRC subtype,
the CpG island methylator phenotype (CIMP), 132 which occurs in 0-44% of
adenomas,133, 134 and up to 50% of CRCs.244 However, associations between
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aberrant gene methylation and cancer have not always been consistent, possibly
due to differences in the various molecular pathways leading to CRC
development.245 For example, MINT1, MINT2, and MINT12 are putative tumor
suppressors, but were less methylated in adenomas from individuals with
multiple polyps relative to those with at least one polyp and high microsatellite
instability (MSI-H) in their adenomas.245 Also, hypermethylation of MINT31 has
been associated with increased CRC risk,246 but also has been associated with
longer disease-free survival among CRC patients.247 These findings highlight the
need for more research on the relationship between promoter gene methylation
and adenoma development or progression.

Few studies have examined epigenetic markers in peripheral blood
leukocytes (PBLs) for early detection of adenomas or CRC. Global
hypomethylation of retrotransposable (LINE-1) elements in PBLs has been
associated with increased odds of adenoma formation in some studies,248-251 and
other studies targeting candidate genes also have had some success identifying
patients with adenomas or CRC, although the results among these investigations
have been mixed.240, 252-256 Epigenetic changes in PBLs may reflect those
observed in target tissues257 or may serve as biologically relevant indicators of
behavioral, environmental, psychosocial, or lifestyle factors that contribute to
adenoma formation.241, 258
This exploratory case-control study tested the hypothesis that adenoma
case status was associated with aberrant methylation of candidate gene
promoters in PBL DNA relative to control colonoscopy patients. A panel of twenty
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candidate gene markers was selected for evaluation following a literature review
based on their potential role in adenoma formation or CRC risk: APC, BRCA1,
CDKN2AP16, CYP24A, CYP27B1, ER-alpha, IGF2, MGMT, MINT1, MLH1,
NGFR, PER1, PER2, PER3, SEPT9, SFRP4, SFRP5, TIMP3, TMEFF2, and
WIF1.105, 240, 241, 259-264

5.3 Materials and Methods

The Epigenetics and Diet in the Carcinogenesis Process (EDCaP) study
was performed among patients undergoing a colonoscopy procedure at a
community endoscopy center in Columbia, SC.265 Prior to their clinic visit, 138
participants provided informed consent, including permission to access medical
records, in accordance with the University of South Carolina’s Institutional
Review Board approval process. Participants completed a questionnaire to
provide information on: demographic (sex, marital status, income, race/ethnicity),
lifestyle (smoking history, diet, physical activity), and occupational (employment
status, job industry, type of shift, history of shiftwork) factors, as well as personal
and family medical history (ever being diagnosed with other diseases, personal
cancer history, family CRC history).

A total of 256 subjects scheduled for a screening or surveillance
colonoscopy were eligible to participate, and 154 were enrolled. Among those
subjects, 138 had complete questionnaire data, and 107 of those participants
provided biospecimens for methylation analysis (Figure 5.1). Information on
cecal intubation, visualization of the appendix, and bowel preparation were
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abstracted from the patient’s medical record to evaluate colonoscopy quality.
Cases were defined as individuals with a complete colonoscopy procedure and
at least one histologically confirmed adenoma based on review by a consulting
clinical pathology laboratory. Controls included patients with a complete
procedure and normal findings, or histopathological findings not requiring
heightened surveillance (normal biopsy, hyperplastic polyp).266

Biological sample collection and laboratory assays

An on-site nurse drew 40cc of blood from each participant for DNA and
RNA extraction. DNA samples obtained from blood were aliquoted and archived
for future studies in genetic and epigenetic factors in colorectal polyp formation.
Normal gastrointestinal (GI) tissue and a polyp samples (if available) were also
extracted during the colonoscopy procedure. All biological samples were stored
at -80oC after collection.

Methylation assays

A peripheral whole blood sample was collected from each participant
using vacutainers containing EDTA anticoagulant. Genomic DNA was isolated
using the PUREGENE genomic DNA purification kit (Gentra Systems,
Minneapolis, MN) according to the manufacturer’s protocol from peripheral whole
blood, normal GI tissue, and polyp tissue. Sodium bisulfite conversion of DNA
was performed using EpiTect kits (QIAGEN, Germantown, MD, USA). Briefly,
DNA (2 µg) was added to the reaction buffer and bisulfite DNA conversion was
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conducted in a Bio-Rad S1000 thermal cycler (Bio-Rad Laboratories, Hercules,
CA, USA) using the manufacturer’s suggested program for the conversion
reaction. Converted DNA was eluted from a spin column in TE buffer and either
used immediately or stored at –20°C. DNA oligonucleotides for primer pairs
were purchased from Integrated DNA Technologies (Coralville, IA, USA, Table
5.1). To ensure that the polymerase chain reaction (PCR) primers were specific
for the detection of methylated DNA, a control human DNA set (EpiTect Control
DNA, QIAGEN Sciences, Germantown, MD) containing positive (bisulfite
converted, 100% methylated) and negative (bisulfite converted, 0% methylated)
control DNA was used. To quantify methylation specific PCR (MSP) results, the
QIAxcel system was used (QIAGEN Sciences, Germantown, MD), which utilizes
a multiplexed fluorescence detection method with a resolution of 3-5 bp for DNA
fragments. The detection sensitivity of QIAxcel system was 0.1 ng/μl DNA in
undiluted amplification reactions. The QIAxcel system was equipped with the
BioCalculator software that produces a tabular display of a variety of peak
properties, including number of peaks as well as the height, width, and area of
each peak. The height of the peak was used for separation of the results into
three methylation categories: high (peak height >0.30), medium (peak height
0.29-0.05), and low (peak height <0.05), or none (no methylation detected).
Results were categorized as either unmethylated or methylated (combination of
medium/low, and high methylation categories). The methylation status of each
sample was normalized via a two-step process. First, a NanoDrop™ Lite
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) was used to

129

measure concentrations of the DNA templates. Subsequent experiments used
the same amount of DNA template for each MSP reaction. To facilitate
quantification, equal volumes of the MSP products were loaded on the QIAxcel
system for analysis. Second, BRCA1 gene methylation was used as an internal
standard since the same amount of DNA template had extremely high
methylation in each sample. The measured peak height of BRCA1 methylation
was then used to normalize the methylation of the genes of interest for each
sample. All methylation assays were performed blinded to case status.

Real-time quantitative PCR (qPCR)

RNA was extracted from PAXgene tubes using PAXgene Blood RNA Kit
from QIAGEN (Germantown, MD, USA). RNA quality was checked via Agilent
Bioanalyzer 2100 and concentration was quantified on NanoDrop. cDNA was
synthesized from total RNA using gene-specific primers according to the Verso
cDNA Kit (Abgene, Rochester, New York). Reverse transcriptase reactions
contained 1 μg of total RNA (1-5 μl of total RNA), 4 μl 5X cDNA synthesis buffer,
1 μl 5 μM dNTP mix, 1 μl 400 ng/μl random hexamers, 1 μl RT Enhancer, 1 μl
Verso Enzyme Mix, and a variable amount of PCR grade water to have a total of
a 20 μl. The 20 μl reactions were incubated in an MJ Research PTC-225
Thermo Cycler in a 96-well plate for 30 min at 42°C, 2 min at 95°C, and then held
at 4°C. cDNAs were stored at -20 oC.

Gene-specific primers were created using Primer3 software. Forward and
reverse sequences were confirmed for their presence within exons and lack of
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single nucleotide polypmorphisms using NCBI’s Basic Local Alignment Search
Tool (BLAST). PCR cycling information is found in Table 5.2. All reactions were
performed in singleplex mode. Each reaction contained 10 μl 2x SYBR Green
PCR master mix (Bio-Rad Laboratories, Hercules, CA), 2 μl of each primer, 0.5-2
μl of cDNA template, and a variable amount of PCR grade water to have a total
reaction amount of 20 μl. The standard curve method was employed and β-actin
was used as the endogenous control to determine levels of expression of cDNA
in study participants. A two-fold 10-point serial dilution was created through the
use of diluted PCR products of β-actin and markers who presented an
association with polyp status. The standard curve produces a linear relationship
between number of threshold cycles (Ct) and the initial known amounts of cDNA,
allowing the determination of the cDNA concentration of unknown samples based
on their Ct value, thereby also giving the number of mRNA copies for each gene
present in unknown samples. The threshold cycle (Ct) is defined as the
fractional cycle number at which the fluorescence passes the fixed threshold.
Each sample was analyzed in duplicate, with a negative template control
included in each run to check for DNA contamination.

Statistical analysis
Statistical analyses were performed using SAS® version 9.2 (Cary, NC).
Frequency distributions of study variables by case status were examined using
the chi-squared test for differences between proportions. Student’s t-test was
used for comparisons among cases and controls for normally distributed
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continuous variables. In instances of non-normally distributed continuous
variables, the Wilcoxon–Mann–Whitney test was used to compare cases and
controls. Unconditional multiple logistic regression was used to estimate odds
ratios (OR) with 95% confidence intervals (CIs), comparing candidate gene
methylation among adenoma cases relative to controls, after adjustment for the
effects of potential confounding factors. Variables considered for inclusion in
adjusted models were known or suspected adenoma or CRC risk factors (age,
sex, race, body mass index [BMI], CRC family history, smoking history, workrelated factors, diet, vitamin and supplement use, physical activity,
sociodemographic characteristics [income, education], personal history of
inflammatory bowel disease), and variables that differed among participants and
non-participants (fruit and vegetable intake). Final models included variables that
were statistically significant (p≤0.05) in the saturated model, or whose inclusion
produced ≥10% change in the parameter estimate for the methylation marker of
interest. Each candidate gene was selected a priori, thus no correction for
multiple testing was performed.267 Due to sparse data, individuals who received a
colonoscopy due to symptoms (presence of gastrointestinal bleeding, fecal occult
blood, iron deficiency, or constipation, n=3) were grouped with patients
undergoing a screening colonoscopy. Sensitivity analyses were conducted to
determine whether associations were driven by data from people with a rightsided polyp, as right-sided hyperplastic polyps have been linked with the serrated
adenoma, MSI-H CRC pathway.268 Sensitivity and specificity, and positive and
negative predictive values (PPV, NPV, respectively) were calculated for
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methylation markers with a statistically significant association with adenoma case
status.

To evaluate agreement of DNA methylation levels found in PBLs, normal
colon tissue, and polyp tissue, the Kappa agreement statistic was used, which
takes on a value of 0 to 1, ranging to no agreement to complete agreement.
Also, linear regression was used to assess how much variation in gene
expression was attributable to methylation status.

Regarding gene expression and adenoma formation, unadjusted logistic
regression was also used to examine the crude association between expression
levels in PBLs and adenoma formation. To detect the true association between
expression levels in PBLs of these genes and adenoma formation, multiple
logistic regression techniques were used and confounders were included into the
model. Potential confounders were screened for in a manner similar to the
protocol for determining the relationship between methylation levels and
adenoma formation. Spearman correlations were used to assess the relationship
between gene expression levels across PBLs, normal tissue, and polyp tissue,
where values range from -1 to +1, where a negative sign indicates an inverse
relationship, and a positive sign signifies a positive relationship. All associations
were considered statistically significant at the p≤0.05 level.
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5.4 Results
Complete data were obtained from 107 of the 154 patients (70%) who
consented to participate (Figure 5.1). The mean age among participants was 60
years old (standard deviation [SD]: ±9 years). European Americans (EAs)
comprised the majority of subjects (73%), and 46% of the population was female
(Table 5.3). With regard to colonoscopy quality, most participants (96%) had a
bowel preparation that was rated as fair or better, and the cecal intubation rate
was 100%. No cases of advanced adenoma (>10 mm in size in any dimension,
high-grade dysplasia, villous histology), serrated adenomatous polyps, or CRC
were identified. The detection rate for any polyp was 65%, and the adenoma
detection rate was 36% (male: 40%, female: 31%), with a mean of 0.7 (SD: ±0.5)
adenomas per person. All procedures with a right-sided hyperplastic polyp (n=7)
were synchronous with adenoma detection in the same patient. Cases were
more likely to be smokers compared to controls (68% vs. 45%, p=0.02), and
were less likely to ever regularly take vitamin D supplements (5% vs. 29%, p
<0.01). Though not statistically significant, cases also had a tendency to be ≥65
years of age (p=0.07), married (p=0.16), to currently drink alcohol (p=0.13), or to
ever regularly take a multivitamin (p=0.07), or vitamin C (p=0.15) compared to
controls.
Effect of methylation in PBLs on adenoma formation

Figures 5.2 and 5.3 present agarose gel images of MSP products for
PER1, PER2, PER3 and MINT1, respectively, in a subsample of participants.
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After adjustment for potential confounding factors, hypomethylation (i.e., no
methylation detected) in the MINT1 (methylated in tumor1; OR: 5.3, 95% CI: 1.028.2) locus, and the PER1 (Period 1; OR: 2.9, 95% CI: 1.1-7.7), and PER3
(Period 3; OR: 11.1, 95% CI: 1.6-78.5) clock gene promoters was associated
with an increased odds of adenoma detection (Table 5.4). When seven subjects
with right-sided hyperplastic polyps were excluded, sensitivity analyses yielded
the following results for hypomethylation of MINT1 (OR: 5.0, 95% CI: 0.9-27.9),
PER1 (OR: 2.8, 95% CI: 1.1-7.5) and PER3 (OR: 9.8, 95% CI: 1.4-70.6, data not
shown). The time of day of sample collection or working at least one year of shift
work did not modify the relationship between clock gene (PER1, PER3) promoter
methylation and adenoma case status (data not shown).

The sensitivity, specificity, PPV, and NPV for hypomethylation of MINT1,
PER1, PER3, and their combinations are presented in Table 5.5. PER1, PER3,
or MINT1 hypomethylation correctly identified 16% to 45% of individuals with
adenomas. Among patients without adenomas, specificity ranged from 71% to
97%. When evaluated in combination, hypomethylation of these genes yielded
sensitivities ranging from 53% to 74%, and specificities ranging from 9% to 36%
(Table 5.5). Among the possible combinations, PER3/MINT1 yielded the highest
sensitivity (74%), and the PER1/PER3/MINT1 combination had the highest
specificity (36%).
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Concordance of methylation in PBLs, normal GI tissue, and polyp tissue
MINT1, PER1, and PER3 did not exhibit significant agreement within
PBLs (Table 5.6). No significant concordances were observed when comparing
PBLs with polyp tissue and normal tissue with polyp tissue.
Effect of methylation on mRNA expression in PBLs, normal GI tissue, and polyp
tissue
Table 5.7 presents information on PER1 and PER3 mRNA expression by
their respective methylation status. Although PER1 expression in normal GI
tissue was lower in methylated samples compared to hypomethylated samples
(1.04 fold change in PER1 expression vs 1.01 fold change in PER1 expression),
this finding was only marginally statistically significant (p-value: 0.06). PER1
methylation in normal GI tissue also explained the largest amount of variance
(approximately 26%) across the three tissue types and among the three markers.
No significant differences in expression by methylation status were found in
PBLs, normal GI tissue, and polyp tissue.
Effect of mRNA expression in PBLs on adenoma formation
Fold change in expression for PER1 and PER3 by case status are found
in Table 5.8. Adjusted analyses show that for a one-unit increase in expression
in PER1 and PER3, there was reduction in the odds of having an adenoma;
however, these findings were not statistically significant.
Correlation of mRNA expression in PBLs, normal GI tissue, and polyp tissue
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Table 5.9 presents Spearman correlations in expression levels across
PBLs, normal GI tissue, and polyp tissue. Significant correlations were seen only
between normal GI and polyp tissues, with correlation coefficients ranging from
0.62 – 0.93. No significant correlations within PBLs and between PBLs and any
tissue were detected.
5.5 Discussion
Identification of novel genes associated with adenoma risk may lead to a
better understanding of carcinogenesis pathways and subsequently improve
CRC screening and prevention efforts. Several studies have targeted bloodbased epigenetic biomarkers to identify CRC cases, and only a few have used
this approach to evaluate the formation of colorectal adenomas, which serve as
precursor lesions for 70-90% of CRC cases. This exploratory case-control study
found that hypomethylation in the MINT1 locus and the PER1 and PER3 clock
gene promoters was more common among adenoma cases relative to controls.
Additional analyses showed minimal agreement between PBLs and both normal
tissues and polyp tissues, though few paired samples were available. However,
strong, positive correlations were observed across normal tissues and polyp
tissues, suggestive that genetic/epigenetic changes that occur during the
carcinogenesis process can also be observed in normal tissue. Furthermore,
promoter methylation did not fully explain the variation in expression of their
respective gene, nor did gene-specific expression yield an association with case
status.
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The MINT1 locus is one of several markers used to characterize CIMP
status among CRC cases.132, 269 Aberrant DNA methylation is considered an
early event in the adenoma→carcinoma sequence,241 and changes in CIMP
markers have been identified in aberrant crypt foci and in colorectal
adenomas.134, 270-272 MINT methylation in adenomas or associated CRC tissue
has been linked with down regulation of mismatch repair (MLH1) protein
expression, microsatellite instability, and BRAF (V600E) mutation relative to
normal tissue.273 However, prevalence of the CIMP phenotype is variable in
adenomas (0-44%)133, 134 as well as normal gastrointestinal tissues.274 To our
knowledge, the MINT1 locus has not been examined as a circulatory marker for
adenoma risk and thus results obtained in the present study require confirmation.

Two of the three candidate genes associated with adenomas in this study
(PER1, PER3) are members of the clock gene family. Clock gene expression is
involved in the maintenance of endogenous circadian rhythms, as well as the
regulation of cellular processes that are considered hallmarks of carcinogenesis
(cell cycle control, DNA damage response, apoptosis).275-277 In colon and other
cancer cell lines, PER1 insertion can activate cell cycle checkpoint proteins,
sensitize cells to ionizing radiation-induced apoptosis, and exert an
antiproliferative effect.116 A hypomethylation zone in the PER1 promoter has
been associated with uncoupling of PER1 transcription from promoter
methylation in cervical cancer cells,243 and may have played a role in the lack of
association between methylation and expression in PER1 in the present study.
Structural or epigenetic variability in E-boxes, particularly the E-box closest to the
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promoter, may play a role in these processes, and mutations within this element
may lead to a reduction of PER1 promoter activity.243, 278 PER1 and PER2
mutations occur in human colorectal tumors,18 and PER expression is reduced in
colorectal adenomas or tumors relative to normal tissue.104, 279-283 In mice, a
mutation in the PER2 gene (PER2m/m) results in altered diurnal rhythms,
deregulated expression of cell cycle control genes, tissue hyperplasias and
tumors,94, 284 and increased colon polyp formation.285 Polymorphisms in the
PER3 gene have been associated with increased odds of adenoma formation,283
and aberrant methylation of PER genes has been observed among leukemia and
other cancer patients.30, 33, 113, 114, 286 However, to the authors’ knowledge, no
studies have examined epigenetic modifications in the PER or other clock genes
in relation to adenoma formation.277, 283

Clock genes facilitate the circadian expression of ~5-10% of the
mammalian transcriptome, and clock-controlled genes include known tumor
suppressors (e.g., p21, Chk2, XPA, ATM) and oncogenes (e.g., β-catenin, c-Myc,
WEE-1).276 Circadian patterns of clock-controlled gene expression occur via
rhythmic epigenetic modification of histones and chromatin.276, 277, 287 Histone
modification may play a role in tumorigenesis,288 although few studies have
examined the role of circadian histone modifications in relation to adenoma or
CRC development.277 Animal model studies have suggested that gene regulation
in the mouse liver is mediated by clock gene interactions with the histone
methyltransferase, MLL3 (mixed lineage leukemia 3), a tumor suppressor that
has been associated with CRC and other cancers.287, 289 PER complexes recruit
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histone-modifying proteins that help orchestrate the circadian expression of core
clock genes, although it is not known whether this function extends to clockcontrolled, cancer-related genes.277, 290
This study had several noteworthy strengths and limitations. Strengths
included the valid ascertainment of adenoma cases and statistical adjustment for
known and suspected adenoma risk factors. The sample size limited power and
precluded examination of the relationship between methylation patterns and
adenoma status within factors that may influence epigenetic processes and
detecting differences in expression by both methylation and case status.
Although each candidate gene was selected a priori following a literature review,
this study was exploratory in nature and the potential for spurious or false
positive findings cannot be eliminated. Also, methylation among specific white
blood cell subsets was not quantified. Methylation patterns do not always vary
among T-cell subsets, and the extent to which methylation differs among PBL
subtypes for PER1, PER3, or MINT1 is not known. This cellular heterogeneity
could play a role in the poor agreement in methylation between PBLs and tissues
within subject and lack of a relationship between methylation and expression
found in the present study, phenomena that have been previously observed.291293

It is further supported by the strong correlations in expression between

normal and polyp tissues, but not between PBLs and normal and/or polyp
tissues. Nonetheless, a lack of standardization for these potential differences
represents a study uncertainty.258, 294, 295 The pattern of promoter
hypomethylation that was observed for PER1 and PER3 in this study was not
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consistent with that expected for a tumor suppressor. Other studies that targeted
clock genes in PBLs indicated that DNA hypomethylation was associated with
breast cancer diagnoses (CLOCK),296 or with advanced stage (II-IV) breast
cancer (TIMELESS),297 whereas promoter hypermethylation was associated with
postmenopausal breast cancer (CRY2),296 and with chronic myeloid leukemia
(PER3)33 relative to controls. The mechanism through which PER1 or PER3
gene methylation may impact adenoma formation is unknown and may depend
on tissue context, timing of expression relative to other cellular processes,
location of epigenetic changes within the gene, or other factors that may disrupt
clock gene expression, such as shift work.276, 277 Time of day of sample
collection in the present study did not modify the relationship between PER1 or
PER3 promoter methylation and adenoma case status (data not shown).
However, more detailed genetic and epigenetic studies of the duration, phase
and amplitude of PER1 and PER3 expression in conjunction with cancer-related,
clock-controlled genes are suggested to help elucidate their role in adenoma
formation. Methylation of non-target tissue (i.e., PBLs) can be influenced by
psychosocial or environmental stressors, or lifestyle risk factors (e.g., diet,
smoking). For example, cancer risk factors that can alter clock gene expression,
such as shiftwork or sleep disturbances, also may exert epigenetic effects.298-302
Global DNA hypomethylation in PBLs was recently observed among night
workers relative to those working days, and among the clock genes examined,
the largest differences in hypomethylation were observed within PER3 loci.300 In
the present study, neither the proportion of current shiftworkers nor those who
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engaged in at least one year of shiftwork (3% and 42% of the study population,
respectively, Table 1) differed by adenoma case status, or by MINT1, PER1, or
PER3 methylation status (data not shown). Future studies would need to
consider the role of these factors when examining the independent effect of
promoter methylation status on health outcomes.
In summary, the identification of peripheral epigenetic markers that are
associated with adenoma risk may lead to a deeper understanding of colorectal
carcinogenesis and facilitate CRC prevention. Results from this study suggest
the need for follow-up blood-based monitoring of MINT1, PER1, and PER3 to
examine their role in adenoma formation and CRC risk, along with an
examination in the relationship between their corresponding normal and polyp
tissues.
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Contacted:
n=256

Declined:
n=102

Consented:
n=154

Incomplete Survey
Data:
n=16

Survey Data:
n=138

No Blood or Poor
Quality DNA:
n=31

Complete Data:
n=107

Controls:
n=69

No polyp or Normal
Finding:
n=37

Adenoma Cases:
n = 38

Hyperplastic Polyp:
n=32

Figure 5.1. Flow chart of participant recruitment and participation in the
Epigenetics and Diet in the Carcinogenesis Process (EDCaP) study.
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Figure 5.2. QIAxel gel analysis for the methylation-specific polymerase chain reaction
(MSP) of PER1 (A) and PER2 (B). Black arrows indicate MSP products of PER1 and
PER2. (A) Lanes 1 and 2 represent a positive control and negative control, respectively.
Lanes 3 through 10 represent a subsample of participants and PER1 methylation.
Subjects #28 and #48 exhibited no methylation; subjects #49, #63, #71, #72, and #74
exhibited low/medium methylation; and subject #48 exhibited high methylation. (B)
Lanes 1 through 10 represent a subsample of participants and PER2 methylation. All
subjects with the exception of subjects #75 and #84 exhibited low/medium methylation.
Subjects #75 and #84 had high methylation.
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Figure 5.3. QIAxel gel analysis for the methylation-specific polymerase chain reaction
(MSP) of PER3 (A) and MINT1 (B). Black arrows indicate MSP products of PER3 and
MINT1. (A) Lanes 1 through 10 represent a subsample of participants and PER3
methylation. Subjects #85 and #112 exhibited no methylation; subjects #83, #84, #90,
#91 exhibited low/medium methylation; and subjects #75, #102, #117, and #132
exhibited high methylation. (B) Lanes 1 through 10 represent a subsample of
participants and MINT1 methylation. Subject #112 had no methylation; subjects #83,
#84, #85, #90, #91, and #102 exhibited low/medium methylation; and subjects #75,
#117, and #132 exhibited high methylation.
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Table 5.1. Primers for Methylation-Specific PCR
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Gene Name

Forward (5’ -> 
3’)

Reverse (5’ -> 
3’)

APC
BRCA1
CDKN2A (p16)
CYP24
CYP27B1
ER-alpha
IGF2
MGMT
MINT1
MLH1
NGFR
PER1
PER2
PER3
SEPT9
SFRP4
SFRP5
TIMP3
TMEFF2
WIF1

TATTGCGGAGTGCGGGTC
TCGTGGTAACGGAAAAGCGC
TTATTAGAGGGTGGGGCGGATCGC
TGTTGATTTTGTGAGTTTAATTCGA
GGTAGTATTTTTCGTTTGTTTGC
ACGAGTTTAACGTCGCGGTC
TAAGTTTGGTTTAGATTCGG
TTTCGACGTTCGTAGGTTTTCGC
GTATTTGTTATTTGGTTTTTGTCGT
ACGTAGACGTTTTATTAGGGTCGC
GAGGGTTTATGTAGATACGA
ATTTAGGTTTACGTGCGTTC
GTTTTTGGTCGGTGGTCGG
CGTCGGTTTGTTGGGATTG
TTTTTTTATTATTGTTTGCGTTATTC
AAGATTTGGCGTTGGGCGGGACGTTC
TCGAGGATTTAGCGGTAAGTATC
TTCGTTATGTCGTTTGTTTTTTTC
GTATTATCGGATAGTCGAGTTTCGA
TCGTGGTAACGGAAAAGCGC

TCGACGAACTCCCGACGA
AAATCTCAACGAACTCACGCCG
GACCCCGAACCGCGACCGTAA
AAACTTTAATATCCGCCCTACGTA
TCAAAACCTCTCTAATCATCTCGAT
ACCCCCCAAACCGTTAAAAC
AAACCCCTAAACTCGAACGA
GCACTCTTCCGAAAACGAAACG
GCTCCTCAATTCTAATTAATCGAA
CCTCATCGTAACTACCCGCG
TATAATCGTACACTTACGTA
GATTAACTAAAAATCTCTTCCCGAC
CGAAACTCCTACGCACCTCC
AAACCGACTCCGCAAACC
CAAATAATCATTTATTCTCCCTACG
ACTCCAACCCGAACCTCGCCGTACG
GAAACCGAAAACAAAAAATAACG
AATAACCCTACGTTCCTTACTCGA
AATAATAACTCCTATTCCTCCTCCG
AAATCTCAACGAACTCACGCCG

Amplicon (bp)
98
86
150
142
139
110
197
81
121
115
176
95
92
160
112
120
136
137
142
176

Table 5.2. Gene-specific primers for PER1, PER3, and β-Actin and qPCR cycling information
Gene Forward sequence
Reverse sequence
Annealing
Number
temperature
of cycles
(oC)
PER1 ATTTGGCTGCTCATGGCCA ATCCTGCTTCAGCACAGAGGT
63
40
ATGCT
CAT
PER3 TATGCAGGGCATCCTCCCT TATGCAGGGCATCCTCCCTTT
60
40
TTGAA
GAA
βCATGTACGTTGCTATCCAG
CTCCTTAATGTCAGGCACGAT
60
40
Actin
GC

Amplicon
(bp)
90
121
250
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Table 5.3. Characteristics of EDCaP study participants
Total
Controls
Cases
population
(n = 69)
(n = 38)
Variable
(n = 107)
n (%)
n (%)
n (%)
Gender
Male
58 (54)
35 (51)
23 (61)
Female
49 (46)
34 (49)
15 (39)
Race
European American
78 (73)
49 (71)
29 (76)
African American
29 (27)
20 (29)
9 (24)
Married
Yes
85 (79)
52 (75)
33 (87)
No
22 (21)
17 (25)
5 (13)
Education
Up to High School
32 (30)
21 (30)
11 (29)
Some College
28 (26)
16 (23)
12 (32)
College Undergraduate
or
47 (44)
32 (46)
15 (40)
Post-Graduate Degree
Income Level
Under $50,000
33 (33)
21 (33)
12 (33)
≥$50,000 to $100,000
44 (44)
29 (46)
15 (42)
≥$100,000
22 (22)
13 (21)
9 (25)
Age Group (Years)
<54
28 (26)
20 (29)
8 (21)
55-64
46 (43)
33 (48)
13 (34)
≥65
33 (31)
16 (23)
17 (45)
2
Body Mass Index (kg/m )
Underweight or normal
20 (19)
14 (20)
6 (16)
Overweight or obese
87 (81)
55 (80)
32 (84)
History of Smoking
Ever
57 (53)
31 (45)
26 (68)
Never
50 (47)
38 (55)
12 (32)
Current alcohol
consumption
Yes
46 (43)
26 (38)
20 (53)
No
61 (57)
43 (62)
18 (47)
Ever regularly taken a
multivitamin
Yes
68 (64)
40 (58)
28 (76)
No
38 (36)
29 (42)
9 (24)
Ever regularly taken a
vitamin C supplement
Yes
31 (29)
17 (25)
14 (38)
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Controls vs.
Cases
p-value1
0.33

0.55

0.16

0.62

0.86

0.07

0.57

0.02

0.13

0.07

0.15

Table 5.3. Characteristics of EDCaP study participants
Total
Controls vs.
Controls
Cases
population
Cases
(n = 69)
(n = 38)
Variable
(n = 107)
p-value1
n (%)
n (%)
n (%)
No
75 (71)
21 (75)
23 (62)
Ever regularly taken a
<0.01
vitamin D supplement
Yes
22 (21)
20 (29)
2 (5)
No
84 (79)
49 (71)
35 (95)
Hemorrhoids
0.18
Yes
67 (63)
40 (58)
27 (71)
No
40 (37)
29 (42)
11 (29)
Procedure reason
<0.01
Routine
34 (32)
30 (43)
4 (11)
screening/Symptoms2
Elevated Risk3
73 (68)
39 (57)
34 (89)
Time of day blood was
0.23
collected
Morning
83 (78)
56 (81)
27 (71)
Afternoon
24 (22)
13 (19)
11 (29)
Worked >1 year of shift
0.99
work over lifetime
Yes
45 (42)
29 (42)
16 (42)
No
62 (58)
40 (58)
22 (58)
Current Work Shift
0.31
Days
53 (47)
33 (48)
20 (53)
Other
4 (3)
4 (6)
0 (0)
Unemployed/Retired
50 (50)
32 (46)
18 (47)
1Χ2 test for differences in proportions between cases and controls.; 2Three
subjects exhibited symptoms (presence of gastrointestinal bleeding,
hematochezia, melena, fecal occult blood, iron deficiency, or constipation) and
were collapsed into screening category; 3Subject had a previous adenomatous
polyp detected (n = 59) and/or a family history of colorectal cancer (n = 20)
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Table 5.4. Unadjusted and adjusted odds Ratios for leukocyte DNA promoter
methylation relative to adenoma case status
Cases
Controls
Candidate
(n =
Crude OR
pAdjusted OR
p(n = 69)
Gene
38)
(95% CI)
value
(95% CI)
value
n (%)
n (%)
Hypomethylation*
23
1.0 (0.4 –
APCa
44 (64)
0.9 (0.4 – 2.0) 0.74
0.97
(61)
2.5)
18
1.5 (0.6 –
BRCA1b
31 (44)
1.1 (0.5 – 2.4) 0.81
0.36
(47)
3.9)
3.7 (1.0 –
5.3 (1.0 –
MINT1d
4 (6)
7 (18)
0.05
0.05
13.5)
28.2)
17
2.9 (1.1 –
PER1e
2.0 (0.9 – 4.5) 0.10
0.03
20 (29)
(45)
7.7)
6.3 (1.2 –
11.1 (1.6 –
PER3f
0.03
0.02
2 (3)
6 (16)
32.9)
78.5)
1.1 (0.3 –
SFRP4e
12 (17)
5 (29) 0.7 (0.2 – 2.2) 0.57
0.89
3.8)
3.7 (0.8 –
SFRP5b
0.09
5 (7)
5 (29) 1.9 (0.5 – 7.2) 0.32
17.1)
25
1.2 (0.4 –
TIMP3g
42 (61)
1.2 (0.5 – 2.8) 0.61
0.78
(66)
3.0)
21
1.5 (0.6 –
TMEFF2h
33 (48)
1.4 (0.6 – 3.0) 0.46
0.36
(55)
3.4)
15
1.3 (0.5 –
WIF1i
24 (35)
1.2 (0.5 – 2.8) 0.63
0.56
(39)
3.2)
Hypermethylation
CDKN2A
17
0.8 (0.3 –
28 (41)
0.8 (0.4 – 1.9) 0.68
0.54
(p16)j
(45)
1.9)
31
0.8 (0.2 –
CYP27B1l
58 (84)
1.2 (0.4 – 3.4) 0.74
0.72
(82)
3.0)
20
0.6 (0.3 –
ER alphaj
31 (45)
0.7 (0.3 – 1.6) 0.45
0.27
(53)
1.5)
28
0.8 (0.3 –
IGF2e
52 (75)
1.1 (0.4 – 2.7) 0.85
0.57
(74)
2.0)
16
0.9 (0.4 –
MGMTh
0.9 (0.4 – 2.1) 0.88
0.80
28 (41)
(42)
2.1)
34
0.7 (0.2 –
MLH1l
63 (91)
1.2 (0.3 – 4.7) 0.76
0.67
(89)
3.1)
12
0.9 (0.3 –
NGFRa
20 (29)
0.9 (0.4 – 2.1) 0.78
0.75
(32)
2.2)
35
0.6 (0.1 –
PER2g
62 (90)
0.8 (0.2 – 3.1) 0.70
0.56
(92)
3.0)
18
0.9 (0.4 –
SEPT9a
32 (46)
1.0 (0.4 – 2.1) 0.92
0.81
(47)
2.1)
150

* - Odds of adenoma status given no methylation detected in the candidate
gene. Note: CYP24A was not included in the table due to all subjects being
unmethylated in the promoter. Adjusted for: a – vitamin D and multivitamin use;
b – vitamin C and vitamin D use and physical activity; c – multivitamin , vitamin
C, and vitamin D use, physical activity, ever smoking, currently drinking
alcohol, being married, and age group; d – multivitamin use, vitamin C and D
use, and ever smoking; e – vitamin C and D use and physical activity; f –
multivitamin use, vitamin C use, vitamin D use, physical activity, ever smoking,
age, and being married; g – multivitamin and vitamin D use, physical activity,
and age group; h – vitamin D use; i – vitamin D use and age group; j - vitamin
d use, physical activity and age; k - vitamin C and D use, physical activity and
age; l – vitamin D use, current drinking alcohol, and age group. OR: odds ratio;
CI: confidence interval
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Table 5.5. Sensitivity, specificity, positive predictive value, and negative predictive value of PER1, PER3, and MINT1
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Controls
Cases
Total
(n)
(n)
(n)
Present
20
17
37
PER1 Hypomethylation
Absent
49
21
70
Total
69
38
107
Present
2
6
8
PER3 Hypomethylation
Absent
67
32
99
Total
69
38
107
Present
4
7
11
MINT1 Hypomethylation Absent
65
31
96
Total
69
38
107
Present
49
21
70
PER1/PER3
Absent
20
17
37
Hypomethylation
Total
69
38
107
Present
45
20
65
PER1/MINT1
Absent
24
18
42
Hypomethylation
Total
69
38
107
Present
63
28
91
PER3/MINT1
Absent
6
10
16
Hypomethylation
Total
69
38
107
Present
44
19
63
PER1/PER3/MINT1
Absent
25
19
44
Hypomethylation
Total
69
38
107
PPV: Positive predictive value; NPV: Negative predictive value

Sensitivity
(%)

Specificity
(%)

PPV
(%)

NPV
(%)

45

71

46

70

16

97

75

68

18

94

64

68

55

29

30

54

53

35

31

57

74

9

31

38

50

36

30

57

Table 5.6. Concordance of methylation in matched PBLs, normal GI tissue, and polyp tissue
Normal GI Tissue

PBLs

MINT1
PER1
PER3

PBLs
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MINT1
PER1
PER3

Normal GI
Tissue

MINT1
PER1
PER3

npairs = 35
Hypomethylated
Hypermethylated
Hypomethylated
Hypermethylated
Hypomethylated
Hypermethylated

Hypomethylated
0
3
7
8
2
9

npairs = 12
Hypomethylated
Hypermethylated
Hypomethylated
Hypermethylated
Hypomethylated
Hypermethylated

Hypomethylated
0
1
1
7
1
2

npairs = 4
Hypomethylated
Hypermethylated
Hypomethylated
Hypermethylated
Hypomethylated
Hypermethylated

Hypomethylated
0
0
2
1
1
0

Hypermethylated
Kappa Coefficient
4
-0.11
28
5
0.22
15
2
0.12
22
Polyp Tissue
Hypermethylated
Kappa Coefficient
0
0
11
1
-0.09
3
1
0.25
8
Polyp Tissue
Hypermethylated
Kappa Coefficient
1
0
3
0
0.5
1
2
0.2
1

p-value
0.52
0.18
0.40

p-value
1.00
0.58
0.37

p-value
1.00
0.25
0.51

Abbreviations: PBLs, peripheral blood leukocytes; GI, gastrointestinal
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Table 5.7. Adjusted means of fold change expression for PER1 and PER3 by methylation status
Fold Change in Expression p-value Explained Variance (%)
PBL Marker
n
Mean (SD)
0.18
PER1
Hypermethylated
57
0.99 (0.05)
0.62
Hypomethylated
26
1 (0.02)
0.06
PER3
Hypermethylated
77
0.99 (0.03)
0.82
Hypomethylated
6
0.99 (0.04)
Normal GI Tissue Marker
25.88
PER1
Hypermethylated
8
1.01 (0.02)
0.06
Hypomethylated
6
1.04 (0.02)
9.18
PER3
Hypermethylated
10
1.02 (0.04)
0.29
Hypomethylated
4
1.05 (0.06)
Polyp Tissue Marker
16.04
PER1
Hypermethylated
2
1.02 (0.07)
0.66
Hypomethylated
6
0.99 (0.02)
0.91
PER3
Hypermethylated
5
0.99 (0.05)
0.82
Hypomethylated
3
1 (0.04)
Note: MINT1 expression could not be measured.
Abbreviations: SD, standard deviation; PBL, peripheral blood leukocyte; GI, gastrointestinal

Table 5.8. Unadjusted and adjusted odds ratios* for gene expression relative to adenoma case status (N = 83)
Candidate Gene
Crude OR
95% CI
Adjusted OR
95% CI
a
PER1
0.003
<0.01 – 181.72
<0.01
<0.01 – 1.86
PER3b
0.06
<0.01 – >999.99
0.34
<0.01 – >999.99
Note: MINT1 expression was not measured.
Abbreviations: OR, odds ratio; CI, confidence interval; * - Odds of adenoma status given for a one unit increase in
expression in the candidate gene. Adjusted for: a – ever smoking, physical activity, and vitamin C and vitamin D use; b
– ever smoking, being married, age, physical activity, ever taking a multivitamin, and vitamin C and vitamin D use
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Table 5.9. Spearman’s correlations of PER1 and PER3 expression in PBLs,
normal GI tissue, and polyp tissue
PBLs
Spearman's
rho

Normal Tissue

Polyp Tissue

PER1

PER3

PER1

PER3

PER1

PER3

1

-0.04

0.26

-0.05

0

0.26

83

0.69
83

0.34
16

0.85
16

1
12

0.42
12

1

-0.37
0.16
16

0.13
0.70
12

0.53
0.08
12

PBLs

PER1

Polyp Tissue

Normal Tissue

PER3

p-value
npairs
Spearman's
rho
p-value
npairs
Spearman's
rho

-0.04
0.69
83

83

0.4
0.12
16

0.26

-0.05

1

0.64

0.79

0.93

0.34
16

0.85
16

16

0.01
16

0.04
7

<0.01
7

0.40
0.12
16

-0.37
0.16
16

0.64
0.01
16

1
16

0.43
0.34
7

0.71
0.07
7

0

0.26

0.79

0.93

1

0.62

PER1

PER3

p-value
npairs
Spearman's
rho
p-value
npairs
Spearman's
rho

PER1

p-value
1
0.42
0.04
<0.05
npairs
12
12
7
7
12
Spearman's
rho
0.13
0.53
0.43
0.71
0.62
PER3
p-value
0.70
0.08
0.34
0.07
0.03
npairs
12
12
7
7
12
Note: MINT1 expression could not be measured.
Abbreviations: PBLs, peripheral blood leukocytes; GI, gastrointestinal
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0.03
12
1
12

Chapter 6
Case-Control Study of the PERIOD3 Clock Gene Length Polymorphism and
Colorectal Adenoma Formation 4

4
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6.1 Abstract
Introduction: Clock genes are expressed in a self-perpetuating, circadian
pattern in virtually every tissue including the human gastrointestinal tract. They
coordinate cellular processes critical for tumor development, including cell
proliferation, the DNA damage response, and apoptosis. Circadian rhythm
disturbances have been associated with an increased risk for colon cancer and
other cancers. This mechanism has not been elucidated, but may involve
mutation or dysregulation of the ‘period’ (PER) clock genes, which have tumor
suppressor properties. A variable number tandem repeat (VNTR) in the
PERIOD3 (PER3) gene has been associated with sleep disorders, differences in
diurnal hormone secretion, and increased premenopausal breast cancer risk.
Colorectal tumors have reduced PER3 expression relative to normal tissue.
However, gene expression or susceptibility related to PER3 has not been
examined in conjunction with adenomatous polyps. This exploratory case-control
study was the first to test the hypothesis that the 5-repeat PER3 VNTR sequence
is associated with increased odds of adenoma formation among 146
colonoscopy patients. Materials and Methods: Information on demographics,
medical history, occupation, and lifestyle was collected prior to colonoscopy.
Cases (n=49) were individuals with at least one histopathologically confirmed
adenoma. Controls (n=97) included patients with normal findings or hyperplastic
polyps not requiring enhanced surveillance. Unconditional multiple logistic
regression was used to calculate odds ratios (ORs) with 95% confidence
intervals (CIs), after adjusting for potential confounding. Results: Adenomas
were detected in 34% of participants (average age: 59±9 years; 65% European
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American [EA]; 72% male). Cases were more likely to possess the 5-repeat
PER3 genotype relative to controls (4/5 OR: 2.1, 95% CI: 0.9-4.8; 5/5 OR: 5.1,
95% CI: 1.4-18.1; 4/5+5/5 OR: 2.5, 95% CI: 1.7-5.4). Examination of the
Oncomine microarray database indicated that PERIOD gene expression in
adenomas was reduced relative to adjacent normal mucosa in several studies.
Discussion: Results suggest a need for follow-up in a larger sample.

6.2 Introduction

According to recent estimates, over 143,000 new patients and more than
51,000 deaths occurred in 2012 in the United States due to colorectal cancer
(CRC), which makes it the third most common and deadly cancer among both
men and women.1 Colorectal adenomatous polyps are the primary precursor
lesions for CRC, accounting for 85-90% of cases.244 Developing a better
understanding of factors related to adenoma susceptibility and progression thus
represents an important goal for CRC prevention.

Disruption of circadian rhythms or clock gene expression is emerging as a
novel and potentially modifiable cancer risk factor, although the
pathophysiological mechanism is incompletely understood.275, 298 The central
circadian pacemaker is located in the suprachiasmatic nuclei (SCN) of the
anterior hypothalamus. Generation of circadian rhythms is accomplished
primarily via photic input from the retina, which synchronizes the reciprocal
transcriptional-translational expression of at least nine core clock genes: PER1,
PER2, PER3, CRY1, CRY2, CLOCK, BMAL1, TIM, and CK1ε.275, 298, 303 In most
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tissues, this system facilitates the diurnal expression of ~10% of the entire
mammalian genome via genetic and epigenetic regulation of clock-controlled
genes. 89, 304-307 Various factors, such as shiftwork, late bedtimes, or poorly timed
light exposure can disrupt endogenous circadian timing, thus altering clock gene
expression and the cellular processes they help regulate.298 Because clock
genes regulate processes that are considered hallmarks of carcinogenesis (cell
cycle control, DNA damage response, apoptosis), their dysregulation may serve
as an underlying biological mechanism linking altered circadian rhythms with
cancer.298, 308-312 Clock gene polymorphisms have been associated with nonHodgkin’s lymphoma and cancers of the breast and prostate.298 Clock gene
polymorphic variation also influences sleep regulation,303, 313, 314 which may
contribute to increases in cancer susceptibility that have been observed among
people who experience circadian rhythm disturbances or sleep disruption.45, 315,
316

For example, shiftwork and sleep disturbances have been associated with

increased CRC risk,106, 316-318 and truncated sleep (<6 hours per night) has been
associated with an increased odds of colorectal adenoma formation relative to
adenoma-free controls.45
The Period (PER) clock genes have immunomodulatory303, 319, 320 and
tumor suppressor properties.29, 298, 308, 315, 321 Mutation or altered expression of
PER genes has been observed among cancer patients relative to controls, within
human tumors relative to adjacent normal tissue, and in experimental cancer
bioassays.19, 29, 31, 32, 104, 105, 116, 298, 308, 322, 323 Whether differential expression of
PER or other clock genes occurs in human adenomas versus normal tissue is
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not known. The PER3 variable number tandem repeat (VNTR, rs57875989)
length polymorphism contains 4 or 5 copies of a 54-bp sequence encoding 18
amino acids. The 5-repeat variant adds several potential phosphorylation motifs
to the gene, and PER3’s interaction with circadian processes may be enhanced
among those individuals.313, 324 The 5-repeat PER3 allele is associated with a
relatively penetrant phenotype that includes morning circadian preference,38, 313,
325

increased cognitive decline in response to sleep deprivation,313 differences in

levels or timing of melatonin or cortisol secretion,40, 324, 326 and a tendency
towards depressive symptoms or an earlier onset of bipolar disorder.24, 327 PER3
is considered a candidate tumor suppressor gene, 19, 29, 321 and the 5/5 PER3
VNTR genotype has been associated with increased premenopausal breast
cancer risk,19 though not consistently.328, 329 Recently, the relationship between
the PER3 VNTR and CRC risk was examined in Greece and no association was
observed, although a relatively small portion of the study population was
homozygous for the 5-repeat allele (<2%), and differences in genotype frequency
among cases and controls were not adjusted for potential confounding.330 The
role of PER3 or other clock genes in human adenoma formation has yet to be
examined in detail. Therefore, this exploratory study tested the hypothesis that
adenoma cases are hetero- or homozygous for the 5-repeat PER3 variant
relative to adenoma-free controls.
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6.3 Materials and Methods

Participants and data from two different endoscopy centers in the
Columbia, SC metropolitan area were pooled for this analysis; the South Carolina
Medical Endoscopy Center Site 1, n=93), and the WJB Dorn Veterans
Administration Medical Center (Site 2, n=53). Participants completed an on-site
interview to collect information on: demographic (sex, marital status, income,
race/ethnicity), lifestyle (smoking history, diet, physical activity), and occupational
(employment status, job industry, type of shift, history of shiftwork) factors, as
well as personal and family medical history (ever being diagnosed with other
diseases, personal history of cancer, family history of CRC). Cases were defined
as individuals with at least one histologically confirmed adenoma, and controls
were subjects with a normal colonoscopy, or a normal biopsy not requiring
heightened surveillance (e.g., hyperplastic polyp).

Genotyping procedure

Genomic DNA was extracted and genotyping for the PER3 VNTR
sequence was performed using previously described methods.24, 331 For
participants recruited from Site 1, the PER3 VNTR sequence was amplified via
polymerase chain reaction (PCR) using the following forward (5′CAAAATTTTATGACACTACCAGAATGGCTGAC-3′ and reverse (5′AACCTTGTACTTCCACATCAGTGCCTGG-3′) primers.19,328 The reactions were
heated to 94°C for 2 minutes followed by 35 cycles at 94°C for 30 seconds, 60°C
for 30 seconds, and 72°C for 45 seconds. Finally, the reactions were extended
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for 7 minutes at 72°C. PCR products were then separated by electrophoresis on
a 3% agarose gel. The PCR primers used for Site 2 assays were: forward, 5’TGGCAGTGAGAGCAGTCCT-3’ and reverse 5’AGTGGCAGTAGGATGGGATG-3’. PCR cycling conditions were as follows: 3
minutes at 94°C ; 35 cycles of 30 seconds at 94°C, 30 seconds at 58°C, and 30
seconds at 72°C; and at 72°C for 30 seconds, PCR products were extended. A
2% agarose gel stained with ethidium bromide was used to separate and
visualize the PCR fragments at 220V for 30 minutes. Both primers provide valid
characterization of the PER3 VNTR19, 24, 35, 328, 330-332 and amplicons from both
methods were confirmed via Sanger sequencing. Duplicate genotyping was
performed in 10% of all samples from both sites for quality control purposes, and
there was 100% concordance among duplicates.24 DNA sequences of amplicons
produced by each set of primers were verified via Sanger sequencing. HardyWeinberg equilibrium (HWE) was examined, and gene frequencies for the PER3
VNTR were in HWE among the entire study population (p=0.74), and among
controls from both sites (p=0.99) or within each site (Site 1: p=0.94; Site 2:
p=0.82, Table 6.1).

Methylation assays

A peripheral whole blood sample was collected from each participant in
Site 1 using vacutainers containing EDTA anticoagulant. Genomic DNA was
isolated using the PUREGENE genomic DNA purification kit (Gentra Systems,
Minneapolis, MN) according to the manufacturer’s protocol from peripheral whole
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blood, normal GI tissue, and polyp tissue. Sodium bisulfite conversion of DNA
was performed using EpiTect kits (QIAGEN, Germantown, MD, USA). Briefly,
DNA (2 µg) was added to the reaction buffer and bisulfite DNA conversion was
conducted in a Bio-Rad S1000 thermal cycler (Bio-Rad Laboratories, Hercules,
CA, USA) using the manufacturer’s suggested program for the conversion
reaction. Converted DNA was eluted from a spin column in TE buffer and either
used immediately or stored at –20°C. DNA oligonucleotides for primer pairs
were purchased from Integrated DNA Technologies (Coralville, IA, USA, Table
6.2). To ensure that the polymerase chain reaction (PCR) primers were specific
for the detection of methylated DNA, a control human DNA set (EpiTect Control
DNA, QIAGEN Sciences, Germantown, MD) containing positive (bisulfite
converted, 100% methylated) and negative (bisulfite converted, 0% methylated)
control DNA was used. To quantify methylation specific PCR (MSP) results, the
QIAxcel system was used (QIAGEN Sciences, Germantown, MD), which utilizes
a multiplexed fluorescence detection method with a resolution of 3-5 bp for DNA
fragments. The detection sensitivity of QIAxcel system was 0.1 ng/μl DNA in
undiluted amplification reactions. The QIAxcel system was equipped with the
BioCalculator software that produces a tabular display of a variety of peak
properties, including number of peaks as well as the height, width, and area of
each peak. The height of the peak was used for separation of the results into
three methylation categories: high (peak height >0.30), medium (peak height
0.29-0.05), and low (peak height <0.05), or none (no methylation detected).
Results were categorized as either unmethylated or methylated (combination of
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medium/low, and high methylation categories). The methylation status of each
sample was normalized via a two-step process. First, a NanoDrop™ Lite
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) was used to
measure concentrations of the DNA templates. Subsequent experiments used
the same amount of DNA template for each MSP reaction. To facilitate
quantification, equal volumes of the MSP products were loaded on the QIAxcel
system for analysis. Second, BRCA1 gene methylation was used as an internal
standard since the same amount of DNA template had extremely high
methylation in each sample. The measured peak height of BRCA1 methylation
was then used to normalize the methylation of the genes of interest for each
sample. All methylation assays were performed blinded to case status.

Real-time quantitative PCR (qPCR)

RNA was extracted from PAXgene tubes using PAXgene Blood RNA Kit
from QIAGEN (Germantown, MD, USA) from participants in Site 1. RNA quality
was checked via Agilent Bioanalyzer 2100 and concentration was quantified on
NanoDrop. cDNA was synthesized from total RNA using gene-specific primers
according to the Verso cDNA Kit (Abgene, Rochester, New York). Reverse
transcriptase reactions contained 1 μg of total RNA (1-5 μl of total RNA), 4 μl 5X
cDNA synthesis buffer, 1 μl 5 μM dNTP mix, 1 μl 400 ng/μl random hexamers, 1
μl RT Enhancer, 1 μl Verso Enzyme Mix, and a variable amount of PCR grade
water to have a total of a 20 μl. The 20 μl reactions were incubated in an MJ
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Research PTC-225 Thermo Cycler in a 96-well plate for 30 min at 42°C, 2 min at
95°C, and then held at 4°C. cDNAs were stored at -20 oC.

Gene-specific primers were created using Primer3 software. Forward and
reverse sequences were confirmed for their presence within exons and lack of
single nucleotide polypmorphisms using NCBI’s Basic Local Alignment Search
Tool (BLAST). PCR cycling information is found in Table 6.3. All reactions were
performed in singleplex mode. Each reaction contained 10 μl 2x SYBR Green
PCR master mix (Bio-Rad Laboratories, Hercules, CA), 2 μl of each primer, 0.5-2
μl of cDNA template, and a variable amount of PCR grade water to have a total
reaction amount of 20 μl. The standard curve method was employed and β-actin
was used as the endogenous control to determine levels of expression of cDNA
in study participants. A two-fold 10-point serial dilution was created through the
use of diluted PCR products of β-actin and markers who presented an
association with polyp status. The standard curve produces a linear relationship
between number of threshold cycles (Ct) and the initial known amounts of cDNA,
allowing the determination of the cDNA concentration of unknown samples based
on their Ct value, thereby also giving the number of mRNA copies for each gene
present in unknown samples. The threshold cycle (Ct) is defined as the
fractional cycle number at which the fluorescence passes the fixed threshold.
Each sample was analyzed in duplicate, with a negative template control
included in each run to check for DNA contamination.
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Statistical analysis

Statistical analyses were performed using the Statistical Analysis Software
(SAS®) computer program (version 9.2, Cary, NC) and the R meta-analysis
package (version 2.14.1, http://cran.r-project.org). Potential differences between
study variables by case status within the entire study population, and within each
site separately, were examined using the chi-squared test for differences
between proportions. Differences in median shiftwork duration by PER3
genotype were compared using the Wilcoxon rank sum test. Unconditional
multiple logistic regression was used to estimate odds ratios (ORs) with 95%
confidence intervals (95% CIs) for PER3 VNTR genotype among adenoma cases
relative to controls using the 4/4 genotype as referent.19, 24 Covariates considered
for inclusion in adjusted models were known or suspected adenoma or CRC risk
factors ( age, sex, race, body mass index [BMI], CRC family history, smoking
history, work-related factors, diet, vitamin and supplement use, physical activity,
sociodemographic characteristics [income, education], personal medical history) ,
and variables that differed among participants and non-participants (sex,
personal cancer history, ulcer diagnosis, lactose intolerance, secondhand smoke
exposure, recruitment site). Final models included variables that were
statistically significant (p≤0.05) in the saturated model, or produced at least a
10% change in the parameter estimate for genotype (decision latitude at work,
procedure reason, recruitment site). Ancillary analyses examined relationships
between lifetime shiftwork and adenoma status; or PER3 genotype and adenoma
status after stratification by procedure reason (screening vs. surveillance
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colonoscopy), shiftwork (none vs. any, or median split on years of lifetime
shiftwork), and methylation status in PER1, PER2, or PER3. Random-effects
meta-analysis was used to evaluate the study hypothesis since recruitment
occurred at two separate sites. The I2 and Q statistics were used to assess
heterogeneity between sites. Oncomine,333 a publically accessible gene
expression microarray database, was queried to examine potential differential
expression of PER1, PER2, and PER3 clock genes in adenomas versus adjacent
normal tissue. Expression levels of PER1, PER2, and PER3 were also
examined for differences by genotype in a subset of participants.

6.4 Results
The median age of the participants was 58 years (25th percentile: 53
years, 75th percentile: 64 years), and they were primarily European American
(65%), and male (72%). Most (69%) participants had engaged in at least one
year of shiftwork (median: 3 years; 25th percentile: 0 years; 75th percentile: 12.3
years). Adenomas were detected in 34% of participants (females: 28%, males:
36%). Compared to controls, cases were more likely to have smoked (78% vs.
56%), have higher decision latitude (57% vs. 29%), and have undergone a
surveillance relative to a screening colonoscopy (59% vs. 40%, Table 6.4).
Additional results on characteristics by site and by case status within each site
are found in Tables 6.5 and 6.6, respectively.

Overall PER3 VNTR genotype frequencies (4/4: 47%, 4/5: 42%, 5/5: 11%)
were consistent with those reported elsewhere (4/4: 35-74%, 4/5: 25-46%, 5/5: 2169

18%).327, 328, 334, 335 Adenoma cases were more likely than controls to possess
one or two copies of the 5-repeat sequence (5/5 OR: 5.1, 95% CI: 1.4-18.1;
4/5+5/5 OR: 2.5; 95% CI: 1.7-5.4, Table 6.7). Shiftwork, or the combined effect of
shiftwork and genotype was not related to adenoma case status (data not
shown).

When analyses were stratified by procedure reason, the 5/5 genotype was
associated with adenoma status among screening patients (OR: 10.7, 95% CI:
1.4-80.7), whereas no statistically significant relationship was observed among
those with the 5/5 genotype receiving a surveillance colonoscopy (OR: 2.3, 95%
CI: 0.5-11.4), or among the other genotypes for either procedure reason (Table
6.8). After stratification by methylation status of PER1, PER2, and PER3
methylation status (hypomethylation or hypermethylation), no statistically
significant relationships were observed (Table 6.9).

The distribution of lifetime shiftwork history varied by PER3 VNTR
genotype (Table 6.10). Those with the 4/4 genotype had greater median lifetime
years of shiftwork (5 years) compared to those with the 4/5 (2 years, p=0.02), 5/5
(0.75 years, p=0.05), or the combined genotype (4/5+5/5: 1 year, p<0.01). When
the data were evaluated using meta-analytic methods, adenoma cases were ~23 times more likely than controls to have at least one 5-repeat allele, although the
confidence intervals were wide and did not achieve statistical significance (4/5
OR: 2.27, 95% CI: 0.43-11.62, pheterogeneity: 0.12, I2: 60%; 5/5 OR: 3.02, 95% CI:
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0.72-12.71, pheterogeneity: 0.84, I2: 0%; 4/5+5/5 OR: 2.35, 95% CI: 0.60-9.21,
pheterogeneity: 0.14, I2: 54%).

Data for PER1, PER2, and PER3 expression in adenomas relative to
normal tissue retrieved from the Oncomine microarray database are presented in
Table 6.11.336-338 A statistically significant reduction in PER3 expression was
observed in adenomas relative to normal tissue among each of the available data
sets, and similar differences were noted for PER1 and PER2 expression (Table
6.11).
Expression levels of PER1, PER2, and PER3 were stratified by genotype
(4/4 genotype vs. 4/5 or 5/5 genotype, Figure 6.1). Those expression levels were
slightly higher for those with at least one 5-repeat allele, the only statistically
significant difference was observed in PER1 expression (p ≤ 0.05). That is,
individuals with at least one 5-repeat allele had higher levels of PER1 expression
compared to individuals without a 5-repeat PER3 genotype.
6.5 Discussion
Few studies have examined the role of the PER3 VNTR on cancer-related
outcomes.19, 328-330 To our knowledge, this exploratory study is the first to
examine the relationship between the PER3 VNTR and human adenoma risk.
Adenoma cases were ~2-5 times more likely to possess the 5-repeat PER3
length polymorphism compared to controls. There are several noteworthy
strengths, limitations and uncertainties associated with this study. Quality criteria
for genotyping and screening colonoscopy adenoma detection rates were
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satisfactory,339, 340 and adjustment for potential confounding by known or
suspected adenoma risk factors did not alter the interpretation of the results. The
meta-analysis indicated that the strength of association between PER3 genotype
and adenoma status was generally consistent with the main analysis and the
results were not strongly impacted by heterogeneity between the sites. Some
imprecise risk estimates with wide confidence intervals were observed due to a
limited sample size, particularly for the stratified analyses. Thus, examination of
possible effect modification by factors such as race, chronotype, procedure
indication (screening versus surveillance), or methylation would benefit from a
larger sample in future studies. Nonetheless, the lower bound of the confidence
intervals suggest a ~40% increased risk for adenoma formation among the 5repeat PER3 variants. PER gene expression was not performed among cases
and controls in the present study, thus changes in expression relative to the
PER3 VNTR genotype could not be evaluated. However, our query of the
Oncomine database indicated that PER3 and to a lesser extent PER1 and PER2
expression was reduced among adenomas compared to normal mucosa, which
is consistent with previous studies that observed a reduction in PER1 and PER3
expression in human colorectal tumors relative to adjacent normal tissue.32, 104,
341

However, findings from the Oncomine query somewhat contradict findings

from Figure 6.1, which show increased PER1 expression among those with at
least one 5-repeat allele. This is an unexpected finding because those with at
least one 5-repeat allele should be at an increased risk for adenoma formation,
and those individuals should have lower PER1 expression. Further investigation
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in the relationships between PER3 VNTR variation and expression of the PER
genes is warranted.
The spectrum of known genetic susceptibility markers does not fully
account for all CRC cases. For example, 10 loci identified from genome-wide
association studies had population attributable risks ranging from 1.7% to
11.9%,342 and another previous study estimates that up to 35% of CRC cases
are due to heritable factors.343 The current study mirrors previous investigations
that have examined clock gene polymorphisms in conjunction with cancer
susceptibility,19, 298, 328, 330 including one that identified an association between the
5-repeat PER3 VNTR sequence and increased odds of premenopausal breast
cancer.19 Evidence suggests that PER3 may function as a tumor suppressor. A
recent study among PER3 knockout mice indicated that 36% of the homozygous
null variants developed chemically-induced mammary tumors compared to 12%
among heterozygotes and 0% among wild-type mice.29 Another recent study
used methylation arrays and stringent selection criteria to screen >14,000 genes
to identify putative tumor suppressors associated with human hepatocellular
carcinoma; PER3 was one of only three candidate tumor suppressor genes
identified.321 Chronic gastrointestinal inflammation is important for adenoma and
CRC development,244, 344 and since PERIOD genes play a role in immune system
regulation, their expression may influence these processes.303, 319, 320 Recently,
another PER3 polymorphism (rs2797685) was associated with inflammatory
bowel disease, a known CRC risk factor.345 The current study attempted to look
at joint effects of the PER3 VNTR and methylation status of PER1, PER2, and
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PER3. Though no statistically significant findings were observed when
examining the joint effect of genetic and epigenetic variation (Table 6.9), future
larger studies should examine these interactive effects since the mechanism
whereby PER3 may exert a tumor suppressor function is currently unknown.
The clock genes exert genetic and epigenetic regulatory effects that
facilitate the circadian expression of ~5-10% of the entire mammalian
transcriptome,89, 304-307 including other known tumor suppressors and oncogenes
(e.g., c-Myc, p53).26, 31, 346 Clock genes also help regulate cellular processes that
are active during carcinogenesis (cell proliferation, DNA damage response,
apoptosis), and clock gene dysregulation may foster adenoma formation by
influencing these pathways.298, 308, 310, 312
Individuals with the 5-repeat PER3 VNTR sequence tend to have relatively
penetrant phenotypic characteristics including delayed sleep phase syndrome,
increased susceptibility to cognitive impairment after sleep deprivation, morning
circadian preference, and differences in the timing or levels of circadian hormone
secretion,40, 313, 324 although some inconsistencies have been reported.36, 38, 347, 348
Whether alterations in sleep and other circadian processes can increase cancer
susceptibility remains to be determined. Studies of shift work and cancer
incidence suggest this is possible.349 In the present study, participants with the 5repeat allele reported less cumulative shiftwork experience relative to those with
the 4/4 genotype (Table 6.10). Additional research is needed to determine
whether this is a chance finding or if individuals carrying these variants are less
tolerant of shiftwork compared to those with the 4/4 genotype. Individuals with
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the 5-repeat allele may be more susceptible to disturbances in circadian
timekeeping.40, 313, 324, 326 For example, those carrying the 5/5 PER3 variant
were sensitive to light-induced melatonin suppression whereas 4/4 homozygotes
were not responsive.326 Because melatonin has potent antioxidant, antiproliferative and anti-inflammatory properties in the gastrointestinal tract, a
reduction in its secretion (e.g., by exposure to light at night) may facilitate
physiologic changes that predispose to increased risks for CRC or other
cancers.106, 275, 298, 316, 317 Although the PER3 has tumor suppressor properties
and its length polymorphism tends to have relatively penetrant phenotypic
characteristics, the role of these factors in cancer susceptibility, if any, remains to
be characterized.
In conclusion, results from this study indicate that individuals with the 5repeat PER3 length polymorphism may be more susceptible to adenoma
formation. The results are consistent with Oncomine data indicating that PERIOD
clock gene expression is reduced in adenomas relative to normal GI tissue.
Further interrogation of interrelationships between the PER3 VNTR and genetic
or epigenetic pathways that may facilitate adenoma risk, such as changes in the
expression of clock-controlled, cancer-related genes, is recommended. Further
elucidation of the PER3 VNTR genotype in relation to circadian rhythm or clock
gene dysregulation may lead to development of novel, modifiable targets for
adenoma and CRC prevention.
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Figure 6.1. Differences in fold change expression of the PER gene family in
blood by PER3 VNTR genotype.
Note: *p≤ 0.05
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Table 6.1. PER3 VNTR gene frequencies among study participants
Entire Population
All Controls
Recruitment Site 1
(n = 146)
(n = 97)
(n = 62)
Genotype
n (%)
HWE p-value
n (%)
HWE p-value
n (%)
HWE p-value
4/4
68 (47)
52 (54)
29 (47)
4/5
62 (42)
0.74
38 (39)
0.99
27 (43)
0.94
5/5
16 (11)
7 (7)
6 (10)
Abbreviation: HWE, Hardy-Weinberg equilibrium

Recruitment Site 2
(n = 35)
n (%)
HWE p-value
23 (44)
11 (31)
0.82
1 (3)
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Table 6.2. Primers for Methylation-Specific PCR
Gene Name

Forward (5’ -> 3’)

Reverse (5’ -> 3’)

PER1
PER2
PER3

ATTTAGGTTTACGTGCGTTC
GTTTTTGGTCGGTGGTCGG
CGTCGGTTTGTTGGGATTG

GATTAACTAAAAATCTCTTCCCGAC
CGAAACTCCTACGCACCTCC
AAACCGACTCCGCAAACC

Amplicon (bp)
95
92
160
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Table 6.3. Gene-specific primers for PER1, PER3, and β-Actin and qPCR cycling information
Gene
Forward sequence (5’ -> 3’)
Reverse sequence (5’ -> 3’)
Annealing
Number
temperature
of cycles
(oC)
PER1
ATTTGGCTGCTCATGGCCAA ATCCTGCTTCAGCACAGAG
63
40
TGCT
GTCAT
PER3
TATGCAGGGCATCCTCCCTT TATGCAGGGCATCCTCCCTT
60
40
TGAA
TGAA
β-Actin CATGTACGTTGCTATCCAGG CTCCTTAATGTCAGGCACGA
60
40
C
T

Amplicon
(bp)
90
121
250
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Table 6.4. Demographic characteristics of study population
Total
Controls
Cases
Population
1
(n = 97)
(n = 49)
Variable
(n = 146)
N (%)
N (%)
N (%)
Sex
Male
105 (72)
67 (70)
38 (78)
Females
40 (28)
39 (30)
11 (22)
Race
European American
94 (65)
58 (60)
36 (73)
African American
51 (35)
38 (40)
13 (27)
Marital Status
Unmarried
Married
Education
Up to High School
Some College
College
Undergraduate or
Post-Graduate
Degree
Income level
Under $50,000
≥$50,000 to
$100,000
≥$100,000
Body Mass Index
(kg/m2)
Underweight or
normal
Overweight
Family History of
Colorectal Cancer
Yes
No
Diagnosis of
Diabetes
Yes
No
History of Smoking
Ever
Never
Work Decision
Latitude

Cases vs.
Controls
p-value2
0.32

0.12

0.46
38 (26)
107 (74)

27 (28)
69 (72)

11 (22)
38 (78)
0.75

52 (36)
40 (28)

34 (35)
25 (26)

18 (37)
15 (31)

53 (37)

37 (39)

16 (33)
0.37

63 (46)
53 (39)

40 (45)
38 (43)

23 (49)
15 (32)

20 (15)

11 (12)

9 (19)
0.22

33 (23)

19 (20)

14 (29)

113 (77)

78 (80)

35 (71)
0.84

25 (17)
120 (83)

17 (18)
79 (82)

8 (16)
41 (84)
0.15

42 (29)
102 (81)

24 (25)
71 (75)

18 (38)
31 (62)

91 (63)
53 (37)

53 (56)
42 (44)

38 (78)
11 (22)

0.01

0.03
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Table 6.4. Demographic characteristics of study population
Total
Cases vs.
Controls
Cases
Population
Controls
(n = 97)
(n = 49)
Variable1
(n = 146)
p-value2
N (%)
N (%)
N (%)
Unknown
74 (51)
51 (53)
23 (47)
Never or Sometimes
21 (14)
18 (19)
3 ( 6)
Often or Always
51 (35)
28 (29)
23 (57)
Age Group
0.11
30-54
45 (31)
34 (35)
11 (22)
55-65
66 (46)
44 (46)
22 (45)
> 65
34 (23)
18 (19)
16 (33)
Reason for
0.03
Colonoscopy
Symptoms/Screening
78 (53)
58 (60)
20 (41)
Surveillance
68 (47)
39 (40)
29 (59)
th
Median (25 percentile, 75th
percentile)
Lifetime Shiftwork
3 (0, 12.3)
5 (0, 15)
2 (0, 10)
0.10
(Years)
1Number of subjects for each variable category may not equal total number of
subjects due to missing data; 2Chi-squared test for differences in proportions
or Wilcoxon rank sum test for differences in medians between cases and
controls
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Table 6.5. Differences in patient characteristics by site
Recruitment Site Recruitment Site
1
2
(N = 93)
(N = 53)
Variable1
N (%)
N (%)
Sex
Male
52 (57)
53 (100)
Female
40 (43)
0 (0)
Race
European American
66 (72)
28 (53)
African American
26 (28)
25 (47)
Marital Status
Unmarried
18 (20)
20 (38)
Married
74 (80)
33 (62)
Education
Up to High School
28 (30)
24 (45)
Some College
24 (26)
16 (30)
College Undergraduate
40 (43)
13 (25)
or Post-Graduate
Degree
Income level
Under $50,000
26 (31)
37 (70)
≥$50,000 to $100,000
40 (48)
13 (25)
≥$100,000
17 (20)
3 (6)
Body Mass Index
(kg/m2)
Underweight or normal3
17 (18)
16 (30)
Overweight
76 (82)
37 (70)
Family History of
Colorectal Cancer
Yes
17 (18)
8 (15)
No
75 (82)
45 (85)
Diagnosis of Diabetes
Yes
28 (31)
14 (26)
No
64 (69)
39 (74)
History of Smoking
Ever
51 (55)
40 (77)
Never
41 (45)
13 (23)
Work Decision Latitude
Unknown
43 (47)
31 (58)
Never or Sometimes
16 (17)
5 (9)
Often or Always
34 (37)
17 (32)
Age group
30-54
23 (25)
22 (42)
55-65
42 (46)
24 (45)
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p-value2

<0.0001

0.02

0.02

0.06

<0.0001

0.10

0.60

0.58

0.01

0.27

0.04

Table 6.5. Differences in patient characteristics by site
Recruitment Site Recruitment Site
p-value2
1
2
(N = 93)
(N = 53)
Variable1
N (%)
N (%)
>65
27 (29)
7 (13)
Reason for Procedure
<0.0001
Screening/Symptoms
25 (27)
53 (100)
Surveillance
68 (73)
0 (0)
4
Case Status
0.94
Controls
62 (67)
35 (66)
Adenomas
31 (33)
18 (34)
th
Median (25 percentile, 75th percentile)
Lifetime Shiftwork
1 (0, 10)
6 (2, 17)
0.0004
(Years)
11Number of subjects for each variable category may not equal total number of
subjects due to missing data ; 2 Chi-squared test for differences in proportions
or Wilcoxon rank sum test for differences in medians between Site 1 and Site
2; 3Three subjects who were in the underweight BMI category (≤18.5 kg/m2);
4No polyps or hyperplastic polyp(s) only
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Table 6.6. Differences in patient characteristics by case status and site
Recruitment Site 1
Recruitment Site 2
1
Total
Controls
Cases
pTotal
Controls1
Cases
3
population (n = 62)
(n = 31) value population (n = 35)
(n = 18)
(n = 93)
(n = 53)
Variable2
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
Sex
0.27
Male
52 (57)
32 (52)
20 (65)
53 (100)
35 (100)
18 (100)
Female
40 (43)
29 (48)
11 (35)
0 (0)
0 (0)
0 (0)
Race
0.18
European American
66 (72)
41 (67)
25 (81)
28 (53)
17 (49)
11 (61)
African American
26 (28)
20 (33)
6 (19)
25 (47)
18 (51)
7 (39)
Marital Status
0.25
Unmarried
18 (20)
14 (23)
4 (13)
20 (38)
13 (37)
7 (39)
Married
74 (80)
47 (77)
27 (87)
33 (62)
22 (63)
11 (61)
Education
0.60
Up to High School
28 (30)
20 (33)
8 (26)
24 (45)
14 (40)
10 (56)
Some College
24 (26)
14 (23)
10 (32)
16 (30)
11 (31)
5 (28)
College Undergraduate or
40 (43)
27 (44)
13 (42)
13 (25)
10 (29)
3 (17)
Post-Graduate Degree
Income level
0.40
Under $50,000
26 (31)
19 (35)
7 (24)
37 (70)
21 (60)
16 (89)
≥$50,000 to $100,000
40 (48)
26 (48)
14 (48)
13 (25)
12 (34)
1 (6)
≥$100,000
17 (20)
9 (17)
8 (28)
3 (6)
2 (6)
1 (6)
2
Body Mass Index (kg/m )
0.85
Underweight or normal4
17 (18)
11 (18)
6 (19)
16 (30)
8 (23)
8 (44)
Overweight
76 (82)
51 (82)
25 (33)
37 (70)
27 (77)
10 (56
Family History of
Colorectal Cancer

0.68

pvalue3

1.00

0.39

0.90

0.50

0.07

0.11

0.82
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Table 6.6. Differences in patient characteristics by case status and site
Recruitment Site 1
Recruitment Site 2
1
Total
Controls
Cases
pTotal
Controls1
Cases
3
population (n = 62)
(n = 31) value population (n = 35)
(n = 18)
(n = 93)
(n = 53)
Variable2
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
Yes
17 (18)
12 (20)
5 (16)
8 (15)
5 (14)
3 (17)
No
75 (82)
49 (80)
26 (84)
45 (85)
30 (86)
15 (83)
Diagnosis of Diabetes
0.01
Yes
28 (31)
13 (22)
15 (48)
14 (26)
11 (31)
3 (17)
No
64 (69)
39 (78)
16 (52)
39 (74)
24 (69)
15 (83)
History of Smoking
0.03
Ever
51 (55)
29 (48)
22 (71)
40 (77)
24 (71)
16 (89)
Never
41 (45)
32 (52)
9 (29)
13 (23)
11 (29)
2 (11)
Missing
1
1
0
0
0
0
Work Decision Latitude
0.08
Unknown
43 (46)
31 (50)
12 (39)
31 (58)
20 (57)
11 (61)
Never or Sometimes
16 (17)
13 (21)
3 (10)
5 (9)
5 (14)
0 (0)
Often or Always
34 (37)
18 (29)
16 (52)
17 (32)
10 (29)
7 (39)
Age group
30-54
23 (25)
16 (26)
7 (23)
0.65
22 (42)
18 (51)
4 (22)
55-65
42 (46)
29 (48)
13 (42)
24 (45)
15 (43)
9 (50)
>65
27 (29)
16 (26)
11 (35)
7 (13)
2 ( 6)
5 (28)
Reason for Procedure
Screening/Symptoms
25 (27)
23 (37)
2 ( 6)
0.002
53 (100)
35 (100)
18 (100)
Surveillance
68 (73)
39 (63)
29 (94)
0 (0)
0 (0)
0 (0)
Median (25th percentile, 75th
Median (25th percentile, 75th
percentile)
percentile)
Lifetime Shiftwork (Years)
0.50 (0,
3.5 (1,
1 (0, 10)
1 (0, 10)
0.36
6 (2, 17)
10 (3, 18)
7)
12)

pvalue3

0.25

0.14

0.26

0.03

1.00

0.11

Table 6.6. Differences in patient characteristics by case status and site
Recruitment Site 1
Recruitment Site 2
1
Total
Controls
Cases
pTotal
Controls1
Cases
p3
population (n = 62)
(n = 31) value population (n = 35)
(n = 18) value3
(n = 93)
(n = 53)
Variable2
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
1No polyps or hyperplastic polyp(s) only; 2 Number of subjects for each variable category may not equal total number of
subjects due to missing data; 3Chi-squared test for differences in proportions or Wilcoxon rank sum test for differences
in medians between cases and controls; 4Three subjects who were in the underweight BMI category (≤18.5 kg/m2);
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Table 6.7. PER3 VNTR genotype by adenoma status
Controls
Cases
(n = 97)
(n = 49) Crude OR
Genotype
95% CI
p-value Adjusted OR1
n (%)
n (%)
4/4
52 (54)
16 (33)
Ref
--Ref
4/5
38 (39)
24 (49)
2.1
0.9 – 4.4
0.06
2.1
5/5
7 ( 7)
9 (18)
4.2
1.3 – 13.0
0.01
5.1
4/5 or 5/5
45 (46)
33 (67)
2.4
1.7 – 4.9
0.02
2.5
Abbreviations: OR, Odds ratio; CI, Confidence interval; VNTR: Variable number tandem repeat
1Adjusted for: decision latitude at work, recruitment site, procedure reason.

95% CI

p-value

-0.9 – 4.8
1.4 – 18.1
1.7 – 5.4

-0.07
0.01
0.02
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Table 6.8. Relationship between PER3 VNTR genotype and adenoma status: stratified by procedure reason
Controls
Cases
Crude
pAdjusted
95% CI
95% CI
1
OR
value
OR2
n (%)
n (%)
Screening 4/4
34 (59)
7 (35)
Ref
--Ref
-(ncases = 4/5
21 (36)
9 (45)
2.1
0.7 – 6.4
0.20
2.2
0.7 – 7.1
20;
5/5
3 (5)
4 (20)
6.5
1.2 – 35.6
0.03
10.7
1.4 – 80.7
ncontrols =
4/5 or 5/5
24 (41)
13 (65)
2.6
0.9 – 7.6
0.07
2.9
0.9 – 8.7
58)

p-value
-0.19
0.02
0.07

188

Surveillan 4/4
18 (46)
9 (31)
Ref
--Ref
--ce
4/5
17 (44)
15 (52)
1.8
0.6 – 5.1
0.29
1.9
0.6 – 5.6
0.29
(ncases
5/5
4 (10)
5 (17)
2.5
0.5 – 11.7
0.24
2.3
0.5 – 11.4
0.30
=29;
21 (54)
20 (69)
1.9
0.7 – 5.2
0.21
2.0
0.7 – 5.6
0.20
ncontrols = 4/5 or 5/5
39)
Abbreviations: OR, Odds ratio; CI, Confidence interval; VNTR: Variable number tandem repeat
1 - Unconditional logistic regression with Firth’s bias correction; 2 - Adjusted for decision latitude at work, recruitment
site.
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Table 6.9. Relationship between PER3 VNTR genotype and adenoma status: stratified by methylation status in PER1,
PER2, and PER3
Methylation
Methylation
Genotype Controls Cases Crude OR1
Adjusted OR2
p-value
p-value
Marker
Status
(95% CI)
(95% CI)
n (%)
n (%)
PER1
4/4
8
3
Ref
-Ref
-4/5
4
6
3.51 (0.57 –
0.17
2.18 (0.25 –
0.48
21.46)
18.79)
Hypomethylation
(ncases = 12;
5/5
1
3
5.67 (0.48 –
0.17
5.90 (0.35 –
0.22
ncontrols = 13)
69.20)
98.45)
4/5 or 5/5
5
9
4.20 (0.77 –
0.10
2.99 (0.40 –
0.29
22.84)
22.38)
4/4
18
7
Ref
-Ref
-4/5
19
9
1.20 (0.37 –
0.76
1.72 (0.48 –
0.40
3.88)
6.11)
Hypermethylation
(ncases = 19;
5/5
5
3
1.57 (0.30 –
0.60
1.84 (0.29 –
0.52
ncontrols = 42)
8.29)
11.59)
4/5 or 5/5
24
12
1.26 (0.42 0.68
1.75 (0.53 –
0.36
3.81)
5.77)
PER2
4/4
3
1
Ref
-Ref
-4/5
2
1
1.40 (0.06 –
0.84
0.62 (0.00 –
0.87
Hypomethylation
33.29)
220.41)
(ncases = 2;
5/5
0
0
9.52 (0.95 –
0.06
2.74 (0.59 –
0.20
ncontrols = 5)
95.79)
12.60)
4/5 or 5/5
2
1
1.40 (0.06 –
0.84
0.62 (0.00 –
0.87
33.29)
220.41)
23
9
Ref
-Ref
-Hypermethylation 4/4
(ncases = 29;
4/5
21
14
1.67 (0.60 –
0.33
1.79 (0.59 –
0.30
ncontrols = 50)
4.63)
5.42)
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Table 6.9. Relationship between PER3 VNTR genotype and adenoma status: stratified by methylation status in PER1,
PER2, and PER3
Methylation
Methylation
Genotype Controls Cases Crude OR1
Adjusted OR2
p-value
p-value
Marker
Status
(95% CI)
(95% CI)
n (%)
n (%)
5/5
6
6
2.47 (0.63 –
0.19
2.74 (0.59 –
0.20
9.70)
12.61)
4/5 or 5/5
27
20
1.84 (0.71 –
0.21
2.01 (0.71 –
0.19
4.81)
5.71)
PER3
4/4
1
2
Ref
-Ref
-4/5
1
2
1.00 (0.04 –
1.00
0.30 (0.00 –
0.62
Hypomethylation
27.26)
32.83)
(ncases = 5;
5/5
0
1
1.98 (0.01 –
0.80
4.34 (0.02 –
ncontrols = 2)
358.88)
1118.84)
4/5 or 5/5
1
3
1.40 (0.06 –
0.84
1.02 (0.03 –
0.99
33.27)
30.00)
4/4
25
8
Ref
-Ref
-4/5
22
13
1.80 (0.63 –
0.27
1.91 (0.60 –
0.27
Hypermethylation
5.11)
6.03)
(ncases = 26;
5/5
6
5
2.54 (0.61 –
0.20
2.34 (0.48 –
0.29
ncontrols = 53)
10.54)
11.43)
4/5 or 5/5
28
18
1.95 (0.73 –
0.18
2.02 (0.68 –
0.20
0.5.22)
5.98)
Abbreviations: OR, Odds ratio; CI, Confidence interval; VNTR: Variable number tandem repeat
1 - Unconditional logistic regression with Firth’s bias correction; 2 - Adjusted for decision latitude at work, recruitment
site, and procedure reason.

Table 6.10. Relationship between PER3 VNTR genotype and lifetime shiftwork
exposure
Lifetime Shiftwork in Years
p-value1
n (%)
Median
25th
75th
percentile
percentile
4/4
67 (47)
5
1
15
-4/5
61 (42)
2
0
10
0.02
5/5
16 (11)
0.75
0
8.5
0.05
4/5 or 5/5 77 (53)
1
0
10
<0.01
1Wilcoxon rank sum test for group differences in medians by genotype
compared to those with the 4/4 genotype; 2 subjects missing information on
lifetime shiftwork; VNTR: Variable number tandem repeat
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Table 6.11. PERIOD gene expression in human adenomas vs. normal tissue1
pReferent Tissue
Pathological Tissue Type PER1
PER2
value
Normal colon
Colorectal adenoma
-1.3
<0.01
-1.2
epithelium (n=22)
epithelium (n=56)
Normal colon
Colon adenoma (n=25)
-1.7
<0.01
-1.2
(n=32)
Normal colon
Rectal adenoma (n=7)
-1.9
<0.01
1.3
(n=32)
Normal colon
Colon adenoma (n=5)
-1.0
0.37
1.6
(n=10)
Normal colon
Colorectal adenoma
-1.2
0.05
1.2
epithelium (n=10)
epithelium (n=5)
1

pvalue

PER3

p-value

Reference

0.05

N/A

N/A

336

<0.01

-2.3

<0.01

337

0.88

-1.7

<0.01

337

0.99

-2.1

<0.01

338

0.94

-1.7

<0.01
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Fold change in mRNA expression in adenomas relative to adjacent normal tissue (number of tissue samples evaluated in
parentheses). Source: www.oncomine.com
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Chapter 7
Conclusion
This dissertation project aimed to accomplish two goals: 1) understand the
scope of sleep disorders in a national sample, and 2) elucidate the genetic and
epigenetic mechanisms of clock genes and their role in adenoma formation, a
precursor lesion for CRC. Sleep disruption has been previously linked to
increased cancer risk, potentially through circadian rhythm disruption; therefore it
is necessary to characterize populations at risk (e.g., shift workers, people with
sleep disorders).

The first project aimed at characterizing sleep disorders over time in a
national sample of veterans. This project found that the prevalence of sleep
disorders have increased nearly six-fold from FY2000 to FY2010. As expected,
apneas were the most commonly-diagnosed sleep disorder, followed by
insomnia. However, it is not known whether or not this increase in sleep
disorders were a true increase due to certain factors (increasing trends in
obesity, PTSD, etc.), increased awareness, or a combination of both. In this
national sample of veterans, PTSD tripled over time; and those with PTSD had
the highest prevalence of sleep disorders (16%). Increase in awareness could
also be attributed to the surge in sleep disorder prevalence, as a national sleep
medicine training and certification program was initiated in 2004-2005.350 Using
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this national sample, etiological models for sleep disorders were also created, as
there is a dearth in the literature on risk factors for sleep disorders, while
simultaneously accounting for other factors. Pre-existing history of PTSD and
being obese resulted in a more than doubling of odds of developing a sleep
disorder in FY2010. Future research will need to be conducted in large, national
samples to confirm findings in the present studies.

Because people with sleep disorders may have genetic alterations or
epigenetic changes that could increase their risk for cancer, the second part of
this dissertation examined relationships in a set of genes involved in the
regulation of circadian rhythms. Circadian rhythms are established in the central
pacemaker, located in the SCN of the anterior hypothalamus, via photic input.
Nine core clock genes have been found to play a role in circadian oscillation:
PER1, PER2, PER3, CRY1, CRY2, CLOCK, BMAL1, TIM, and CK1ε.33 ~2-10%
of the diurnal gene expression in most tissues is controlled by this set of genes.89
In particular, the Period (Per) gene family plays a role in immunomodulation20-25
and tumor suppression.26, 27 However, environmental (e.g., shiftwork) 91-93 and/or
genetic factors (genetic polymorphisms or epigenetic modifications)30, 94 can
confuse the master clock, affecting physiological processes involved in
tumorigenesis, such as cell proliferation and apoptosis.95 Disruption of these
processes has been suspected of increasing the risk of cancer in certain
populations (e.g., shiftworkers),96 and these effects have been confirmed in
animal model studies.97 Previous research found that genetic polymorphisms,19,
28, 29

variable expression in tumor tissues,30-32 and aberrant methylation33 within
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the Per genes have shown some promise as novel biomarkers of cancer, which
warranted the second project.

In a case-control pilot study where the methylation status of 20 candidate
markers in PBLs were examined for their relationships with adenoma formation,
individuals with hypomethylation in the promoters of three markers (PER1,
PER3, and MINT1) were 3 to 11 times more likely to have adenomas compared
to adenoma-free controls, after controlling for multiple confounders.

Although

aberrant methylation of PER genes has been observed among leukemia and
other cancer patients,30, 33, 113, 114, 286 little is currently known about the MINT1
locus, and all three markers had not been previously examined in PBLs in
relation to adenoma formation. It is suspected that clock-controlled genes, which
include known tumor suppressors (e.g., p21, Chk2, XPA, ATM) and oncogenes
(e.g., β-catenin, c-Myc, WEE-1),276 may be dysregulated, thus potentially
promoting a carcinogenic microenvironment.

In addition to examining epigenetic variation and adenoma risk, an
additional study of the second project was undertaken, specifically focusing on
the PER3 VNTR, a tandem repeat that contains four or five copies of a 54-bp
sequence encoding 18 amino acids, with the 5-repeat variant adding several
phosphorylation motifs. In this study, subjects with adenomas were anywhere
from 2 to 5 times more likely to possess at least one 5-repeat variant compared
to controls. This association may be partially mediated by alterations in circadian
processes (i.e., delayed sleep phase syndrome, cognitive impairment after sleep
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deprivation, morning circadian preference, and differences in the timing or levels
of circadian hormone secretion)40, 117, 313 among those with at least one 5-variant
repeat. Although this finding was not consistent with a previous study that
examined PER3 VNTR polymorphisms and CRC,351 a prior study has observed
an association between the 5-repeat variant and premenopausal breast cancer,19
suggesting that PER3 may act as a tumor suppressor; however, more studies will
need to confirm findings observed in this study.

In closing, although it is unclear as to why sleep disorder prevalence is
increasing over time, it is clear that a subset of the population may be increasing
their risk for adverse health events, including cancer, and genetic and/or
epigenetic mechanisms may be partially mediating this pathway. Elucidation of
these mechanisms may not only allow for understanding the association between
circadian disturbances and cancer, but to also develop novel biomarkers from
readily-accessible sources, such as blood.
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